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W hose side is your favourite
Rinding an effective treatment for intra­
abdominal infections has become much 
easier since the advent of cephalosporins. 
Their broad spectrum of activity has greatly 
improved the prognosis for many patients 
with serious infections.
The trouble is, the cost of cephalosporins has 
been making many hospital pharmacists 
(and cost control staff) see red. It is also now 
increasingly more difficult for many hospital 
formulary committees to be able to strike an 
agreeable balance between effectiveness 
and cost control.
New Cefizox™ may be the answer everyone's 
been looking for. Not only does it give much 
wider pathogen coverage* (including B. 
fragilis) than cefoxitin,1'2 but its superior 
dosage schedule (example: q!2h vs q6h) 
may make Cefizox™ much less expensive?'4 
It even has packaging designed for easy 
identification.
So if the cost of effective cephalosporin 
therapy is just too much for your hospital to 
handle, consider new Cefizox™ Its 
combination of efficacy and low cost may 
just be what everybody ordered.
C efizox”
ceftizoxime sodium
A cephalosporin that plays favourites with everybody.
PAAB
CCPP SKSF SMITH KLINE SfRENCH CANADA LTD. 1989 ■ ■ under licence ofFujisawa Pharmaceutical Co., Ltd., Osaka, Japan
CX:M:189CA
' Refers to in vitro coverage does not necessarily imply clinical coverage.
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QUILL ON SCALPEL This section provides a medium through which Canadian surgeons can declare themselves, 
briefly and informally, on the day-to-day affairs of surgery.
Bone Banking, 1989: Challenges and 
Opportunities
Richard L. Cruess, MD, FACS, FRCSC
Dean, Faculty o f  Medicine, McGill University. Montreal, PQ
For surgical procedures involv­ing the musculoskeletal system, 
a bone bank is of great benefit and 
sometimes essential. In general, 
bone from banks is used to provide 
structural stability, to replace recip­
ient tissue, in surgery for malignant 
disease, during complex reconstruc­
tive procedures and, finally, to in­
duce new bone formation by means 
which are now becoming clearer. As 
in so many other fields of clinical 
endeavour, research into methods 
of procuring and preserving bone 
and utilizing bone banks has pro­
ceeded in stepwise fashion rather 
than in a logical and orderly one. In 
many instances, research appears to
follow the emergence of clinical 
problems.
It is firmly established that a 
properly utilized autograft repre­
sents the method of choice whenev­
er feasible. The absolute lack of 
immunologic response and the pos­
sibility of new-bone formation by 
the recipient’s own cells drawn from 
the grafted material represent ad­
vantages that can never be 
matched, aside from the relatively 
rare opportunity for fresh grafts 
from a genetically identical individu­
al (i.e., an identical twin). The ideal, 
however, is not always possible. At 
times, the amount of bone required 
is greater than can be harvested
from the patient, the type of bone 
required is not available, the pa­
tient’s bone is not suitable because 
of disease or the risk to the patient 
is too great. In an attempt to over­
come these difficulties, many alter­
native methods have been tried. 
Artificial substances and bone from 
different living species have been 
used, but both methods have been 
associated with an unacceptable 
rate of failure from both mechanical 
and biologic causes. Thus, bone 
banking has remained the standard 
alternative to the autograft. Howev­
er, such a bank must conform to 
contemporary standards, otherwise 
the recipient may be seriously
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CRUESS
harmed. In addition, the bank must 
adhere to contemporary legal and 
ethical standards, or the institutions 
and individuals involved run the 
risk of losing public trust, or worse.
Russell, Hu and Raso, the au­
thors of an article on bone banking 
in this issue (pages 231 to 236) 
deserve our thanks. They have dem­
onstrated that a large number of 
Canadian hospitals are maintaining 
bone banks and that a disturbingly 
high percentage are not doing so in 
a way that fully utilizes present-day 
scientific knowledge. Moreover,
BOOK REVIEWS
SURGICAL ANATOMY OF HEAD 
AND NECK. Jelena Krmpotic-Neman- 
ic, Wolfgang Draf, Jan Helms. 331 pp. 
Illust. Springer-Verlag New York, 
Inc., New York, 1988. $214.50 (US). 
ISBN 0-387-17414-1.
The idea of an anatomy atlas with a 
special orientation to surgical proce­
dures has, I believe, always held a 
special appeal for surgeons.
The authors of this atlas, an anato­
mist with otolaryngologic clinical train­
ing and two practising otolaryngolo­
gists, appear well suited to the task of 
integrating anatomy with surgical pro­
cedures of the head and neck area, 
which frequently has been viewed as 
problematic because of the compression 
of vital anatomical structures in a rela­
tively restricted anatomical space. They 
have divided their chapters into the 
neck and thorax, the larynx and thyroid 
gland, the face, the oral cavity and oral 
pharynx, the nose, the paranasal sinus­
es and maxillary space, the eye and its 
orbital adnexa, the ear, the middle and 
posterior cranial fossae, the skull and 
gross anatomy of the central nervous 
system, the topography and variations 
of extra- and intracranial vessels, and 
the paraganglia. Other sections of the 
book deal with references, a subject
there does not appear to be enough 
inter-institutional collaboration, re­
sulting in a disturbingly high num­
ber of “casual” bone banks. At the 
very least, every institution main­
taining a bank should look at its 
present methods and their long- 
range implications. Great oppor­
tunities are apparently available for 
inter-institutional collaboration and 
for regional banks, which would 
not preclude the maintenance of 
sub-banks in smaller hospitals, so 
that some material would be avail­
able to the unfortunate surgeon
index which is reasonably thorough, 
and an index of operations and surgical­
ly important anatomic relationships.
The 233 illustrations, mostly in col­
our, are lucidly drawn and beautifully 
reproduced with appropriate labelling of 
anatomical structures; indeed, the work 
of the medical artist, Adita Shubert, is 
very much a feature, as it should be. 
With the illustrations, the authors have 
provided a commentary of the anatomi­
cal structures depicted, usually with 
reference, en passant, to surgical con­
cerns, but also including a distinct 
paragraph covering operative proce­
dures only by name. References to the 
various areas depicted are also given for 
further perusal.
The lofty ambition of this book 
serves to remind the reader of its con­
tinuing deficiencies. Its great breadth 
militates against what could have been 
a detailed explanation of many head and 
neck procedures, for it is unlikely, as 
the authors wished, that the neurosur­
geon will use this book alone in prepar­
ing for neurosurgical procedures. A 
greater integration of the anatomy as 
depicted in detailed application to the 
relevant surgical procedures would have 
been of more practical use than a mere 
listing under the various sections of 
procedures that take place in the area.
(and patient) who requires it in the 
middle of the night. The study by 
Russell and colleagues provides a 
baseline for evaluating Canadian 
performance in the future, and it is 
not irrational to hope that a mul­
ticentre study could be instituted to 
look prospectively at the results of 
large numbers of procedures carried 
out according to standardized (Ca­
nadian) methodologies. Clearly, it is 
timely to do this, as the next inte­
resting results will be partly mecha­
nical and biologic, but, more impor­
tantly, in part epidemiologic. ■
The parathyroid anatomy, which has 
important current application because 
of the growing frequency of hyperpara­
thyroidism is particularly lacking in this 
respect. Much work has been done on 
delineating abnormal parathyroid anato­
my, knowledge of which is so important 
to effective surgical treatment and 
which is not well covered in this atlas. 
Similarly, the sections dealing with de­
monstration of the facial nerve should 
have provided more detail of the dissec­
tion on which the success of parotidec­
tomy depends and should have included 
reference to the work of Hayes Martin, 
a pioneer in facial nerve-sparing ma­
neuvers. The section on recurrent laryn­
geal nerve demonstration would also 
have been enhanced by more detail as 
would that on the superior laryngeal 
nerve, the demonstration of which is 
important in safe thyroid surgery. 
There are other such areas and, al­
though this volume does not purport to 
be an atlas of surgery, its purpose could 
have been subserved by at least demon­
strating the anatomy of some of the 
standard head and neck procedures that 
are firmly established in the surgical 
armamentarium.
continued on page 237
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CORRESPONDENCE
Doctor or Mister?
To the editors. Possessing the de­
grees and thus the associated titles 
discussed by Eibel (Can J Surg 
1988; 31: 452-453) and Cairns 
(Can J Surg 1988; 32: 83-84), I 
believe I am in a position to add 
some further insight. Having spent 
5 years at medical school to earn 
the MB, BS (Bachelor of Medicine 
and Bachelor of Surgery), with its 
purely honorary title “Dr.” , I can 
still remember the enormous pride 
one felt when, 4 years later, earning 
the FRCS entitled one to reassume 
the title of “Mr.” (surely a case of 
inverted snobbery?). Of course, re­
verting to “Dr.” took place when­
ever restaurant tables needed book­
ing, bank managers needed sweet­
ening or garage mechanics needed 
persuading that your car was the 
most important on the road and its 
repair warranted a little queue 
jumping!
The surgical mastership (MS) and 
its equivalent doctorate of medicine 
(MD) are offered by the University 
of London and several other British 
universities (Oxford and Cambridge 
award similar degrees but with dif­
ferent letters, e.g., MChir). These 
are thesis degrees awarded follow­
ing a viva voce, for 1 or more years 
of unsupervised original research 
presented in bound form to the 
three examiners. These are called 
advanced degrees to differentiate 
them from the PhD which is called 
a higher degree, since work for the 
latter has been supervised. It is with 
typical British understatement that 
the degrees of MD and MS, the
highest the university can award 
(DSc is awarded by peer election), 
carry no honorary title.
C.J. de Gara, MB, MS, FRCS(Edin), 
FRCS
Surgical resident,
McMaster University,
1200 Main St. W,
Hamilton, Ont.
L8N 3Z5
To the editors. I read with interest 
Eibel’s paper entitled “Doctor or 
Mister” in the November 1988 
issue of the journal (pages 452 and 
453) and thought it excellent.
However, I must challenge the 
comments of Cairns in his letter on 
the same subject (Can J Surg 1989; 
32: 83-84). The granting of the 
degree of Bachelor of Medicine and 
Bachelor of Surgery (MB, ChB) by 
the excellent Scottish universities 
or (MB, BS) by those lesser institu­
tions south of the border(!) entitles 
the individual to call himself “Doc­
tor”. Should that individual then 
submit a thesis for the degree 
“MD” — this is, indeed, a “higher 
degree” — the title remains “Doc­
tor”. If he then pursues a career in 
internal medicine, he will seek his 
membership in the Royal College of 
Physicians (MRCP) and after a 
number of years is elevated to fel­
lowship (FRCP), which is an added 
honour. Alternatively, if the individ­
ual pursues a surgical career, he 
will obtain his fellowship (FRCS) 
and will then become “Mr.”. The 
latter designation is entirely along 
the lines as described by Eibel.
Contributions to the Correspondence section 
are welcome. They should be typewritten 
and double spaced.
Accordingly, Dr. Cairns is mis­
taken in the points which he enu­
merates in his letter, apart from the 
fact that, indeed, a London surgeon 
would be somewhat “put out” to be 
referred to as “Dr.”!
As one who has been “Mr.” , 
“Dr.”, “Mr.” and now “Dr.” again 
— I should know!
Graham C. Fraser, MB, ChB, FRCS, 
FRCS(Edin), FRCSC, FACS, FAAP
Ste. 210,
Medical-Dental South Tower,
Oakridge Centre,
650 West 41st Avenue,
Vancouver, BC 
V5Z2M9
To the editors. I found Eibel’s 
article in the November 1988 issue 
(pages 452 and 453) and Cairns’ 
subsequent letter in the March issue 
(pages 83 and 84) very interesting. 
I believe I can add some informa­
tion.
First, I would explain that one 
can get onto the British Medical 
Register in three different ways.
•  By obtaining a university de­
gree in medicine. Different universi­
ties give different “letters” , but 
basically they represent the degrees 
of Bachelor of Medicine and Bache­
lor of Surgery. Variations include: 
MB, BS; MB, BCh; MB, ChB; BM, 
BCh. The Irish universities grant an 
MB, BCh, BAO, the last letters 
standing for Bachelor in the Art of 
Obstetrics.
•  By passing “conjoint” . This is 
a diploma issued conjointly by the 
Royal College of Physicians and the
CJS, VOL. 32, NO. 4, JULY 1989 229
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Royal College of Surgeons and can 
be taken in London or Dublin. The 
“letters” for this are LRCP, MRCS 
(Licentiate of the Royal College of 
Physicians, Member of the Royal 
College of Surgeons).
•  By passing an examination 
conducted by the Society of Apoth­
ecaries (London or Dublin). The 
Society was founded by James 1 and 
given powers of examination and 
the right to grant licences to prac­
tise medicine by an act of Parlia­
ment in 1815. Here, the “letters” 
are LMSSA (Licentiate in Medicine 
and Surgery of the Society of 
Apothecaries) or LSA for short.
At this stage three points should 
be made: (a) all of the above, on the 
registry, are entitled to the courtesy 
title of doctor; (b) the British MB, 
BCh (or similar) is equivalent to the 
North American MD; (c) the MD in 
Great Britain and Ireland is a higher 
degree, which can be obtained ei­
ther by examination or by thesis, 
according to the regulations of the 
university concerned.
With regard to the title “Doctor 
or Mister?” , the historical back­
ground must be examined. The 
Company of Barber-Surgeons was 
incorporated in 1461, but it had no 
disciplinary powers. It was reincor­
porated in 1540 with disciplinary 
powers. In 1745, as Dr. Eibel cor­
rectly states, the barbers and the 
surgeons were separated by George 
II. I have always been under the 
impression that when the surgeons 
were “turned loose”, the physicians 
of London, who were incorporated 
in 1518, didn’t regard these sur­
geons as “proper doctors” and re­
fused to call them “doctors” , using 
instead the title of “mister”. At first 
this was regarded as a slur, but 
subsequently became used with 
pride. A good analogy is the story 
of how in World War I the Kaiser 
referred to the British Expedition­
ary Force as “This contemptible 
little army...” — later the veterans
were proud to call themselves “The 
Old Contemptibles” .
Another historical term of inter­
est is that of apothecary, which was 
a term used for those who prepared 
and sold drugs. This meaning is 
maintained in the United States, 
Scotland and in continental Europe. 
As seen, in England the term came 
to refer to a general medical practi­
tioner, and many of the older dis­
pensary doctors were qualified 
LMSSA.
G. Keith Thomas. MB, BCh, BAO, 
FRCS, FRCSC
Medical Arts Building,
17 Dunedin St..
Orillia. Ont.
L3V 5T3
To the editors. Further to the 
Dr./Mr. appellation of British sur­
geons so eruditely explained by 
Eibel (Can J Surg 1988; 31: 452- 
453) and taken up by Cairns (Can J 
Surg 1989; 32: 83-84), I was 
pleased to see that Cairns finds 
these “curious customs...have a 
certain charm” but sorry that he 
considers them “perverse...rather 
like driving on the left hand side of 
the road”.
There is usually a good reason 
for these curious customs that orig­
inate in “the old country”. For 
example, it is a lot easier to mount 
a horse from the left side when 
girded with one’s sword (unless of 
course one is left-handed) than to 
do so from the right, something 1 
would not advise Dr. Cairns to 
attempt lest he end up performing 
an operation upon himself that he 
might regret!
Peter Rees-Davies, FRCS, FACS,
FRCSC
8444 Yank Gulch,
Talent.
OR 97540.
USA
This list is an acknowledgement of 
books received. It does not preclude 
review at a later date.
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REVIEW ARTICLE
B on e Banking in Canada: a Review
Gordon Russell, MB, ChB, MSc, FRCS;* Richard Hu, MD;* V. Jim Raso, MASct
Transplantation of human tissues has become increasingly popular, and associated 
with this increase are reports of the transmission of diseases including acquired 
immune deficiency syndrome. To reduce the risk of transmitting disease through 
transplantation, careful scrutiny of current tissue transplantation procedures is 
necessary. Bone banking in Canada was evaluated by questionnaire, sent to the head 
operating room nurse of every Canadian hospital listed in the 1986 Canadian 
Medical Directory as having 100 or more beds. From this questionnaire, the authors 
identified 60 bone banks in Canada, many of which failed to meet recommended 
guidelines. The authors review the literature relating to bone banking procedures 
and present in detail the results of their survey.
La transplantation de tissus humains est de plus en plus populaire. On rapporte 
maintenant en rapport avec cette pratique, la transmission de diverses maladies, 
dont le syndrome d’immunodeficience acquise. Afin de reduire le risque de 
transmission de maladies, il devient necessaire de scruter soigneusement les 
techniques actuelles de transplantation de tissus. Les banques d’os du Canada ont 
ete evaluees a l’aide d’un questionnaire, lequel fut adresse a l’infirmiere chef du 
service de chirurgie de chacun des hopitaux canadiens inscrits dans l’edition 1986 
du Canadian Medical Directory comme possedant 100 lits ou plus. A partir de ce 
questionnaire, les auteurs ont identifie 60 banques d’os au Canada, dont plusieurs 
qui ne rencontrent pas les exigences des lignes directrices recommandees. Les 
auteurs commentent la litterature relative aux techniques de conservation des os et 
ils presentent le detail des resultats de leur enquete.
O llier1 established the scientific basis for bone transplantation 
in the mid-19th century with his 
studies on the osteogenic properties 
of bone and periosteum, and the 
beneficial influence of freezing in 
preserving these characteristics. In 
a report dated 1881, Macewan,2 a 
Glasgow surgeon, described the use 
of bone grafts to reconstruct the 
lost bone of a child’s humerus. In 
1907, Lexer3 transplanted a whole
Accepted for publication Jan. 16, 1989
knee joint. The first reported use of 
preserved bone in orthopedic sur­
gery was by Inclan in 1942.4 Since 
then, the use of allograft bone and 
bone banking have become com­
mon.
The function of a bone bank is to 
supply safe and efficacious donor 
bone. Suggested protocols for es­
tablishing and maintaining bone 
banks are numerous. Procedures 
for donor selection, bone procure­
ment, processing, storage and dis­
tribution have been suggested.5-21
To evaluate the present status of 
bone banking in Canada in relation 
to published protocols, we sent out 
a comprehensive questionnaire to 
404 Canadian hospitals.
Methods
The questionnaire (Fig. 1) was 
sent in March 1987 to the head 
operating room nurse of every Ca­
nadian hospital listed in the 1986 
Canadian Medical Directory as hav­
ing 100 or more beds. It was de­
signed to evaluate present practices 
for donor selection, procurement, 
storage, record keeping and donor 
and recipient consent in relation to 
the use of allograft bone.
Findings
The questionnaire results were 
analysed in January 1988, by which 
time 284 (70.3%) of the 404 ques­
tionnaires had been returned.
Regional response rates are 
shown in Table I. The poor re­
sponse from Quebec is probably a 
result of the questionnaire being 
sent in English only.
Sixty bone banks were identified; 
approximately one in every five Ca­
nadian hospitals with more than 
100 beds had a bone bank. The 
number of banks in each province 
as a percentage of responders is 
listed in Table II. There was a 
substantially larger proportion of 
bone banks in Alberta than in the
From the *Department o f  Surgery, Division o f  Orthopaedic Surgery, University o f  Alberta, 
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other provinces, and this was re­
flected in that the smallest hospital 
in Canada to have a bank is in 
Alberta (Table III).
Of the 60 hospitals that had a 
bone bank, 4 returned insufficient 
information in the questionnaire, 
leaving 56 for analysis. Of these, 43 
(77%) bone banks had existed for 
more than 5 years, 10 (18%) for 1
to 5 years and 3 (5%) for less than 1 
year. Bone banks were classified as 
regional if they supplied bone to 
other cities, institutional if they 
supplied bone to other hospitals in 
the same city and casual if they 
used the bone only in their own 
hospital. In this survey, 77% were 
casual, 14% institutional and 9% 
regional.
Supervision
Table IV identifies the person or 
persons who were in charge of the 
banks. Eighty-eight percent were 
operated, at least in part, by nurs­
ing staff. Physicians were involved 
in the operation o f 80% of regional 
banks, 25% of institutional banks 
and only 9.3% o f casual banks.
Do you have a Bone Bank in your hospital? Yes
If Yes, please answer the following questions.
If No, please return the questionnaire in the envelope 
provided.
How long have you had a Bone Bank?
_____  Less than 1 year
_____  1 - 5  years
_____  More than 5 years
Who is responsible for looking after it?
_____  Doctor
_____  Nurse
_____  Technician
_____  Other
How would you describe your Bone Bank?
(a) Regional (e.g., you procure bone from 
cadavers and supply the bone to other
hospitals in other cities) Yes __
(b) Institutional (e.g., you procure bone 
from cadavers and supply bone to other
hospitals in your city) Yes __
(c) Casual (e.g., you procure bone from 
cadavers or living donor, such as femoral 
heads, and use them in your own hospital
only) Yes ___
Do you obtain consent from the donor in the case
of living donors (femoral heads, etc.)? Yes __
Do you obtain consent from the donor's next of kin
in the case of cadaver bone retrieval? Yes ___
Do you screen the donor (dead or alive) for the 
following:
Malignancy anywhere? Yes __
Infection anywhere? Yes
Toxic substances (drugs, etc.) Yes __
Metabolic bone disease (e.g., osteomalacia, 
osteoporosis) Yes
Diseases of unknown etiology (e.g., rheumatoid
arthritis, ankylosing spondylitis, avascular
necrosis) Yes ___
ABO blood groups Yes __
Rhesus factor Yes __
AIDS virus Yes __
Venereal disease Yes __
Hepatitis Yes __
What is the age limit for your donors? (Underline one in each
column)
Any Age Any Age
Skeletally immature 75 years
Skeletally mature 70 years
Over 15 years 65 years
Do you screen the allograft for infection
- on collection Yes
- on implantation Yes
No — 10. If you procure cadaver bone, is it retrieved in:
a ) The operating room Yes No
b) The morgue Yes . No _
c ) Either of the above Yes . No
d) Another site (specify) Yes , No
11. Who harvests the cadaver bone?
a ) Surgeon Yes ___ No ___
b) Resident Yes ___ No ___
c) Technician Yes No
d) Nurse Yes ___ No ___
e ) Other Yes ___ No ___
12. How do you preserve the bone?
a ) Regular freezer Yes _ No
b) Freeze to -70<>C or -80oc Yes ___ No
No
c ) Freeze-dry Yes — No —
d) Other (specify) Yes — No ___
No
13. What is the maximum time after death that you 
would retrieve cadaver bone?
a ) Less than 12 hours Yes No
No
b) 12 - 24 hours Yes — No —
c) More than 24 hours Yes ___ No ___
No - 14. What is the longest time you would keep the bone for?
No — a ) Less than 1 month Yes ___ No
b) 1 - 3  months Yes ___ No ___
No
c) 3 - 6  months Yes — No —
No
d) More than 6 months Yes — No —
No
15. What is your procedure for record keeping?
a ) Computer Yes — No —
No ___ b) Notebook Yes ___ No ___
c ) Flow sheet Yes ___ No ___
No ___ d) Other Yes ___ No ___
No ___ e) None kept Yes — No ___
No ___ 16 . What is the bone used for?
No — a ) Tumour surgery Yes — No ___
No — b) Reconstructive surgery Yes ___ No ___
No ___ c) Trauma
d) Other (specify) Yes — No ___
17. Do you obtain informed consent from any patient 
receiving or expected to receive any allograft 
bone? Yes No
18. Do you have any feedback as to whether the bone 
graft was successful, infection rates, and other 
complications? Yes No
19 . How many orthopedic surgeons do you have on staff?
No
No
FIG. 1. Allograft survey questionnaire sent to all Canadian hospitals having more than 100 beds.
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Screening Procedures
Screening procedures for donor 
selection varied (Table V). Regional 
banks screened more than institu­
tional or casual banks. Rhesus fac­
tor was surveyed least (25%); less 
than 50% of centres screened for 
blood type, human immunodeficien­
cy virus (HIV), venereal diseases or 
potentially toxic substances. Fifty- 
two percent screened for metabolic 
bone disease, 55% for hepatitis and 
71% for malignancy. Most banks 
(93%) excluded endogenous infec­
tion on collection; cultures were 
repeated at the time of implantation 
in 80% of hospitals.
Preservation
Bone was stored in a regular 
freezer at colder than — 25 °C in 
57% of banks, and in deep freezes 
at approximately — 75°C in the 
remainder. None of the respondents 
used freeze-drying as a method of 
storage. Sixty-one percent stored 
bone for longer than 6 months, 
even when a regular freezer was 
used.
Procurement o f  Donor Bone
Sixteen of the 56 bone banks 
(29%) procured cadaver bone; in 15 
(94%) of these, this was performed 
in the operating room. Bone was 
retrieved within 12 hours of death 
in 12 (75%) of the cases and within 
24 hours in the remainder. Skeletal- 
ly immature individuals and those 
older than 70 years were not ex­
cluded as donors in the majority of 
centres.
Consent
All banks that harvested cadaver 
bone obtained consent from the 
next of kin. In contrast, only one 
hospital obtained consent from liv­
ing donors (such as those who 
donate femoral heads during hip 
surgery). Nineteen (34%) of hospi­
tals obtained informed consent from 
patients who were expected to re­
ceive allografts.
Strict records were kept in all but 
one bone bank. Thirty-eight (68%) 
obtained additional information on 
the outcome of the graft in each 
case.
Discussion
Our results indicate that changes 
are needed in the running of many 
Canadian bone banks. Similar find­
ings were reported from Australia.17 
It has been estimated,12 probably 
conservatively, that bone grafts are 
used 200 000 times annually in the 
United States. It is obviously impor­
tant that the use of allograft bone 
in orthopedic surgery be kept as 
safe as possible for the recipient’s 
well-being and to avoid possible 
medicolegal problems.
Donor Selection
Criteria for excluding donors can 
be divided into three categories: 
transmitting infection, transferring 
noninfective disorders and other 
factors.
Transmitting infection. To mini­
mize the risk of infecting a recipi­
ent, donor bone should come from 
a living donor or cadaver with no 
active systemic infection and an 
afebrile course while in hospital. 
Patients who were on a respirator 
for more than 72 hours14 or who 
died within 72 hours of major sur­
gery, ran a higher risk of bacter­
emia1618 and should be excluded as
Table III. S m a lle s t H o s p ita l in  E ach
P ro v in c e  to  H ave a B on e  B an k
Province/territory No. of hospital beds
A tla n t ic  p ro v in c e s 1 6 2
Q uebec 241
O n ta rio 1 6 5
M a n ito b a 3 2 0
S a s ka tch e w a n 2 9 9
A lb e r ta  and  N W T 1 0 0
B r it is h  C o lu m b ia 3 4 0
Table IV. P e rs o n s  P a r t ia lly  o r  W h o lly
R e s p o n s ib le  fo r  th e  B o n e  B a n k
No. in Proportion of
Person category respondents, %
P h y s ic ia n 11 2 0
N urse 49 8 8
T e c h n ic ia n 6 11
O th e r 4 7
Table 1. P ro v inc ia l R e sponse  R ate to  th e  Q u e s tio n na ire
Province/territory
No. of
respondents
No.
surveyed
Response 
rate, %
A tla n tic  p ro v in ce s 27 36 75
Q uebec 55 119 46
O ntario 106 143 74
M an itoba 13 16 81
S aska tchew an 16 17 94
A lb e rta  and N W T 23 23 100
B ritish  C o lu m b ia 44 50 88
Canada 2 8 4 4 0 4 70
Table II. N u m b e r o f  B one B an ks  by P ro v ince
Province/territory
No. of 
bone banks
No. of
respondents
% of respondents 
with bone banks
A tla n tic  p ro v in ce s 7 27 26
Q uebec 11 55 20
O ntario 17 106 16
M an ito ba 2 13 15
S aska tchew an 4 16 25
A lb e rta  and N W T 13 23 57
B ritish  C o lu m b ia 6 44 14
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donors. Severe trauma, causing 
skin damage (such as major burns 
or multiple puncture wounds), is a 
contraindication for the same rea­
son. Chronic parenteral drug abus­
ers should also be excluded.
High-dose steroids administered 
for longer than 7 days increase the 
risk of infection and patients sub­
ject to this therapy should be ex­
cluded.
Other contraindications to dona­
tion are: a history of viral hepatitis 
or unexplained jaundice,1416-21-22 ve­
nereal disease,14'1648'21 tuberculosis, 
leprosy or other granulomatous dis­
ease,14-18-23 malaria,14'16 slow-virus 
diseases (e.g. Creutzfeldt-Jakob 
disease),16'21-24 rabies16-24'25 and 
AIDS.1625-28
Despite testing of donors for HIV 
antibody using enzyme immunoas­
say, HIV transmission has been re­
ported.26 Revisions were made to 
the American Association of Tissue 
Banks Standards for Bone Banking 
in January 1988.27 There has now 
been a confirmed case of the trans­
mission of AIDS by banked bone.28 
These reports led representatives 
from the American Association of 
Tissue Banks, the American Acade­
my of Orthopaedic Surgeons, the 
Food and Drug Administration and 
Centers for Disease Control to meet 
in August 1988 to make recommen­
dations for preventing HIV trans­
mission by bone transplantation. 
They are as follows: for donors of 
bone allografts, as well as other 
organ and tissue allografts, the as­
sessment of risks of HIV infection 
should include reviewing the do­
nor’s medical record, testing the 
donor for HIV antibody and inter­
viewing living donors. The inter­
view should consist of standardized 
questions that identify risks for HIV 
infection. The donor’s responses to 
these questions should be recorded 
on a form signed by the donor 
acknowledging that the recorded 
responses are correct. The complet­
ed form should be kept in the tissue 
bank with other records from the 
donor.
All living donors of bone should 
be retested at least 90 days after 
tissue procurement, and only bone 
from living donors negative for HIV 
antibody on this repeat testing 
should be distributed for transplan­
tation. Bone from donors not avail­
able for retesting, including cadav­
eric donors, should be used when 
bone from retested living donors is 
not available or is not appropriate 
for use in the anticipated surgical 
procedure.
Transferring noninfective disor­
ders. Any malignant lesion except 
basal cell carcinoma is a contraindi­
cation to bone donation.16 It has 
been shown that a tumour can be 
passed to a recipient in renal trans­
plants and these tumours can con­
tinue to grow and metastasize.29 
Inflammatory disease, such as rheu­
matoid arthritis, or ankylosing 
spondylitis, disease of unknown eti­
ology, metabolic bone disease and 
autoimmune disease are also con­
traindications to bone donation.16
In cases of death from unknown 
cause, a complete autopsy must be 
performed on potential donors. Fail­
ure to do so excludes them as 
donors because of the risk of occult 
disease.16
Other factors. Donor death from 
poisoning, and previous radiothera­
py to the tissues to be harvested are 
both contraindications.1621 Certain 
laboratory tests must be conducted
on potential donors and their bone. 
In addition to the tests for viral 
hepatitis, syphilis and AIDS, rhesus 
typing should be performed because 
of the risk of rhesus immunization 
from allograft bone.30 The American 
Association for Tissue Banking also 
recommends that ABO and tissue 
typing be performed for future as­
sessment of graft failures. Tissue 
should be cultured for aerobic and 
anaerobic bacteria and, in the case 
of cadaver retrieval, blood, urine 
and pleural fluid should be cul­
tured.
The age of the donor is impor­
tant if massive allografts are re­
trieved. Long bones from skeletally 
immature donors have open epiphy­
ses, and in bones from older pa­
tients with osteopenia, the intrinsic 
structural properties may be com­
promised. The age of the patient is 
not important if the retrieved bone 
is processed into chips or pow­
der.1516'31
Cadaver bone should be taken 
within 12 hours of death or 24 
hours if the body has been refriger­
ated since death. Implementing 
these criteria will minimize the risks 
of transmitting disease to recipi­
ents.
Procurement of Bone
There are two basic methods of 
procuring bone: sterile retrieval in 
an operating room using full aseptic 
technique and unsterile retrieval fol­
lowed by sterilization of the bone.
Table V. Current Screening Procedures Performed in Canada
No. of Proportion of
Screening for bone banks respondents, %
Malignancy 40 71
Infection 52 93
Toxic substances 26 46
Metabolic bone disease 29 52
Disease of unknown etiology 36 64
ABO blood group 15 27
Rhesus factor 14 25
Human immunodeficiency virus 19 34
Venereal disease 27 48
Hepatitis 31 55
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Methods of sterilization include 
boiling, autoclaving or treatment 
with /3-propriolactone, ethylene 
oxide or antibiotic solutions. These 
can either alter the bone’s biologic 
or biomechanical properties or re­
sult in the formation of toxic sub­
stances which must be removed 
from the bone before it is used.732 
Radiation sterilization has been rec­
ommended but also has a detrimen­
tal effect on bone.33 Ideally, bone 
should be retrieved using an aseptic 
technique to avoid the problems 
associated with sterilization.
At the time of procurement, cul­
tures must be taken, and after ca­
daver procurement a full autopsy 
must be performed to exclude oc­
cult diseases. Bone must be pack­
aged in a suitable sterile container 
in preparation for storage.541-14’16'31
Storage
Each of the three methods of 
storage has advantages and disad­
vantages. Canadian bone banks use 
either a regular or a deep freezer. If 
a regular freezer is used, some 
autolysis occurs, so the bone 
should not be kept longer than 6 
months.12 If a deep freeze is used, 
autolysis is reduced and bone can 
be kept longer; bone kept for over 2 
years in this way has been used 
successfully.14 The use of freeze­
drying has definite advantages — 
storage at room temperature, indefi­
nite shelf life and earlier transporta­
tion. The disadvantage of this meth­
od is the costly equipment required 
for the process.34-35 For most bone 
banks, the best method of storage 
is deep freezing to -7 0 °C  or be­
low. Close monitoring of the freezer 
temperature is required, a tempera­
ture-monitoring system linked to an 
alarm is recommended, and bone 
should be discarded if the freezer 
temperature rises above — 15°C.14 
Problems resulting from the an­
tigenicity of bone are not clear, and
much research in this area is in 
progress.36~43 No recommendations 
can be made at present in regard to 
tissue typing of bone grafts. There 
seems to be little doubt that fresh 
allograft causes a host immune re­
sponse,41-43 but in a study compar­
ing freeze-dried allograft to frozen 
allograft there was little difference 
in outcome.44 Freeze-drying may re­
duce the antigenicity of bone more 
than deep freezing, which in turn 
may be better than regular freez­
ing.42
Informed Consent
In the US, the Uniform Anatomi­
cal Gift Act45 authorizes donation 
by any person 18 years of age or 
older before death, and donation by 
next of kin after death.
Donation of bone from living do­
nors also requires consent,16-31 but 
we found that this is obtained in 
only 2% of Canadian bone banks. 
Any person who may receive allo­
graft bone should sign an informed 
consent preoperatively.16-31 Again, 
this is not routinely done in Cana­
da.
Record Keeping
Finally, it cannot be stressed 
enough that good record keeping is 
essential. All donor and recipient 
information must be recorded, to­
gether with information on date of 
retrieval, storage and use of the 
allograft. Feedback regarding infec­
tion, failure or other problems 
which may be associated with the 
allograft should be meticulously re­
corded.
It is also important that a physi­
cian be involved in the operation of 
every bone bank.
Summary
Our questionnaire showed that
many inadequacies exist in the op­
eration of Canadian bone banks. We 
have summarized the recommended 
guidelines for the successful and 
safe operation of a bone bank, and 
hope that this information will help 
to improve the quality of bone 
banking in Canada.
We thank Donna O'Brien, Drs. D.W.C. 
Johnston, M. Lavoie and L. Davis and 
Pauline McCormick for their help dur­
ing the preparation of this paper.
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SESAP VI Question
Item 300
The serum abnormality LEAST likely to occur during total parenteral 
nutrition (TPN) is an elevated
(A) aspartate amino transferase (SGOT)
(B) alkaline phosphatase
(C) alanine amino transferase (SGPT)
(D) gammaglutamyl transferase (GGT)
(E) bilirubin
For the incomplete statement above, select the one completion that is 
best of the five given.
For the critique of Item 300 see page 270.
(Reproduced by permission from SESAP VI Syllabus; Surgical Educa­
tion and Self-Assessment Program No. 6. For enrolment in the Surgical 
Education and Self-Assessment No. 6, please apply to the American 
College of Surgeons, 55 East Erie St., Chicago, IL 60611.)
236
Il
►
i
t
►
►
►
\
;
►
►
t
►
►
i
'
►
►
i
►
:
BOOK REVIEWS
continued from page 228
In spite of its shortcomings, this 
book goes a long way to fulfilling its 
goal of showing the surgical anatomy 
of the head and neck. It is beautifully 
produced with excellent illustrations, 
glossy paper, and printing that is clear, 
uncrowded and easy to read. Few other 
such books are available, and leafing 
through its pages is both enjoyable and 
generally edifying. This book will be 
well used by head and neck surgeons, 
otolaryngologists, plastic surgeons, 
general surgeons and neurosurgeons to 
some extent. For residents in these 
specialties it will help in preparing them 
for their operative experience. Institu­
tional libraries should obtain this book 
to permit senior students with develop­
ing clinical exposure an anatomical in­
sight into procedures they are being 
called upon to assist at and help them 
understand the anatomy from the view­
point of effective treatment.
Irving B. Rosen, MD, FRCSC, FACS
Ste. 445,
Mount Sinai Hospital,
600 University Ave.,
Toronto, Ont.
M5G 1X5
CURRENT OPERATIVE SURGERY: 
UROLOGY. Edited by A.R. Mundy. 
225 pp. Illust Balliere Tindall, Lon­
don; W.B. Saunders Company Canada 
Limited, Toronto, Ont., 1988. 
$145.25. ISBN 0-7020-1141-X.
This is yet another text on operative 
urologic surgery, and the author asks 
“why another?”. This book is devoted 
to newer techniques; it is not a com­
plete textbook since many well-estab­
lished procedures are not mentioned. 
The text is well written by recognized 
experts. Each of the excellent diagrams, 
which make up the numerous illustra­
tions, clearly demonstrates a stage in a 
procedure.
Two chapters make this text worth 
having — one is by Patrick Walsh on 
radical retropubic prostatectomy and 
the other by Richard Turner-Warrick 
on urethral stricture surgery. These are 
complete, detailed “how to do it” de­
scriptions of complex, infrequently per­
formed operations. They offer the sur­
geon expert advice on technical details 
and should be read before performing 
these procedures. There are also two 
chapters on pediatric urology and two 
on surgery for impotence.
This is a useful book for urologists 
because it provides expert advice on 
infrequently performed surgical proce­
dures. I highly recommend it.
Norman G. Futter, MB, FRCSC
Head o f Urology,
Ottawa General Hospital.
501 Smyth Rd.,
Ottawa, Ont.
K1H 8L6
REOPERATIVE ARTERIAL SUR­
GERY. Edited by John J. Bergan and 
James S.T. Yao. 620 pp. Illust. Grune 
& Stratton, Inc., Orlando, Fla.; W.B. 
Saunders Company Canada Limited, 
Toronto, 1986. $147.50. ISBN
0-8089-1789-7.
In the last 30 years, great advances 
have been made in vascular surgery. 
The natural history of both untreated 
and treated disease has been recog­
nized. With experience, surgeons have 
learned that reoperative arterial surgery 
is now less a problem of technical 
failure and more a problem of the 
progression of the distal disease proc­
ess. This is why this multiauthored 
book is welcome.
The editors have collected papers 
from authors who are experts and write 
from personal experience. The book 
succeeds in covering basic science con­
siderations, including an excellent chap­
ter on smooth-muscle-cell proliferation. 
Standardized reporting of arterial re­
construction, an area that has required 
addressing, is the subject of a well-writ- 
ten chapter; its recommendations will 
help us evaluate our own results and 
those of others. The use of computed 
tomography and duplex scanning in 
arterial reconstruction are well covered, 
and graft thrombosis and its relation to 
hematology, especially platelet function, 
are discussed. A major gap in the book 
is that there is little on heparin-induced 
thrombocytopenia. Good insight is 
given into causes and treatment of graft
failure and, in particular, the infected 
graft, a devastating complication of vas­
cular surgery. In-situ bypass is a rela­
tively new procedure with a definite 
learning curve, because problems have 
been common in early experience with 
this technique. The postoperative prob­
lems of valve cusps and fistulas are 
described in detail since the authors of 
this section have one of the largest 
experiences with this procedure. Al­
though the area of repeat surgery is 
well covered, a chapter on when not to 
operate or to perform amputation as a 
primary procedure in patients with end- 
stage vascular disease and including 
cost-benefit analysis would have been 
helpful. The chapters on special prob­
lems in reoperative surgery, including 
recurrence of renal artery stenosis, ar­
terial trauma and thoracic outlet syn­
drome, are informative. Recurrent vas­
cular insufficiency is extensively cov­
ered, and this section gives more in­
sight, and perhaps more controversy, 
into the natural history of the treated 
disease.
Overall, this is an excellent book 
with few limitations; it should be in the 
library of all residents and surgeons 
who do vascular surgery.
F.M. Ameli, MB, ChB, FRCS, FACS, 
FRCSC
Ste. 313,
E.K. Jones Building,
The Wellesley Hospital.
160 Wellesley St. E,
Toronto, Ont.
M4Y 1J3
DERMATOLOGIC SURGERY. Princi­
ples and Practice. Edited by Randall K. 
Roenigk and Henry H. Roenigk, Jr. 
1431 pp. Illust. Marcel Dekker, Inc., 
New York, 1989. $150.00 (US). ISBN 
0-8247-7926-6.
This multiauthored text is divided as 
follows: 7 chapters each on basic surgi­
cal principles and standard dermatolog­
ic surgical procedures, 3 on advanced 
dermatologic surgical procedures, 7 on 
regional dermatologic surgery, 14 on 
surgical treatment of skin disease, 4 on
continued on page 286 
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Activity against a great majority of significant 
pathogens — for most patients, appropriate 
bactericidal coverage with single-agent 
antibiotic: PRIMAXIN® i.v.
Clinical efficacy — Kager and Nord evaluated 
164 patients with intra-abdominal infections 
and observed 91% cure or improvement.1
Good tolerability profile — similar to cefazolin. t  Avoids the potential nephrotoxicity 
or ototoxicity experienced with the 
aminoglycosides.
No cross-resistance has been observed between 
imipenem and other beta-lactam antibiotics.3
PRIMAXIN® I.V. is not active against Corynebacterium group JK,
Fusobacterium varium, Mycobacterium spp., Chlamydia spp., Streptococcus 
faecium, Pseudomonas maltophilia, and some strains of: P. cepacia,
P. pseudomallei, methiciilin-resistant staphylococci, and Flavobacterium spp.
1. Kager, L., Nord, C.E.: Imipenem/cilastatin in the treatment of intra­
abdominal infections: A review of worldwide experience, Rev Infect Dis 
7(suppl 3): S518-S521, July-August 1985.
2. Calandra, G.B., Ricci, F.M., Wang, C., Brown, K.R.: Safety and tolerance 
comparison of imipenem/cilastatin to cephalothin and cefazolin,
J Antimicrob Chemother 12 (suppl D): 125-131,1983.
3. Quinn, J.P. et al.: Resistance to imipenem in Pseudomonas aeruginosa:
Clinical experience and biochemical mechanisms, Rev Infect Dis 10(4):
892-898, July-August 1988.
Monotherapy with
■SI PRIMAXIN* i.v.(imipenem and cilastatin sodium for injection)
A BETTER CHOICE THAN 
AMINOGLYCOSIDE COMBINATIONS 
FOR EMPIRIC THERAPY OF MANY 
INTRA-ABDOMINAL INFECTIONS
t  Please consult M onograph for full details on adverse reactions
®  Trademark Merck Sr Co,, Inc./Merck Frosst Canada Inc., R.U.
TEN-89-CDN-2164-JA PAAB
For prescribing information see page 290
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Physical Stability of a Total Nutrient Admixture for Total Parenteral Nutrition
Mervyn Deitel, MD, FRCSC;*t Lloyd C. Smith, MD, FRCSC;* Karen L. Friedman, BSc;t 
Peter J. Lea, PhD;$ David J.W. Grant, DPhil;§ Hudson K.H. Giang, MD;*
Battista Calvieri;$ Joseph Go, BSc;§ Toan B. To, MD*
The stability of a total nutrient admixture (TNA) has been postulated to be less than 
7 days in refrigerated storage. When a TNA destabilizes, lipid particles coalesce and 
enlarge. Liposomes larger than 6 pm can obstruct pulmonary capillaries. A TNA 
containing 1500 ml of 7% Vamin, 1000 ml of 50% dextrose and 500 ml of 10% 
Intralipid, including the usual electrolytes, minerals and vitamins, was studied. 
Liposome size was measured in the original Intralipid and the TNA at intervals up 
to 14 days at 4°C followed by 2 days at 22°C. There was a small increase in 
liposome size up to 16 days. However, the number of particles larger than 6 /am was 
insignificant (by light microscopy, 3.9 ± 2.4 [± SD] per 20 high-power fields; by 
Coulter counter, 99.8% smaller than 1.9 /jm, with 0% larger than 6 /xm; and by 
electron microscopy, 100% smaller than 2.0 ftm). The osmolality and pH of the TNA 
were 1472 ± 31 mOsm/kg and 5.5 ± 0.1 respectively (mean ± SD), with no 
significant change during the study times. The authors concluded that this TNA 
remains physically stable when refrigerated for 14 days and at room temperature for 
a further 2 days.
II a ete postule que la stability des melanges nutritifs complets (MNC) ne depasse 
pas 7 jours quand ceux-ci sont conserves au refrigerateur. Quand un MNC devient 
instable, les particules lipidiques s’unissent par coalescence et augmentent de taille. 
Des liposomes plus grand de 6 peuvent obstruer les capillaires pulmonaires. On 
a etudie un MNC renfermant 1500 ml de Vamin a 7%, 1000 ml de glucose a 50% et 
500 ml d’lntralipide a 10%, et comprenant les electrolytes, mineraux et vitamines 
habituels. La taille des liposomes a ete mesuree dans la solution d’lntralipide 
d’origine et dans le MNC, a divers intervalles jusqu’a concurrence de 14 jours 
lorsque conserves a 4°C, suivi par 2 jours a 22°C. On a observe une legere 
augmentation de la taille des liposomes apres 16 jours. Neanmoins, le nombre de 
particules de plus de 6 gm etait insignificant (au microscope optique, 3.9 ± 2.4 [± 
ET] par 20 champs a forte puissance; au compteur Coulter, 99.8% avaient plus petit 
de 1.9 /xm avec 0% plus grand de 6 /xm; et au microscope electronique, 100% avaient 
plus petit de 2.0 /xm). L’osmolalite et le pH du MNC etaient, respectivement, de 
1472 =t 31 mOsm/kg et de 5.5 ± 0.1 (moyenne ± ET) et il n’y a pas eu de 
changement significatif durant l’etude. Les auteurs concluent que ce MNC demeure 
physiquement stable lorsqu’il est refrigere pendant 14 jours, puis conserve a la 
temperature embiante pendant 2 autres journees.
From the *Department o f Surgery, fDepartment o f  Nutritional Sciences, fDepartment o f  
Anatomy and §Department o f  Pharmacy, University o f Toronto and St. Joseph’s Health Centre, 
Toronto, Ont.
Presented at the 11th annual meeting o f the Canadian Association o f General Surgeons, held in 
conjunction with the 57th annual meeting o f the Royal College o f  Physicians and Surgeons o f  
Canada, Ottawa, Ont., Sept. 25, 1988
Accepted for publication Dec. 5, 1988
Reprint requests to: Dr. M. Deitel, St. Joseph's Health Centre Research Foundation, 30 The 
Queensway, Toronto, Ont. M6R 1B5
Conventional intravenous nutri­tion has been given as a solu­
tion of amino acids combined with 
dextrose and a separate line deliver­
ing a lipid emulsion. This technique 
was unsatisfactory because of the 
difficulties in managing two sepa­
rate administration systems. The 
first clinical use of a single solution 
containing all the necessary daily 
nutrients in one silicone rubber bag 
was described by Solassol and col­
leagues,1 in 1976. Since then, the 
total nutrient admixture (TNA) sys­
tem has become popular in Europe, 
but it has been slow to gain accep­
tance in North America.
Use of the TNA system in North 
America became possible when eth­
ylene vinyl acetate bags became 
available, because they contain no 
toxic plasticizer. Before this, the 
TNA had to be put in polyvinyl 
chloride bags, which contain di-2- 
ethylhexyl-phthalate (DEHP); the 
DEHP plasticizer is dissolved by 
lipid and has been implicated as a 
cause of toxicity in animals and 
neonates.2
The use of an “all-in-one” system 
has obvious advantages: there is 
less manipulation of the infusion 
system and a lower potential for 
contamination, nursing time is de­
creased, as is the number of tubings 
and pumps, patient mobilization is 
easier, it is a simpler system for 
home TPN and it is cost saving. 
The disadvantage of the system is 
that the components are in a deli­
cate balance. If the relative concen­
trations of the involved constituents
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are not within certain limits, large 
lipid droplets may form. Liposomes 
greater than 6 /am entering the 
circulation have been shown to ob­
struct pulmonary capillaries.3 Natu­
rally occurring chylomicrons mea­
sure 0.5 to 1.0 nm in diameter. The 
critical diameter of the liposomes in 
a TNA is between 6 and 15 ^m, as 
liposomes 15 or larger will be 
removed by the standard “in-line” 
filter.
The stability of a TNA is there­
fore measured by the ability of the 
liposomes to remain dispersed with­
in the water phase. The time limit 
on the stability of a TNA has been 
suggested to be less than 7 days.4 1 
The purpose of this study was to 
find out how long the TNA remains 
stable while in refrigerated storage.
the Coulter counter were used to 
gauge liposome size. The studies 
were performed on the TNA at 0 
hours, after 2 days at 22°C (room 
temperature), after 7 days at 4°C 
(refrigerator storage) followed by 2 
days at 22°C and after 14 days at 
4°C followed by 2 days at 22°C. 
(The 2 days at room temperature
correspond to patient delivery time.) 
The studies were also performed on 
standard Intralipid at 0 hours.
Results
On direct observation, we sought 
creaming, which indicates the for-
■ 3 '
Method
The TNA studied consisted of 
1500 ml of 7% Vamin (KabiVitrum, 
Sweden), 1000 ml of 50% dextrose 
and 500 ml of 10% Intralipid (Kabi­
Vitrum, Sweden). Daily require­
ments of electrolytes, trace ele­
ments and vitamins were incorpo­
rated into the solutions (Table I).
To evaluate the stability of the 
TNA, visual observation, light mi­
croscopy, electron microscopy and
T a b le  1. C o m p o s it io n  o f  th e  T o ta l N u trien t
A d m ix tu re
V a m in -N  7% , m l 1500
D e x tro se  5 0 % , m l 1 000
In tra lip id  10% , m l 5 0 0
S o d iu m  c h lo r id e , m m o l 40
P o ta s s iu m  p h o sp h a te , m m o l 24
M a g n e s iu m  s u lfa te , m m o l 10
C a lc iu m  g lu con a te , m m o l 4 4
M V I-1 2  (U S V ), m l 10
H eparin , U 2 0 0 0
Iro n  d e x tra n , m m o l 0 .036
M T M A  (tra c e -4 , IM S ), m l 2
R a n itid in e , m g 190
T o ta l v o lu m e , m l 3 1 0 0
M V I =  M u lt i-V ita m in  In fu s io n , U S V  =  U .S.
V ita m in s  Inc., M T M A  = m u lt ip le  trace
m e ta l a d d itiv e , IM S  =  In te rn a tio n a l M ed ica-
t io n s  S y s te m s .
FIG. 1. Light microscopy. Two larger liposomes each measured 2 jtm, and were 
among hundreds of tiny fat droplets, fraction of micrometer in size (X 1000).
FIG. 2. Scanning electron photomicrograph (day 16) shows increase in particle 
diameter to mean of 0.513 /um (range from 0.223 to 0.803 nm) (X 15 000).
CJS, VOL. 32. NO. 4. JU LY 1989 241
DEITEL, ET AL.
mation of a layer of aggregates at 
the admixture surface. No creaming 
was noted in any of the solutions at 
any of the study times.
Light microscopy was used at 
1000 X magnification (Fig. 1). The 
stage and eyepiece micrometer 
scales were used for measurement. 
Liposomes of diameter greater than 
5 ^m were found at a rate of 2 /20  
high-power fields (HPF) at 0 hours, 
with a maximum of 6 /2 0  HPF at 
16 days, and a mean (± SD) of 3.9 
± 2 .4 /20  HPF over the study times 
to 16 days. These rare liposomes 
were among thousands of non- 
measurable ones which were seen 
to be a fraction of a micrometer in 
size. The largest liposome observed 
measured 15 jun.
Electron microscopy revealed 
that particle size increased up to 16 
days (Figs. 25 and 3). However, no 
liposomes exceeding 2 /nm in diame­
ter were found. Mean (± SD) fat- 
particle size at 16 days was 0.5 ± 
0.3 /um (Fig. 4).
The Coulter counter similarly 
demonstrated that liposome size in­
creased up to 16 days. However, 
99.8% of liposomes remained less 
than 1.9 /urn in diameter, with none 
greater than 6 /rm (Table II).
The mean pH was 5.5 ± 0 .1  and 
the mean osmolality 1472 ±  31 
mOsm/kg (Table III). There was a 
trend toward a very slight decrease 
in pH and increase in osmolality 
with time, but neither was statisti­
cally significant.
Discussion
The main problem with the TNA 
is maintaining the lipid in solution. 
Phospholipid has been added to the 
lipid to act as an emulsifying agent. 
The emulsifying agent serves as a 
surface film and orients its polar 
(hydrophilic) end at the liposome 
surface and its nonpolar (hydropho­
bic) end in the interior of the lipo-
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some. The fat droplets normally 
repel each other because of a nega­
tive charge (zeta potential) on their 
surface. Thus, the emulsifier acts as 
a mechanical and electrical barrier 
to coalescence.6
Changes in the pH of the solu­
tion will affect the ionization of the 
emulsifying agent. These effects 
occur at the hydrophilic end of the
molecule. As pH decreases, the elec­
trical charge of the emulsifying 
agent is lost and the repulsive 
forces are decreased.3 A total loss of 
repulsive force would occur at a pH 
of approximately 2.5.7
Dextrose in solution is acidic and 
can markedly decrease the pH of 
lipid emulsions, thereby destabiliz­
ing the TNA. Aggregation (floccula-
FIG. 3. Transmission electron micrographs (day 16) substantiated variations found 
in particle size. Because transmission electron microscopy uses ultrathin section 
(70 nm) which slices liposomes at various levels, scanning electron micrographs 
were used for accurate measurement of diameters (X 45 000).
FIG. 4. Mean diameter of liposomes (±  SD) in TNA at various study times after 
storage at 4°C and 22°C. Control Intralipid is represented by hatched bar at left. 
Interestingly it has larger liposome diameter but less variation in size than freshly 
made up TNA.
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Table II. Population Distribution of Fat Particles Analysed by the Coulter Counter TA II Over 16 Days
Percent population of particles
Channel
no.
Size,
^m*
Days at 4°C 
22°C
0
0
0
2
7
0
7
2
14
0
14
2
1 0.60 0.00 0.00 0.00 0.00 0.00 0.00
2 0.76 77.13 76.90 81.71 90.32 82.24 83.61
3 0.95 16.58 16.56 14.55 7.25 14.07 13.39
4 1.20 4.15 4.39 2.58 1.61 2.47 2.12
5 1.51 1.39 1.42 0.78 0.51 0.77 0.59
6 1.90 0.49 0.48 0.25 0.19 0.28 0.19
7 2.40 0.16 0.16 0.08 0.08 0.10 0.06
8 3.02 0.06 0.06 0.03 0.03 0.03 0.02
9 3.81 0.03 0.02 0.01 0.01 0.01 0.01
10 4.80 0.01 0.01 0.00 0.00 0.01 0.00
11 6.05 0.00 0.00 0.00 0.00 0.00 0.00
12 7.62 0.00 0.00 0.00 0.00 0.00 0.00
13 9.60 0.00 0.00 0.00 0.00 0.00 0.00
14 12.10 0.00 0.00 0.00 0.00 0.00 0.00
15 15.24 0.00 0.00 0.00 0.00 0.00 0.00
16 19.20 0.00 0.00 0.00 0.00 0.00 0.00
'Size indicates the upper threshold of each channel, measuring all liposomes larger than the previous channel.
Table III. pH and Osmolality of the Total Nutrient Admixture
Days at 4°C 0 0 7 7 14 14
22°C 0 2 0 2 0 2
pH 5.5 5.4 5.6 5.6 5.6 5.5
Osmolality, mOsm/kg 1420 1466 1465 1510 1493 1483
tion) of liposomes creates larger 
droplets which rise and coalesce, 
leading to separation of the emul­
sion. Electrolytes are destabilizing if 
added directly to a lipid emulsion. 
When added in the TNA, cations 
will neutralize the negative charges 
of the liposomes, causing a de­
crease in repulsive forces and ag­
gregation. This reaction is in­
creased dramatically with the diva­
lent cations, such as calcium and 
magnesium.3
The amino acids have a stabiliz­
ing effect on the liposomes6 by 
acting as a buffer which protects 
the pH of the solution. Also, the 
amino acids are thought to adsorb 
to the liposome-water interface, 
thereby increasing the mechanical 
barrier. The trace elements do not 
destabilize TNA solutions.8 The po­
tentially delicate balance of a TNA 
demands that different combina­
tions of the essential constituents 
be tested to ensure that the solution 
is stable.
Conclusion
From our findings, we conclude 
that the TNA system using 7% 
Vamin, 50% dextrose and 10% In­
tralipid, with electrolytes, vitamins 
and minerals, is stable with respect 
to liposome aggregation for at least 
14 days at 4°C and a further 2 days 
at 22°C.
We thank Judy Chong, Albert Chaiet, 
Fred Harris, Sigmund Krajden and 
Milan Fuksa and the Department of 
Photography of St. Joseph's Health 
Centre for their valuable assistance.
Addendum
In subsequent studies, in which 
we used 10% FreAmine, 50% dex­
trose and 10% Soyacal, we found 
that the admixture remained stable 
for 28 days at 4°C followed by 2 
days at 22°C.
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Comparison of Marlex and Gore-tex to 
Repair Abdominal Wall Defects in the Rat
John L. Murphy, MD, FRCSC;* Joel B. Freeman, MD, FRCSC;t Paul G. Dionne, MD, FRCPC$
Marlex and Gore-tex, two prosthetic materials used to close abdominal wounds, were 
compared with respect to strength and adhesion formation. A 2.5 X 3.5-cm 
full-thickness area of abdominal wall was excised in 32 CD rats. The defect was 
repaired using identically sized patches of Marlex or 1-mm Gore-tex, determined by 
alternate assignment, and sutured with continuous 4-0 Gore-tex. Adhesion 
formation was graded at necropsy and recorded photographically in each animal.
The mean adhesion index (none = 0, maximal = 4) was 1.37 ±  0.12 and 2.62 ± 
0.12 (mean ± SEM) for Gore-tex and Marlex groups respectively (p < 0.005, 
unpaired f-test). A template was used to fashion 2-cm coronal strips of abdominal 
wall for tensile-strength testing. The relative strengths were 2.67 ±  0.14 and 3.02 
±  0.16 kg/cm  (mean ± SEM) for the Gore-tex and Marlex groups respectively (NS). 
Histologically, there were more epithelioid giant cells and less collagen formation in 
the Gore-tex group. Abdominal wall reconstruction with Gore-tex resulted in wound 
strength equal to that of Marlex and fewer adhesions. Gore-tex is preferred when 
prosthetic material and viscera are in close proximity.
Les fibres Marlex et Gore-tex, deux materiaux prothetiques utilises pour refermer 
les plaies abdominales, ont ete companies pour leur resistance et leur propension a 
former des adherences. On a excise chez 32 rats CD un lambeau pleine epaisseur de 
2.5 X 3.5 cm de la paroi abdominale. La breche fut refermee a l’aide de pieces de 
dimensions identiques, en alternant Marlex et Gore-tex de 1 mm, suturees avec du 
Gore-tex 4-0 continu. Pour chaque animal, la formation d’adherences fut cotee a 
l’autopsie et enregistree a l’aide d’un appareil photographique.
L’index moyen d’adherence (aucune =  0, maximum = 4) a ete de 1.37 ± 0.12 et 
de 2.62 ± 0.12 (moyenne ± erreur type), respectivement, pour les groupes Gore-tex 
et Marlex (p < 0.005, test t pour valeurs non appariees). Un gabarit fut utilise pour 
fabriquer des bandes de 2 cm de paroi abdominale en vue d’en mesurer la force de 
tension. Les resistances relatives ont ete de 2.67 ± 0.14 et 3.02 ± 0.16 kg/cm 
(moyenne ± erreur type), respectivement, pour les fibres Gore-tex et Marlex (NS). A 
l’histologie, on a observe plus de cellules epitheloi'des geantes et moins de formation 
de collagene dans le groupe Gore-tex. La reconstruction de la paroi abdominale a 
l’aide de fibre Gore-tex a permis d’obtenir une resistance de plaie egale a celle de la 
fibre Marlex mais avec moins d’adherences. Le Gore-tex est preferable quand le 
materiel prothetique et les visceres sont tres rapproches.
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A bdominal wall defects that can­not be closed primarily may 
require patching with prosthetic 
material. The major concerns when 
using prosthetic materials are infec­
tion, hernia recurrence, wound 
strength, bowel adherence, fistula 
formation and ease of handling. The 
ideal characteristics for these pros­
thetic materials were clearly defined 
in 1953 by Clarke and associates.1 
Polypropylene mesh (Marlex), the 
primary material utilized in this 
clinical situation, has given accept­
able results.23 However, we have 
noted dense adhesions between 
Marlex and abdominal viscera. 
These adhesions present serious 
technical problems, particularly if 
repeat laparotomy is required. Gore- 
tex (W.L. Gore & Associates, Flag­
staff, Ariz.) is a polytetrafluoro- 
ethylene microporous material used 
extensively for vascular conduits. A 
Gore-tex soft-tissue patch has been 
introduced for repairing abdominal 
wall defects. The purpose of the 
present study was to compare Gore- 
tex and Marlex with respect to 
strength and adhesion formation.
Methods
In 32 CD rats weighing between 
435 and 718 g, anesthesia was 
induced with 5% halothane and 
maintained with 1% to 2% halo­
thane by mask. The abdominal hair 
was clipped and the abdomen pre­
pared with iodine solution. Under 
sterile conditions, a 4.0-cm midline 
incision was made with approxi­
mately 3 cm of undermining on 
each side. Small bleeders were con­
trolled with pressure. A full-thick-
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ness abdominal wall defect was de­
lineated with a 3.0 X 3.5-cm stain­
less steel template and a sterile 
marking pen. The outlined area was 
then excised. Each rat was alter­
nately assigned to receive precut 
Marlex or Gore-tex (1 mm thick). 
The sterile Marlex or Gore-tex was
I . \
FIG. 1. Diagram showing incision and 
orientation of specimen as removed 
from each rat at necropsy.
FIG. 2. Strength testing on rat no. 19, 
experiment rat no. 6. Tracing depicts 
force and deflection point (arrow) from 
which strength of interface is calculat­
ed.
placed in a consistent orientation 
and then sutured, beginning in the 
midline caudally with continuous 
4-0 tapered Gore-tex. The wound 
was irrigated with Kefzol (Eli Lilly 
Canada, Inc., Scarborough, Ont.), 
500 mg in 500 ml of 0.9% saline. 
The wound was closed with inter­
rupted subcutaneous sutures of 4-0 
coated Polyglactin and a continu­
ous subcuticular 4-0 monofilament 
polypropylene suture. The rats were 
then given 1.5 ml of Ringer’s lac­
tate solution subcutaneously. They 
were marked for identification and 
housed in individual cages. They 
were fed laboratory food and water 
and inspected daily.
After 107 to 140 days, the ani­
mals were again anesthetized with 
5% halothane and killed with an 
intra-cardiac injection of sodium 
thiopental. A laparotomy was per­
formed through a U-shaped incision 
based caudally on the abdominal 
wall (Fig. 1). The findings were 
documented with numbered photo­
graphs.
Adhesions were graded as fol­
lows: 0 = none; 1 = minimal, 
requiring only gentle gauze dissec­
tion; 2 = moderate, gentle dissec­
tion augmented with limited sharp 
dissection; 3 = extensive sharp dis­
section required.
A central 2-cm strip of the patch 
and attached muscle was separated 
leaving the cranial and caudal ends 
for pathological examination (Fig. 
1). The central strip was placed in a 
thermal container filled with chilled 
normal saline. The cranial and cau­
dal portions of the sample were 
fixed in 10% formalin.
The tensile strength of the cen­
tral strips was tested twice within 4 
hours of harvesting on a Model 
TTLD Instron Tensiometer (Instron 
Corp., Canton, Mass.). The tensiom­
eter was calibrated and run with a 
cross-head speed of 5 cm/min and 
a chart speed of 10 cm/min. The 
tissue strips were tested at the left 
and right junctions (Fig. 1). They 
were held in place with a jaw-clamp 
placed on the muscle and the patch. 
The breakaway strength was calcu­
lated from the deflection point doc­
umented on the graph paper (Fig. 
2). The location of the break was 
documented as prosthetic, interface 
or muscle wall. The width of the 
strip was measured. The results 
were calculated as kilograms of 
traction required for the width in 
centimetres of the central strip. His­
tologic studies included hematoxy­
lin and eosin staining and examina­
tion under polarized light to assess 
collagen formation and orientation.
This protocol was reviewed and 
approved by the Animal Care Com­
mittee of the Health Sciences Cen­
tre, University of Ottawa.
Results
There were 10 early seromas in 
the Gore-tex group; they resolved 
within 3 weeks without interven­
tion. One rat in the Marlex group 
had a mild cellulitis which resolved 
spontaneously.
The adhesion index in the Gore- 
tex group was 1.37 ± 0.12 (mean 
± SEM) compared with 2.62 ± 
0.12 in the Marlex group (p < 
0.005, Table I). Two strips could 
only be tested once for strength due
Table 1. Adhesion Formation and Strength Testing (Means ± SEM)
Adhesion index Strength, kg/cm
Group (n =  16) (n =  31)
Marlex
Gore-tex
2.62 ± 0.12— i *
1.37 ± 0 .1 2 — 1
3.02 ± 0 .1 6 — , .  
2.67 ± 0 .1 4 — |T
*p < 0.005, fp  > 0.05 (unpaired t-test). 
Muscle failures (jT =  3.21 kg/cm).
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to inadequate tissue. The point of 
disruption was 3.02 ± 0.16 kg/cm 
(mean ± SEM) for Marlex versus 
2.67 ± 0.14 kg/cm for Gore-tex 
(NS). In the Marlex group, 15 strips 
separated in the muscle rather than 
at the muscle-prosthetic interface.
The samples were studied under 
light microscopy and polarized light 
microscopy. In the Marlex group, 
there were chronic inflammatory 
cells, fibroblasts and rare giant 
cells. Fine collagen fibres were po­
larized in proximity to the Marlex 
strands and frequently appeared to 
encircle them. The reaction was 
diffuse and did not appear to spare 
the Marlex material. In the Gore-tex 
group there was a focal reaction 
predominantly of giant cells. The 
fibroblasts were less numerous and 
the polarization examination sug­
gested less collagen (Figs. 3 and 4).
Discussion
Little criticism can be made of 
the efficacy and strength of Marlex 
under a wide variety of clinical 
conditions.2-5 The purpose of this 
study was to assess adhesion forma­
tion (the major disadvantage of 
Marlex), which may lead to bowel 
obstruction or fistula formation. We 
postulated that Gore-tex might 
offer certain advantages in this re­
gard. At the same time, we thought 
it crucial to measure the relative 
incorporated strength of Gore-tex 
compared to Marlex.
The scoring system used to as­
sess the degree of adhesion forma­
tion was perhaps oversimplified. On 
the other hand, it translates easily 
to clinical situations. Jenkins and 
colleagues6 suggested that there 
was no difference in adhesion for­
mation between the two materials. 
However, only two of the eight rats 
in their 8-week Gore-tex group sur­
vived to be analysed. Sher and 
associates7 found that omentum re­
acted to both materials in a similar 
fashion intra-abdominally at 2 and 4 
weeks. Their results suggested en­
casement of both materials up to 8 
weeks. Our data at 14 weeks with 
16 animals in each group showed 
that the adhesions in the Gore-tex 
group would be more easily handled 
at repeat laparotomy.
Strength is commonly assessed 
by measuring bursting pressure8 or 
testing with a tensiometer.9 We 
elected to use the latter. After 60 
days, bursting-pressure testing 
tends to rupture sites other than 
the hernia repair, such as the ingui­
nal canals.6810 Jenkins and associ­
ates6 also used tensiometer testing.
Their data were inconclusive and 
their groups small, due to a high 
rate of dehiscence. Our data failed 
to show significant strength differ­
ences between Gore-tex and Marlex. 
Both materials formed secure inter­
faces with rat abdominal wall. How­
ever, there is potential error in this 
interpretation. In 15 rats from the 
Marlex group, disruption occurred 
in the actual muscle rather than at 
the muscle-Marlex interface. The 
unproven assumption is that the 
interface in these strips was strong­
er. This suggests that Marlex may 
be stronger and more dependable 
than Gore-tex, but further experi­
mentation is required to prove this.
FIG. 3. Collagen formation in Marlex sample. Collagen fibres are enhanced when 
viewed under polarized light (right) (hematoxylin and eosin, original magnification 
X 40).
FIG. 4. Giant cell formation (arrow) in Gore-tex sample (hematoxylin and eosin, 
original magnification X 40).
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The histologic findings of more 
giant cells and less collagen in the 
Gore-tex group are important. Cal- 
nan11 suggested that giant cell for­
mation indicates tissue intolerance. 
A marked giant cell infiltrate may 
reflect instability of the surrounding 
tissue. In a recent review, John­
ston12 concluded that the function 
of the multinucleated giant cell was 
not clear. This cell is still consid­
ered a macrophage in the terminal 
stage of development as seen in 
granulomatous diseases. The factor 
interferon gamma, released from 
stimulated human T lymphocytes, 
may promote this development.13 
Sher and colleagues7 found that the 
material used did not influence the 
degree of giant cell infiltration 2 to 
8 weeks after Marlex or Gore-tex 
insertion. Increased giant cell prolif­
eration was a histologic feature in 
our rats implanted with Gore-tex. 
The long-term implications are be­
yond the scope of this paper. Elliott 
and Juler14 compared Gore-tex and 
Marlex and found that Marlex tend­
ed to be more distorted by dense 
scarring but that it lacked both 
focal adherence to muscle and a 
neofascia. We did not note these 
features. However, these authors’ 
data lend support to our hypothesis 
that Gore-tex may lack the strength 
that is commonly seen with Marlex. 
The early finding of a polymorpho­
nuclear infiltrate surrounding the 
material was similar in both groups 
in the study of Elliott and Juler.14 
The early findings were not re­
viewed in our study.
Clinical experience with both 
materials has been satisfactory. 
There was only one colonic fistula 
in 94 patients with Marlex implan­
tations noted in the follow-up peri­
od of recent reports.2' 4 Lewis3 made 
an effort to keep the material ex- 
trafascial. This technique was rec­
ommended by Hedderich and col­
leagues5 when Marlex is used in the 
septic abdomen. In the absence of
omentum they suggested that 
bowel be separated from the materi­
al daily to avoid dense adhesion 
formation. Some Marlex-related fis­
tulas may heal. Macmillan and Free­
man15 reported a case of gastrocu- 
taneous fistula which healed in the 
presence of Marlex used for a revi­
sion gastroplasty.
Experience with Gore-tex as an 
abdominal soft-tissue patch is limit­
ed. Bauer and colleagues16 reported 
reasonable results in 28 patients; 
the hernia recurrence rate was 11% 
and the infection rate was 7%. In 
the infected group there was a 
failure to demonstrate healing. The 
length of follow-up averaged only 
2.3 years.
Conclusions
In rat full-thickness abdominal 
defects, Gore-tex formed adhesions 
that were notably easier to dissect 
from underlying viscera than those 
formed by Marlex. This property 
would be ideal in situations where 
viscera and the prosthetic material 
must be in apposition. Gore-tex 
formed an interface with similar 
strength. However, the high per­
centage of muscle failures in the 
Marlex group suggests a stronger 
interface. The finding of less colla­
gen and increased giant cell forma­
tion may portend long-term failures 
with Gore-tex. This will require 
careful clinical follow-up. Gore-tex 
would seem to be best used in clean 
abdominal wounds in which omen­
tum cannot protect the underlying 
viscera from adhesion formation.
We thank Ms. Missa Davie and the staff 
of the Animal Care Unit, Health Sci­
ences Centre, University of Ottawa.
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BCefizox-
sterile ceftizoxime sodium
THERAPEUTIC CLASSIFICATION
Antibiotic
ACTION
In vitro studies indicate that the bactericidal action of ceftizoxime results from in­
hibition of cell-wall synthesis in aerobic and anaerobic gram-positive and gram­
negative organisms. In vitro, ceftizoxime shows a strong affinity for penicillin­
binding proteins la, lbs and 3 of E. coli.
INDICATIONS AND CLINICAL USES
CefizoxTM (sterile ceftizoxime sodium) may be indicated in the treatment of the 
infections listed below when caused by susceptible strains of the designated 
microorganisms:
LOWER RESPIRATORY TRACT INFECTIONS caused by Streptococcus sp. (includ­
ing S. pneumoniae but excluding enterococci); Klebsiella sp.; Proteus mirabilis; 
Escherichia coli; Haemophilus influenzae (including ampicillin-resistant strains); 
Staphylococcus aureus (including penicillinase-producing but excluding 
methicillin-resistant strains); Serratia sp.; and Enterobacter sp.
URINARY TRACT INFECTIONS caused by Escherichia coli; Staphylococcus epider- 
midis; Pseudomonas aeruginosa; Proteus mirabilis; Klebsiella sp.; Serratia 
marcescens; and Enterobacter sp.
Due to the nature of the underlying conditions which usually predispose patients to 
Pseudomonas infections of the urinary tract, a good clinical response accompanied 
by bacterial eradication may not be achieved despite evidence of in vitro sensitivity.
INTRA-ABDOMINAL INFECTIONS caused by Escherichia coli; Staphylococcus 
epidermidis; Streptococcus sp. (excluding enterococci); Klebsiella sp.; Bacteroides 
sp. (including B. fragilis); Peptococcus sp.; and Peptostreptococcus sp.
SEPTICEMIA caused by Streptococcus sp. (excluding enterococci but including S. 
pneumoniae)-, Staphylococcus aureus (excluding methicillin-resistant strains); 
Escherichia coli; Bacteroides sp. (including B. fragilis); Klebsiella sp.; and Serratia 
marcescens.
SKIN STRUCTURE INFECTIONS caused by Staphylococcus aureus (excluding 
methicillin-resistant strains); Staphylococcus epidermidis; Escherichia coli; 
Klebsiella sp., (including K. pneumoniae); Streptococcus sp. (excluding enterococci 
but including Group A B-hemolytic Streptococcus pyogenes); Proteus mirabilis; 
Serratia sp.; Enterobacter sp.; Bacteroides sp. (including B. fragilis); Peptococcus 
sp., and Peptostreptococcus sp.
BONE AND JOINT INFECTIONS caused by Staphylococcus aureus (excluding 
methicillin-resistant strains); Proteus mirabilis; Peptococcus sp.; and Pepto­
streptococcus sp.
Specimens for bacteriologic culture should be obtained prior to therapy in order to 
identify the causative organisms and to determine their susceptibilities to cefti­
zoxime. Therapy with CefizoxTM may be initiated before results of the susceptibility 
studies are known. However, modification of the treatment may be required once 
these results become available.
CONTRAINDICATIONS
CefizoxTM (sterile ceftizoxime sodium), is contraindicated in persons who have 
shown hypersensitivity to ceftizoxime or other members of the cephalosporin group 
of antibiotics.
WARNINGS
Before therapy with CefizoxTM (sterile ceftizoxime sodium) is instituted, careful 
inquiry should be made to determine whether the patient has had previous hyper­
sensitivity reactions to cephalosporins, penicillins, or other drugs. CefizoxTM 
should be given cautiously to penicillin-sensitive patients. Antibiotics, including 
CefizoxTM, should be administered with caution to any patient who has demon­
strated some form of allergy, particularly to drugs. If an allergic reaction to Cefi­
zoxTM occurs, its administration should be discontinued. Serious acute hyper­
sensitivity reactions may require epinephrine and other emergency measures. 
Pseudomembranous colitis has been reported with the use of CefizoxTM (and other 
antibiotics). Therefore, it is important to consider this diagnosis in patients adminis­
tered CefizoxTM who develop diarrhea.
Treatment with broad-spectrum antibiotics alters normal flora of the colon and may 
permit overgrowth of Clostridia. Studies indicate a toxin produced by Clostridium 
difficile is one primary cause of antibiotic-associated colitis.
Mild cases of colitis may respond to drug discontinuance alone. Moderate to severe 
cases should be managed with fluid, electrolyte and protein supplementation as 
indicated. When the colitis is not relieved by drug discontinuance or when it is 
severe, consideration may be given to the administration of oral vancomycin or 
other suitable therapy. Other possible causes of colitis should also be considered.
PRECAUTIONS
General: Transient elevations of BUN and serum creatinine have been observed in 
clinical studies. However, there is no other evidence that CefizoxTM (sterile cefti­
zoxime sodium) has produced alterations in renal function. Renal status should be 
periodically evaluated, especially in seriously ill patients.
Prolonged use of CefizoxTM may result in the overgrowth of nonsusceptible 
organisms including species originally sensitive to the drug. Careful observation of 
the patient is essential. If superinfection occurs during therapy, appropriate 
measures should be taken.
CefizoxTM should be administered with caution to individuals with a history of 
gastrointestinal disease, particularly colitis.
Impaired Renal Function: Since ceftizoxime is excreted primarily in the urine, 
patients with impaired renal function (i.e., creatinine clearance S1.32 mL/s or 
<79 mL/min) should be placed on a special dosage schedule recommended under 
DOSAGE AND ADMINISTRATION. Normal dosages in these individuals are likely to 
produce excessive serum concentrations of ceftizoxime.
Drug Interactions: The concomitant administration of some cephalosporins and 
aminoglycosides has caused nephrotoxicity. The effect of administering CefizoxTM 
concomitantly with aminoglycosides is not known.
Pregnancy: The safety of CefizoxTM in pregnancy has not been established. The 
use of CefizoxTM in pregnant women requires that the likely benefit from the drug 
be weighed against the possible risk to the mother and fetus. The pharmacokinetics 
of CefizoxTM in pregnant patients has not been investigated. Reproduction studies 
performed in rats and rabbits have revealed no evidence of impaired fertility or harm 
to the fetus caused by ceftizoxime. Animal reproduction studies, however, are not 
always predictive of human response.
Labour and Delivery: The safety and efficacy of CefizoxTM use during labour and 
delivery has not been investigated.
Nursing Mothers: Ceftizoxime is excreted in human milk in low concentrations 
(less than 4% of serum concentrations at 1 hour after dosing). The clinical signifi­
cance of this is unknown; therefore caution should be exercised if CefizoxTM is to 
be administered to a nursing woman.
Infants and Children: The safety of CefizoxTM in infants less than 6 months of age 
has not been established. In children six months of age and older, treatment with 
CefizoxTM has been associated with transient elevated levels of eosinophils, 
SGOT, SGPT and CPK (creatine phosphokinase). The CPK elevation may be related 
to intramuscular administration.
Elderly Patients: The elimination of ceftizoxime may be reduced due to an age- 
dependent reduction in renal function.
ADVERSE REACTIONS
CefizoxTM (sterile ceftizoxime sodium) is generally well tolerated.
Adverse
Reaction
Incidence
<1%
Incidence 
>1% but <5%
Hypersensitivity: Rash
Pruritus
Fever
Liver: Transient elevation of SGOT, 
SGPT and alkaline phosphatase
Blood: Neutropenia
Leukopenia
Thrombocytopenia
Transient eosinophilia
Thrombocytosis
Positive direct Coombs’ test
Renal: Transient elevation 
of BUN and creatinine
Local: Injection site: burning, cellulitis, 
phlebitis (with IV administration), 
pain, induration, tenderness, 
parasthesia
Genitourinary: Vaginitis
Gastro­
intestinal:
Diarrhea, Nausea, Vomiting, Pseudomembranous colitis
No disulfiram-like reactions have been reported with CefizoxTM
TREATMENT OF OVERDOSAGE
No case of acute overdosage has been reported to date; consequently there is no 
specific information available on symptoms or treatment. In cases of suspected 
overdosage, supportive therapy should be instituted according to symptoms. Serum 
ceftizoxime levels can be reduced by hemodialysis.
DOSAGE AND ADMINISTRATION
CefizoxTM (sterile ceftizoxime sodium) may be administered either intramuscularly 
or intravenously after reconstitution.
Dosage and route of administration should be determined by the condition of the 
patient, severity of the infection and susceptibility of the causative organism(s). The 
intravenous route may be preferable for patients with bacterial septicemia, or other 
severe or life threatening infections.
The usual course of treatment should be 7-14 days, and should normally continue at 
least 48 hours after evidence of bacterial eradication has been obtained. For 
B-hemolytic streptococcal infections, a minimum of 10 days of treatment is 
recommended.
DOSAGE
Adults: The recommended daily dosage of CefizoxTM is 1 to 12 grams admin­
istered in equally divided doses every 8 or 12 hours (see Table 1 below).
TABLE 1
Type of Infection Daily Dose 
(Grams)
Frequency and Route
Uncomplicated 
Urinary Tract
1 500 mg q12h, IV or IM
Other Sites 2-3 1 g q8h or q12h, IV or IM
Severe or 
Refractory
3-6 1 g q8h, IV or IM, to 
2g q8h orq12h, IVor IM*
Life-Threatening 9-12 3or4g  q8h IV
•When administering 2 g intramuscularly, the dose should be divided and injected 
into different large muscle masses.
Because of the serious nature of urinary tract infections due to Pseudomonas 
aeruginosa and because many strains are only moderately susceptible to CefizoxTM, 
higher dosage may be appropriate when urinary tract infections are caused by 
these organisms. Other therapy should be instituted if the response is not prompt.
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Adults with Impaired Renal Function: In patients in whom the creatinine clearance 
is 1.32 mL/s (79 mL/min) or less, the dosage of CefizoxTM must be reduced. Follow­
ing an initial loading dose of 500 mg to 1.0 g IM or IV, the maintenance dosing 
schedule presented in Table 2 should be followed in patients with reduced renal 
function.
TABLE2
Renal
Function
Creatinine 
Clearance 
mL/s mL/min
Less Severe 
Infections
Life-Threatening
Infections
Mild
Impairment
0.83-1.32 50-79 500 mg 
q8h
750 mg to 1.5 g 
q8h
Moderate to 
severe impairment
0.08-0.82 5-49 250 or 500 mg 
q12h
500 mg to 1.0 g 
q12h
Hemodialysis
patients*
0-0.07 0-4 500 mg q48h or 
250 mg q24h
500 mg to 1.0g 
q48h or 500 mg 
q24h
*ln patients undergoing hem odialysis no additional supplemental dosing is 
required. DOSING, HOWEVER, SHOULD  BE SCHEDULED  SO THAT THE PATIENT 
RECEIVES THE DOSE AT THE END O F  THE DIALYSIS. When started 24 hours after 
administration of 1 g of CefizoxTM, hem odia lysis has been shown to reduce serum 
levels by 50%.
When only the serum creatinine level is  available, creatinine clearance may be 
calculated from the following formulae (for patients 18 years and over only). The 
serum creatinine level should represent renal function at the steady state.
Males:
Creatinine Clearance Weight (kg) x (140 - age)
(mL/min) 72 x serum creatinine (mg/100 mL)
Creatinine Clearance 
(mL/s)
Weight (kg) x 140 - age)
49 x serum creatinine ( /xmol/L)
Females: 0.85 of the above values
Infants and Children: The following dosage schedule is recommended:
TABLE 3
Age Group Unit Dosage Frequency and Route
Infants (6 mo-2 yrs.), 
and 50 mg/kg IV or IM q6h or q8h, IVorIM
Children (2-12 yrs.)
The pediatric dosage should not exceed the maximum adult dosage for serious 
infections.
ADMINISTRATION
Intramuscular: The reconstituted so lution of CefizoxTM  should be injected well 
within the body of a relatively large muscle, such as the gluteus. When administer­
ing 2 g IM doses, the dose should be divided equally and then injected into different 
large muscle masses.
Intravenous: Injection (bolus): The reconstituted so lution of CefizoxTM should be 
injected slowly over 3 to 5 minutes, d irectly or through the tubing system by which 
the patient is receiving another com patib le intravenous solution. During adm inistra­
tion of the solution containing CefizoxTM, it is desirab le to temporarily discontinue 
administration of the other solution.
Intermittent or continuous infusion: The further diluted reconstituted solution of 
CefizoxTM should be administered over a 20 to 30 m inute period.
NOTE: CefizoxTM solutions should not be physica lly mixed with any other drug. 
There is a known incompatibility w ith am inoglycoside antib iotics. Therefore, they 
should not be physically mixed with CefizoxTM so lu tions nor administered at the 
same site.
PHARMACEUTICAL INFORMATION
CHEMISTRY
Trade Name: CEFIZOXTM 
Proper Name: Ceftizoxime Sodium
Chemical Name: Sodium (6R-[6°>, 7B(Z)]]-7 -[[(2 ,3 -d ihydro -2-im ino-4-th iazo ly l) 
(m ethoxyim ino)acetyl]am ino]-8-oxo-5-th ia-1-azabilcyclo[4.2.0] o c t-2 -e n e -2 -  
carboxylate
Structural Formula:
MN---------
hX J
n^ch. % A
, H  - i —
Molecular Formula: C i 3 H i 2 N 5 0 5 S 2 Na 
Molecular Weight: 405.38
Description: Ceftizoxime Sodium is a white to pale yellow  crystalline powder.
Composition: CefizoxTM via ls contain ceftizoxime sodium (expressed in terms 
of free acid). The sodium content o f each gram of CefizoxTM jS approximately 
60
mg (2.6 mEq sodium ion).
Solutions of CefizoxTM range from colourless to pale yellow, depending upon the 
diluent and volume used. The so lution should be d iscarded if it becomes cloudy. 
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CANADIAN ASSOCIATION OF GENERAL SURGEONS
Merck-Frosst Symposium: Complicated 
Intra-abdominal Sepsis of Biliary, 
Pancreatic and Colonic Origin
Moderator: N.V. Christou, MD, FRCSC*
Panelists: Ori D. Rotstein, MD, FRCSC;t Edward Bradley, III, MD;$
Paul Belliveau, MD, FRCSC, FACS§
Introduction (N.V. Christou)
Intra-abdominal sepsis accounts for 
a large proportion of hospital 
deaths in surgical patients. Much 
progress has been made in under­
standing the pathophysiology of the 
host-bacterial interaction and the 
contribution of new antibiotic regi­
mens and surgical drainage modali­
ties to the outcome of severe intra­
abdominal sepsis. This symposium 
addresses three main areas of life- 
threatening surgical sepsis: compli­
cated biliary tract sepsis, pancreatic 
sepsis and colonic and rectal perfo­
ration. The symposium is in a ques- 
tion-and-answer format, using actu­
al surgical cases [small type] to 
highlight the problems encountered 
in these conditions. Each panelist 
uses his own clinical and research 
experience as well as the consensus
from the literature in responding to 
these difficult questions. The panel­
ists were chosen because of their 
expertise in each problem area.
Complicated Biliary Tract 
Sepsis (O.D. Rotstein*)
A 62-year-old man had a right inguinal 
and umbilical hernia repair on Jan. 14, 
1988. Postoperatively, his abdomen be­
came distended and he had right upper 
quadrant pain. Ultrasonography showed 
a distended gallbladder with stones. A 
HIDA scan was consistent with acute 
cholecystitis. The patient was treated 
conservatively because of the previous
*Donna I. McRitchie, Department of 
Surgery, Toronto General Hospital, Uni­
versity of Toronto, helped substantially 
in the preparation of this portion of the 
symposium.
surgery. He was discharged home on 
Jan. 27, 1988. Elective cholecystectomy 
was scheduled 6 weeks later.
Dr. Christou: What is the value of 
"urgent” cholecystectomy in acute 
cholecystitis?
Dr. Rotstein: The relative benefit of 
immediate versus delayed cholecys­
tectomy for acute cholecystitis has 
been addressed frequently in the 
literature. One viewpoint1 holds 
that initial conservative therapy fol­
lowed by interval cholecystectomy 2 
to 3 months later is optimal. The 
advocates cite, as factors favouring 
delayed intervention, the low mor­
tality associated with interval chole­
cystectomy and the diagnostic un­
certainty and high risk associated 
with operation in the acute situa­
tion.
The advantages of early opera­
tion were shown in a randomized 
trial of 140 patients who received 
either early or delayed operation for 
acute cholecystitis.2 Although there 
was no difference in the death rate, 
total hospital stay was shortened 
(10.1 days versus 18.9 days), dura­
tion of fever was reduced and lost 
work days were lowered by 50% as 
a result of early intervention. One 
minor drawback of early operation 
in this and other studies2-4 is that 
wound infection occurs more fre­
quently. However, the overall mor­
bidity is substantially lower in the
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conjunction with the 57th annual meeting o f  the Royal College o f Physicians and Surgeons o f 
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group of patients having early oper­
ation if one considers those in 
whom conservative treatment fails 
(13% to 20%) or those who refuse 
operation once symptoms disap­
pear. Patients in the latter group 
risk serious complications with life- 
threatening ones developing in 15% 
to 28%.5
The technical difficulty of early 
operation is also cited as further 
justification for delay. However, ex­
perienced surgeons have found no 
difference in the level of difficulty 
between the two operations; con­
versely, junior surgeons have had 
more difficulties with early interven­
tion as measured by duration of 
operation and the frequency of op­
erations requiring “senior” assis­
tance.2 In the series of Jarvinen and 
Hastbacka,3 length of operation and 
frequency of minor operative com­
plications were equal in both 
groups.
In summary, the benefits of early 
cholecystectomy generally outweigh 
the risks (Table I6'9). Serious com­
plications of conservative therapy 
are avoided, there is no increase in 
mortality or serious morbidity and 
costs to both the system and the 
patients are minimized because hos­
pital stay and duration of incapaci­
tation are shortened. Finally, there 
is no risk of further complications 
developing in the interim between 
the acute attack and elective sur­
gery.
He underwent a cholecystectomy 6 
weeks later.
Dr. Christou: Should antibiotics be 
used prophylactically for elective 
cholecystectomy?
Dr. Rotstein: There are three major 
questions regarding prophylactic 
use of antibiotics for cholecystecto­
my: who should get them?, what 
drug should be used? and for how 
long should it be administered? An­
tibiotics should be administered
prophylactically to patients at high 
risk for postoperative wound infec­
tion. Chetlin and Elliott6 evaluated, 
retrospectively, 1421 biliary opera­
tions over a 5-year period. One- 
third of bile cultures were positive 
and septic complications were 40 
times more frequent in those who 
had positive cultures (infection rate 
1.3% in negative cultures versus 
46% in positive cultures). Certain 
clinical features were associated 
with a high degree of culture-posi­
tive bile. Conversely, in patients at 
low risk, the rate of culture-positive 
bile was only 17%. Of particular 
interest was the fact that infecting 
organisms were identical to the bili­
ary organisms in 37 of 39 cultures. 
The high overall rate of septic com­
plications in this series (16%) oc­
curred almost entirely in those pa­
tients with positive bile cultures. 
The organisms recovered were 
gram-negative in 69% (Escherichia 
coli, Klebsiella, Aerobacter and 
Pseudomonas) and gram-positive in 
31% (Enterococcus, Streptococcus 
and Staphylococcus).
Based on their ability to identify 
patients at high risk for postopera­
tive wound infection, Chetlin and 
Elliott10 examined the efficacy of a 
first generation cephalosporin as 
antimicrobial prophylaxis in high- 
risk biliary tract surgery. Prophy­
lactic antibiotics decreased the 
wound infection rate from 27% to 
4%.
Subsequent studies1112 have con­
firmed these data, showing the effi­
cacy of “selective” use of prophy­
lactic antibiotics in cholecystecto­
my. The high-risk patient can al­
most always be identified preopera- 
tively from clinical findings. Only 
those with unsuspected common- 
bile-duct stones escape detection. 
However, they are identified soon 
after the beginning of the opera­
tion, and antibiotics can be given 
before the wound is closed. There 
appears to be no role for the pro­
phylactic use of antibiotics in the 
low-risk group. Wound infection 
rates are less than 4% and will not 
be altered by antibiotics. Some au­
thors13 have suggested the intra­
operative use of Gram’s staining 
of the gallbladder bile to identify 
accurately those at high risk. While 
this is conceptually attractive, the 
practical aspects of this technique 
make it unfeasible in most hospi­
tals.
The common infecting organism 
dictates the choice of antibiotic and 
it should be borne in mind that high 
tissue levels rather than steriliza­
tion of the bile is the aim of prophy­
laxis.14 Although gram-negative en­
teric organisms, gram-positive 
aerobes, anaerobes and Enterococ­
cus are all frequently isolated, it 
appears that prophylaxis need not 
cover all possible microorganisms 
recovered from the bile. The first 
generation cephalosporin, cefazolin 
is highly effective in prophylaxis of 
the biliary tract.11 Moreover, it is 
inexpensive and has few side- 
effects. It should be administered 
intravenously just before operation 
when there is adequate time to 
allow the development of appropri­
ate tissue levels and yet prevent 
significant clearance. Three doses 
(one preoperatively and two postop- 
eratively) have been considered opti­
mal for prophylaxis, although some 
studies suggest that a single periop­
erative dose is sufficient.1112
On postoperative day 6, a wound infec­
tion was diagnosed clinically. The 
wound was opened and drained of pus,
Table I. Risk Factors for Patients Who 
Undergo Cholecystectomy
Age > 70 yr6 
Obstructive jaundice7 
Common duct stones, with or without 
jaundice7
Acute cholecystitis7 
Previous biliary surgery8 
Operation within 1 mo of acute 
cholecystitis9
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which showed gram-negative organisms 
on Gram’s staining.
Dr. Christou: Should antibiotics be 
used to treat wound infections and, 
if so, which ones?
Dr. Rotstein: As a general principle, 
antibiotics are not required for a 
wound infection. Complete open 
drainage of the wound is adequate 
unless the host is immunocompro­
mised, such as a patient who has an 
indwelling prosthetic device or 
signs of systemic infection. In such 
cases, drainage plus antibiotics is 
appropriate.
Two days later Klebsiella and Bacter- 
oides fragilis were cultured. The patient 
was treated with Dakin’s packs and 
cefazolin, 500 mg orally every 8 hours 
for 10 days. The patient was discharged 
home 2 days later, but was readmitted 
after 7 days because of persistent fever. 
Examination and abdominal ultrasonog­
raphy demonstrated a subphrenic ab­
scess. This was aspirated under com­
puted tomographic guidance, and pus 
was identified which showed gram­
negative organisms and grew Klebsiella 
oxytoca, B. fragilis and Streptococcus 
group D. A pigtail catheter was placed 
to drain the subhepatic space. He was 
treated with netilmicin and met­
ronidazole.
Dr. Christou: What is the appropri­
ate antibiotic choice for empiric 
therapy, or should one wait for 
sensitivity results?
Dr. Rotstein: Empiric antibiotic 
therapy for a subphrenic abscess 
that develops after cholecystectomy 
should include coverage of the com­
mon biliary organisms already cited. 
Ampicillin plus an aminoglycoside 
plus an antianaerobe would be ap­
T a b le  II. Complications of Endoscopic 
Sphincterotomy
Complication %
Hemorrhage 46
Acute pancreatitis 19
Cholangitis 17
Other 18
propriate. In this case, culture of 
the aspirated pus grew the microor­
ganisms originally recovered from 
the bile; therefore, the above regi­
men would constitute definitive 
therapy. The need to include antibi­
otics directed against Enterococcus 
has been hotly debated.15 Because 
this microorganism is a well-defined 
pathogen in the biliary tree, our 
practice is to provide specific cover­
age for it in infections related to the 
biliary tract.
After 2 days, fever and rigors developed 
and cholangitis was suspected. Endo­
scopic retrograde cholangiopancreatog­
raphy (ERCP) showed a dilated common 
bile duct with debris in the base. A 
papillotomy was carried out, releasing 
pus under pressure.
Dr. Christou: What would consti­
tute an appropriate drainage proce­
dure — ERCP or operative drain­
age?
Dr. Rotstein: Traditional manage­
ment of cholangitis includes vigor­
ous replacement of fluids, intrave­
nous administration of antibiotics 
and early operation. However, early 
endoscopic drainage now represents 
the initial treatment of choice when 
medical therapy fails in centres 
where the expertise is readily avail­
able. Leese and associates16 showed 
that endoscopic sphincterotomy in 
cases of acute cholangitis resulted 
in successful stone clearance in 
90%. Both death and complication 
rates were lower for endoscopic 
sphincterotomy than for operative 
drainage, even though patients who 
underwent sphincterotomy were 
significantly older and sicker than 
those who underwent operation.
The complications of sphinc­
terotomy include hemorrhage, pan­
creatitis and cholangitis (Table II).17 
As with any procedure, inexperi­
ence is associated with lower suc­
cess rates and more complications.18 
Failure of endoscopic sphincteroto­
my is usually due to the inability of 
the endoscopist to clear the duct of 
stones completely. The use of a 
nasobiliary catheter or repeat at­
tempts at stone removal may reduce 
the incidence of recurrent cholangi­
tis. However, even if sphincteroto­
my fails, the option of surgical 
decompression still remains.
The patient was stabilized and was 
discharged from the intensive care unit 
to the ward 4 days later. Repeat com­
puted tomography showed a small sub- 
hepatic collection, in the same area as 
previously, not drained because of a 
blocked catheter. This collection, aspi­
rated under tomographic guidance, pro­
duced 6 ml of bloody, thick fluid. 
Again, the aspirate grew K. oxytoca, B. 
fragilis and Streptococcus group D. 
Blood cultures were positive for the 
same organisms. All organisms were 
sensitive to the antibiotics used.
Dr. Christou: What are the possible 
explanations for this failure? Which 
is at fault, the antibiotics or the 
surgery?
Dr. Rotstein: Although the organ­
isms were the same and were sensi­
tive to the antibiotics used, the 
abscess persisted. Antibiotic treat­
ment in the face of established 
infection, specifically abscess, is 
fraught with problems. Several 
questions should be asked when 
antibiotic therapy fails: (a) Is the 
antibiotic the one of choice? (b) Are 
the systemic levels adequate? (c) Do 
the antibiotics penetrate the ab­
scess? and (d) Is there adequate 
activity of the antibiotic in the ab­
scess.
Clearly, in this patient, the antibi­
otics were appropriate for the in­
fecting organisms. Drug levels of 
aminoglycosides were not stated, 
but there is a tendency to under­
dose aminoglycosides rather than 
overdose them. It is generally 
thought that antibiotics do not pen­
etrate well-established abscesses. 
This thinking was challenged by 
Wells and colleagues19 who demon-
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strated that antibiotics can pene­
trate into abscesses, achieve ade­
quate intra-abscess levels and cause 
notable killing of bacteria within 
the abscess. However, abscesses re­
mained even though more than 99% 
of the bacteria were killed. This 
finding suggests that, with respect 
to established abscesses, viable bac­
teria represent only one factor con­
tributing to the persistence of the 
infection and that once an abscess 
is mature, even small numbers of 
bacteria may be sufficient to perpet­
uate it. Other factors, such as the 
presence of an abnormal microenvi­
ronment, bacterial toxins and ne­
crotic debris, may contribute to the 
inability of host phagocytes to re­
solve the infection. Surgical or per­
cutaneous drainage not only re­
duces the numbers of bacteria but 
also reverses many of these factors.
Computed tomography showed an in- 
trahepatic abscess, which was drained 
under tomographic guidance and pro­
duced thick pus, which, on Gram’s 
staining, contained mixed gram-positive 
cocci and gram-negative rods.
Dr. Christou: What would be ap­
propriate empiric antibiotic therapy 
at this time?
Dr. Rotstein: Intrahepatic abscess 
is a well-recognized complication of 
cholangitis. Table III shows the 
common organisms involved and 
the etiology of this disease.20 Em­
piric antibiotic therapy should in­
clude coverage of these microorga­
nisms. Our choice is usually am- 
picillin, metronidazole and an ami­
noglycoside.
Two days later K. oxytoca, Enterococ­
cus, Streptococcus group D and B. 
fragilis were reported to be growing 
from the pus; Enterococcus was report­
ed in both samples and Streptococcus 
group D and K. oxytoca in the aerobic 
blood culture taken previously. The 
patient was treated with netilmicin, met­
ronidazole and ampicillin. He was well
for 3 days, then his condition deterio­
rated; at that time a repeat computed 
tomogram showed reduction in the size 
of the original abscess, but in two, new, 
separate areas of the liver additional 
abscesses were suspected. He was taken 
to the operating room on Apr. 17, 1988 
to drain and evacuate the subhepatic 
abscess and to provide better drainage 
of the new abscesses. The drainage was 
not satisfactory and the patient deterio­
rated. His body temperature increased 
and multiple organ failure was progres­
sive.
Dr. Christou: What would be the 
appropriate antibiotic to use at this 
point?
Dr. Rotstein: Antibiotic therapy 
was probably adequate; there is 
usually no need to switch antibiot­
ics unless there is evidence that 
resistance has developed or there 
are specific complications due to 
the antibiotic itself (e.g., a decline 
in renal function because of amino­
glycosides).
Because of increasing renal failure, anti­
biotic therapy was changed. Imipenem 
therapy, 500 mg every 12 hours, was 
started and this was increased 5 days 
later to 500 mg every 8 hours. The 
patient suffered an upper gastrointesti­
nal hemorrhage despite H2 blocker 
therapy. Angiography showed that the 
source of bleeding was the pan­
creaticoduodenal artery at the level of 
the ampulla in the area of the sphinc­
terotomy. He underwent operation to 
control the bleeding. Pus from the 
subhepatic area was again cultured and 
grew Klebsiella, B. fragilis, a-hemolytic 
Streptococcus and Candida. Four days 
later the patient suffered a respiratory 
arrest and died. At autopsy, a persistent 
right subphrenic abscess was identified 
together with a large abscess in the 
right lobe of the liver. On careful 
postmortem cultures, both abscesses 
were sterile.
Dr. Christou: If both cavities were 
sterile, what went wrong?
Dr. Rotstein: The chain of events 
that ultimately led to this patient’s 
death is seen frequently in surgical 
practice. In this case, a well-recog­
nized complication of cholangitis 
(Table IV), namely intrahepatic ab­
scess, initiated a sequence that in­
volved repeated attempts at abscess 
drainage, multiple antibiotic regi­
mens, progression of septic foci and 
multiple system organ failure.
Patients with multisystem failure 
represent an immunocompromised 
host in whom there is usually glob­
al failure of normal host-defence 
mechanisms, both specific and non­
specific.21 23 Furthermore, the sys­
temic consequences of major sepsis 
affect not only organ systems, but 
probably act at the cellular level to 
impair such basic processes as 
phagocytosis, chemotaxis and cyto­
kine secretion.7-21 Once the spiral of 
sepsis and multiple system organ 
failure has been entered, death usu­
ally follows. Prevention lies in ag­
gressive and timely drainage of sep­
tic foci and at times nonseptic foci, 
such as fracture hematomas,24 in 
combination with the appropriate 
antibiotics. It is hoped that future 
research in this area will delineate 
some of the mechanisms involved in 
this process and allow us to manip­
ulate the process more specifically 
to control the sepsis.
Table III. Organisms Found in Liver 
Abscesses
Gram-negative 
Escherichia coli 
Klebsiella sp 
Enterococcus 
Proteus sp 
Gram-positive 
Staphylococcus 
Streptococcus 
Anaerobes 
Bacteroides 
Streptococcus
Table IV. Common Causes of Hepatic
Abscess
Cause ■>/o
Benign or malignant biliary tract
disease 50
Intra-abdominal infection 15
Direct extension trauma or
hematogenous dissemination 15
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Pancreatic Sepsis (E. Bradley,
III)
A 78-year-old man was admitted to 
hospital because of abdominal pain, 
vomiting and a serum amylase value of 
1122 U/L. The abdominal x-ray series 
showed a colonic cut-off sign, and clini­
cal and radiologic findings were com­
patible with acute pancreatitis. Ul­
trasonography was attempted, but was 
limited due to gas in the overlying 
colon. The patient was treated with 
nasogastric suction and intravenous flu­
ids. Two days later his temperature 
increased to 39°C and his leukocyte 
count increased to 18.6 X 109/L . The 
chest x-ray film showed pneumonia of 
the left lower lobe and culture of the 
urine grew Enterococcus, more than 10 
colonies per millilitre. Ampicillin, 1 g 
every 6 hours, was started. Another 
abdominal series demonstrated air-fluid 
levels in the right upper abdomen and 
questionable edema of the re- 
troperitoneum. A blood sample was ob­
tained for culture. On day 3, ul­
trasonography of the upper abdomen 
showed a small stone in the gallbladder, 
whose wall was slightly thickened. A 
HIDA scan gave equivocal findings. The 
serum amylase level was now 127 U/L. 
Computed tomography showed a thick­
ened edematous pancreas but no retro­
peritoneal abscess, and there was no 
dilatation of the biliary system. On the 
following day, the blood culture grew 
Klebsiella pneumoniae. The patient was 
given netilmicin, 100 mg intravenously 
every 8 hours.
Over the next 7 days, the patient was 
treated with nasogastric suction and 
total parenteral nutrition. His condition 
deteriorated on day 10; he was con­
fused and his body temperature was 
39°C. A computed tomogram of the 
abdomen showed a large abscess in the 
retroperitoneal area filling the lesser 
sac. At operation, necrotic hemorrhagic 
pancreatitis was noted with a large 
abscess at the base of the mesocolon 
extending from the head to the tail of 
the pancreas with extensive phlegmon. 
The pancreatic abscess was drained and 
a cholecystectomy, cystic duct cholangi­
ography, gastrostomy and feeding jeju- 
nostomy were carried out. There was no 
choledocholithiasis, and bilateral axiom 
sumps were inserted to drain the ab­
scess as best possible. Cultures from 
this area grew Klebsiella sp. The patient 
did not improve and 5 days later he still 
had signs of sepsis with a temperature
of 39°C. A computed tomogram of the 
abdomen revealed a reaccumulation of 
the pancreatic collection extending to­
ward the spleen and the left paracolic 
gutter. He underwent surgery for fur­
ther drainage of these abscess cavities.
Dr. Christou: Dr. Bradley, would 
you comment on the management 
of this patient.
Dr. Bradley: This case is typical of 
the complicated clinical course ex­
hibited by many patients with sec­
ondary pancreatic infections. In sur­
gical cases there is a wide range of 
death rates (from 10% to 59%) and 
an alarming frequency of major 
morbidity (60% to 93%).25 While 
some may view these results as 
disturbing, medical treatment of pa­
tients with secondary pancreatic in­
fections results in a death rate 
approaching 100%.
The pathophysiology of second­
ary pancreatic infections begins 
with thrombotic and cytolytic con­
sequences of acute pancreatitis. It is 
becoming clear that pancreatic ne­
crosis precedes the secondary devel­
opment of infections. Only 40% of a 
group of 145 patients with severe 
acute pancreatitis and pancreatic 
necrosis who underwent pancreatic 
resection were found to have tissue 
cultures positive for bacteria.26 
These observations have been inter­
preted to mean that bacterial inva­
sion of pancreatic necrosis is a 
secondary phenomenon. The pan­
creatic necrosis demonstrated in 
each of these patients ranged from 
gross to microscopic and from limit­
ed to diffuse. Whether the extent of 
parenchymal necrosis is also a de­
terminant of the chances of su- 
prainfection is not presently known.
The mechanism for suprainfec- 
tion of the devitalized retroperitone­
al tissue is not clear. Although it 
has been proposed that regional 
inflammation permits direct tran­
scolonic migration of enteric bacte­
ria through an otherwise intact in­
testinal mucosa, little proof exists 
for this hypothesis. Recently, Wells 
and colleagues9 demonstrated that 
suprainfection can follow the hema­
togenous route as a result of defec­
tive phagocytes. In the experimen­
tal animal, they demonstrated that 
viable bacteria can be transported to 
necrotic tissue by phagocytes and 
then released upon the death of the 
carrier. Regardless of the mecha­
nism of secondary infection, the 
colon is likely the source of the 
offending organisms. The bacteria 
involved in secondary pancreatic in­
fections are primarily enteric. The 
most common organisms in de­
scending order of frequency are: E. 
coli, K. pneumoniae, Streptococcus 
faecalis, Staphylococcus aureus, 
Pseudomonas aeruginosa, Proteus 
mirabilis, Streptococcus spp, En- 
terobacter aerogenes and B. fragi- 
lis.27 However, secondary infections 
due to Candida albicans are being 
reported with increasing frequency, 
suggesting that fungal cultures 
should be obtained in addition to 
routine aerobic and anaerobic cul­
tures.
The choice of a particular antibi­
otic for the management of acute 
pancreatitis and its complications is 
a matter of concern. Little work has 
been done in humans on specific 
antibiotic penetrance into pancreat­
ic tissue and the levels of various 
antibiotics in pancreatic juice. As an 
example, several studies purporting 
to show “lack of effect of prophy­
lactic antibiotics” in preventing sec­
ondary infections in acute pan­
creatitis have used ampicillin as the 
study drug, yet ampicillin is known 
not to appear in pancreatic tissue or 
juice. The small volume of data on 
antibiotic penetrance into pancreat­
ic tissue that does exist suggests 
that the following agents are ex­
creted in human pancreatic juice in 
clinically substantial concentra­
tions: cefotaxime, ceftazidime, cip­
rofloxacin, trimethoprim-sulfame-
254 CJS, VOL. 32, NO. 4, JULY 1989
COMPLICATED INTRA-ABDOMINAL SEPSIS
thoxazole, rifampin and Chloromy­
cetin. In contrast, none of the ami­
noglycosides tested (including ami­
kacin, gentamicin, tobramycin or 
netilmicin) reached therapeutic con­
centrations in human pancreatic 
juice. On the basis of current 
knowledge of tissue penetrance and 
the bacteria commonly responsible 
for pancreatic infections, cef­
tazidime is the best single agent for 
prophylaxis in severe acute pan­
creatitis. Established secondary 
pancreatic infections, however, 
should be treated according to dem­
onstrated organisms and sensitivi­
ties.
Terminology in secondary pan­
creatic infections needs to be more 
precise. Death rates range widely 
between the various conditions — 
from 10% with infected pseudocysts 
to 25% with pancreatic abscesses, 
all the way to 50% and more with 
infected pancreatic necrosis.28 Fur­
thermore, surgical management can 
vary from simple external drainage 
to extensive retroperitoneal debride­
ment and open packing. Clearly, 
these secondary infections must be 
properly defined and characterized 
to establish a meaningful prognosis 
and direct appropriate therapy.
In reports of more than 1100 
cases of secondary pancreatic infec­
tions published between 1966 and 
1987, only 11 authors attempted to 
differentiate between infected pan­
creatic necrosis, pancreatic abscess 
and infected pseudocyst. Moreover, 
no two authors proposed definitions 
that were the same! This lack of 
precise disease definitions necessi­
tates re-evaluation of the natural 
history of acute pancreatitis. In ad­
dition, ritual acceptance of long­
standing treatment regimens for 
secondary pancreatic infections 
should be questioned.
The following operational defini­
tions are suggested for clinical dif­
ferentiation of the different forms of 
pancreatic “sepsis”.
•  Pancreatic necrosis. Sterile 
pancreatic or peripancreatic necro­
sis, microscopic or macroscopic, 
patchy or diffuse, limited or exten­
sive.
•  Infected pancreatic necrosis. 
Necrosis positive for bacteria or 
fungi on smear or culture.
•  Pancreatic abscess. A collec­
tion of purulent material in the 
region of the pancreas which is 
positive for bacteria and bounded by 
adjacent tissues and organs.
•  Infected pseudocyst. A local­
ized collection of infected material 
in the region of the pancreas, en­
closed by well-developed fibrous 
walls with or without communica­
tion with the pancreatic ductal sys­
tem.
Because of the demonstrated im­
portance of necrosis in the patho­
physiology of pancreatic infections, 
initial diagnostic efforts should cen­
tre on whether an episode of acute 
pancreatitis has resulted in pancre­
atic or peripancreatic necrosis. 
Buchler and colleagues29 have 
claimed that serum levels of C-reac- 
tive protein greater than 0.1 g /L  
are highly accurate in distinguish­
ing pancreatic necrosis from acute 
interstitial (edematous) pancreatitis. 
Since C-reactive protein is a general 
“acute phase protein”, which is 
elevated in many situations, confir­
mation of these observations would 
represent an important advance in 
the diagnosis and management of 
these cases.
It may also be possible to detect 
pancreatic necrosis by large-bolus 
contrast-enhancing computed to­
mography. Although computed to­
mography, in general, represents 
the best method of evaluating sec­
ondary pancreatic infections,26 rec­
ognition of pancreatic necrosis in 
the absence of a secondary collec­
tion has not been possible until 
now. Several groups have recently 
reported impressive success in dem­
onstrating pancreatic necrosis by
dynamic contrast pancreatography, 
in which the progress of a 150 to 
200-ml intravenous bolus of con­
trast material is followed in the 
pancreatic parenchyma by comput­
ed tomography.30-21 
Another important consideration 
is the distinction between inflamma­
tion and infection. It is often not 
possible to distinguish the clinical 
signs of sepsis (tachycardia, fever, 
elevated leukocyte count and ab­
dominal tenderness) due to pancre­
atic inflammation from similar find­
ings caused by secondary pancreatic 
infections.32 Guided transcutaneous 
needle aspiration of pancreatic col­
lections noted on computed tomog­
raphy has become a valuable ad­
junct for this important distinction. 
If bacteria are present on Gram’s 
staining of aspirated material, the 
diagnosis of secondary pancreatic 
infection is established and surgical 
drainage is indicated.33-34 
Treatment of infected pancreatic 
necrosis is primarily surgical. While 
guided transcutaneous drainage of 
infected pseudocysts can be effec­
tively and safely performed by radi­
ologic means, particulate necrotic 
material present in other forms of 
secondary pancreatic infection can­
not be drained through small- 
calibre Ring catheters. For this rea­
son, guided transcutaneous drain­
age of pancreatic necrosis is notori­
ously unsuccessful35-36 and surgical 
debridement and drainage are re­
quired. Such observations under­
score the necessity for precise defi­
nitions which permit clear differen­
tiation between the various causes 
of pancreatic sepsis.
A number of controversies con­
tinue to surround the surgical man­
agement of pancreatic sepsis, prin­
cipally whether surgery should be 
early or delayed and whether drain­
age should be closed or open. Re­
cent clinical studies have demon­
strated significantly lower operative 
death rates when exploration is de-
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layed until after the second week of 
illness.37 Unfortunately, randomized 
studies comparing the risks of early 
versus delayed surgery do not exist.
Several workers continue to ad­
vocate debridement and closed 
drainage employing multiple 
sumps.38 Others, ourselves includ­
ed, favour debridement and open 
drainage for patients with infected 
pancreatic necrosis.3940 Repeated 
dressing changes associated with 
open drainage have all but eliminat­
ed persistent sepsis as the principal 
cause of death in these patients. 
However, if closed drainage is se­
lected, an extremely low threshold 
for re-exploration is required, since 
approximately one-half of patients 
treated thus will require reoperation 
for persistent or recurrent sepsis. 
Overall death rates for pancreatic 
abscesses and infected pancreatic 
necrosis have been reduced to 10% 
to 20% by aggressive and en­
thusiastic surgical management.
With particular regard to the 
78-year-old patient in the case re­
port, the initial conservative man­
agement of his severe biliary pan­
creatitis was quite appropriate. One 
week later, sepsis became apparent 
and a computed tomogram was pos­
itive for “abscess” . Exploration was 
correctly undertaken at about 2 
weeks (delayed intervention). Chole­
cystectomy, gastrostomy and jeju- 
nostomy were done along with 
closed sump drainage. In the pres­
ence of pancreatic and peripancreat- 
ic necrosis, we would have preferred 
open drainage and would have 
avoided cholecystectomy or gastros­
tomy at that time. Unfortunately, 
the approach chosen did not result 
in improvement and re-exploration 
was necessary. At that point, even 
staunch advocates of closed drain­
age would have changed to open 
drainage.
The patient was treated with a “mesh- 
zipper” open drainage approach, which
included laparotomy three times daily in 
the surgical intensive care unit. Ten 
days later he was still febrile, having a 
body temperature of 38.5 °C. The re- 
troperitoneum was not draining pus and 
the mesh was removed after 12 days. 
Thirty days later he was still febrile 
(39.2°C). Computed tomography of the 
abdomen showed no further collections. 
He was discharged home 55 days later.
Dr. Christou: Why the persistent 
fever? Does this indicate continued 
infection?
Dr. Bradley: The persistently febrile 
course of this patient after open 
drainage is not characteristic of the 
procedure. Usually, temperature 
continues to decline and is general­
ly normal by the third to fourth 
dressing change. Two possibilities 
exist for the persistent temperature 
elevation: undrained purulence (re­
peated computed tomograms are 
useful) and Candida sepsis (fungal 
cultures are part of our routine in 
these cases). Almost all of our pa­
tients with open drainage have been 
healed within 3 months. Neither 
abdominal flaps nor skin grafting 
have been necessary.
In conclusion, recent advances in 
diagnosis and management have 
markedly improved the prognosis of 
patients with pancreatic sepsis. To­
day, timely and appropriate treat­
ment will return most of these 
patients to productive lives.
Colonic and Rectal Perforations
(P. Belliveau)
A 72-year-old man had a 1-day history 
of lower abdominal pain spreading to 
the right side of the abdomen as the 
day progressed. He had a history of 
rheumatoid arthritis for which he took 
prednisone 5 m g/d as well as indome- 
thacin 25 mg 3 times daily and 50 mg 
at bedtime. He also had a heart pace­
maker. There was no history of hematu­
ria, no vomiting and he had had three 
soft bowel movements without bleeding 
earlier in the day. There was no previ­
ous surgery to the abdomen. He had
mild cushingoid facies, a temperature of 
38.5°C, pulse 100 beats/min and blood 
pressure 120/70 mm Hg. The abdomen 
was obese and mildly distended. Bowel 
sounds were present, but rare, and 
palpation elicited guarding in all quad­
rants with marked tenderness in the 
right lower quadrant. Testing for occult 
blood in the stool was negative. The 
leukocyte count was 20.0 X 109/L , 
hematocrit 0.37, plasma glucose level 
6.88 mmol/L, serum urea nitrogen 
level 1.04 mmol/L urea and serum 
creatinine level 132.6 /xmol/L. Abdomi­
nal films showed few air fluid levels and 
free intraperitoneal air. He was given 
ampicillin 1 g, netilmicin 80 mg and 
clindamycin 600 mg intravenously as 
well as hydrocortisone 100 mg intrave­
nously, and taken to the operating 
room, where a moderate amount of thin 
turbid fluid without gross fecal contam­
ination was found. The sigmoid colon 
had a pinpoint perforation surrounded 
by inflammatory tissue, suggesting a 
ruptured abscess. The abdomen was 
irrigated with a solution of cefazolin 1 
g /L  and a Hartmann resection of perfo­
rated diverticulitis with end colostomy 
using healthy sigmoid was fashioned. 
The abdomen was irrigated again with 
antibiotic solution and the fascia closed. 
The subcutaneous tissue was packed 
open. Cultures of the fluid grew E. coli 
and Klebsiella sp. Apart from an attack 
of syncope on day 6, he remained 
afebrile and antibiotics were stopped 
after 7 days. He was restarted on his 
regular prednisone and the wound was 
covered with Steri-strips on day 13. He 
was transferred to a convalescent hospi­
tal.
Dr. Christou: Dr. Belliveau, would 
you comment on the surgical and 
antibiotic management of this pa­
tient.
Dr. Belliveau: The management of 
acute colonic perforations has been 
controversial for several decades. 
Surgical judgement is often the 
final recommendation, but there are 
a few concepts that have become 
more generally accepted in the last 
10 years.
Important factors that influence 
the outcome of colonic perforations 
include host immunocompetence, 
shock, steroid therapy, fecal con-
256 CJS, VOL. 32. NO. 4, JULY 1989
COMPLICATED INTRA-ABDOMINAL SEPSIS
tamination, ability to localize the 
septic process and the type of anti­
biotic therapy. Causes of perfora­
tion are multiple; they include trau­
ma, inflammatory bowel disease, 
collagen abnormalities, steroid 
usage and diverticulitis.
The case presented illustrates 
two risk factors, diverticulitis and 
steroid use; both may weaken the 
wall of the colon and prevent local­
ization of the sepsis by the host’s 
natural defences. Diverticular perfo­
ration must then be divided first 
into localized or walled-off perfora­
tion, where the patient has been 
able to overcome the spread of pus 
or stool and he may be constitution­
ally well, and, second, into free 
perforation with generalized perito­
nitis, where the host’s ability to 
localize has been overcome or sup­
pressed as in cases of perforation in 
patients with renal transplants. In­
deed, in one study reporting perfo­
rations of the colon in renal homo­
graft recipients, only 6 of 27 pa­
tients with free perforation survived 
while in those with localized perfo­
ration 12 of 17 survived.41 Factors 
that contribute to morbidity and 
mortality include delay in diagnosis 
(mean 2 to 8 days depending on the 
dosage of steroids [more or less 
than 20 mg]), confusing the condi­
tion with rejection, the degree of 
spread of sepsis and reduction of 
immunosuppression.
The diagnosis is not always sim­
ple, and radiologic imaging studies 
should utilize abdominal series and 
soluble contrast studies. Computed 
tomography and ultrasonography 
may help in diagnosing abscess for­
mation. Free intraperitoneal gas on 
abdominal films warrants rapid fluid 
resuscitation and antibiotic adminis­
tration to cover both aerobes and 
anaerobes. Generally, in the acute 
setting, an aminoglycoside com­
bined with clindamycin or met­
ronidazole, or a single agent, such 
as cefoxitin or more recently imipe-
nem, is efficacious in limiting mor­
bidity in these abdominal catastro­
phes.
The choice of surgical procedure 
is wide, but certain approaches have 
been shown to reduce mortality. 
Classen and associates,42 in 1976, 
reported on the use of staged proce­
dures for perforated diverticulitis. 
In 203 patients who underwent 
transverse colostomy and drainage, 
there was a 7.9% death rate. How­
ever, second-stage resection had a 
0.7% death rate and the colostomy 
closure 3.9%. Himal and col­
leagues,43 in 1977, proposed selec­
tive management for perforated di­
verticulitis. They reported a 25% 
death rate in 47 patients with local 
perforation who underwent a colos­
tomy, whereas in a few patients 
who had resection or exterioriza­
tion there were no deaths. In 20 
cases of free perforation, colostomy 
was associated with a 30% death 
rate and resection or exteriorization 
with a 15% rate. Eng and col­
leagues,44 also in 1977, reported on 
46 patients with perforation of the 
colon and found that in 8 patients 
with generalized peritonitis treated 
by resection and colostomy, and in 
27 patients treated by resection and 
anastomosis for localized abscess, 
there were no deaths. In a large 
collected series of 1300 patients 
reported by Greif and associates45 
there was a 2% death rate when 
resection was done for localized 
abscess compared with 12% for co­
lostomy without resection; also, a 
12% death rate in patients with 
generalized peritonitis treated by 
resection compared favourably with 
a 29% rate when only a colostomy 
was used.
These data support the current 
trend toward resection and proxi­
mal end colostomy in cases of free 
perforation, whereas localized per­
foration in patients without ob­
struction who can undergo mechan­
ical and antibiotic bowel preparation
may be treated, with good results, 
by resection of the affected seg­
ment, including the abscess and all 
the distal diverticular disease down 
to the rectosigmoid junction with 
primary anastomosis.
An 88-year-old woman presented with a 
2-week history of dark urine and pale 
stools. She appeared jaundiced but oth­
erwise well. The serum bilirubin level 
was 156 /xmol/L, serum alkaline phos­
phatase 1109 U/L, serum urea nitro­
gen level 7.14 mmol/L urea and serum 
creatinine 972.4 ^mol/L. Ultrasonogra­
phy of the abdomen showed a dilated 
common bile duct and choledocholithia- 
sis. In preparation for surgery, her 
hematocrit was found to be 0.26, 
down from a level of 0.38 2 months 
earlier. She had occult blood in the 
stool. A barium enema was performed 
and on the initial films the radiologist 
commented on retroperitoneal barium 
extravasation. She underwent colonos­
copy. A mucosal defect was noted at the 
11-cm level. Abdominal films showed 
free air, but the patient remained 
asymptomatic. Clindamycin, 600 mg in­
travenously every 8 hours and gen­
tamicin, 40 mg every 12 hours were 
started. Her temperature 2 days later 
was 38.6°C. She remained stable and 
on hospital day 8 she was afebrile, her 
leukocyte count was 15.4 X 109/L  and 
her hemoglobin was 100 g/L . She had 
diarrhea but no pain. Antibiotics were 
changed to cefoperazone, 1 g intrave­
nously every 8 hours and metronidazole 
500 mg orally three times a day. Com­
puted tomography showed no pelvic 
abscess but persistent dilatation of the 
common bile duct. Two days later ce­
foperazone was increased to 2 mg intra­
venously every 8 hours and she under­
went an uncomplicated common-bile- 
duct exploration and choledo- 
choduodenostomy. Follow-up rectal ex­
amination showed no tenderness or per­
sistent fistula.
Dr. Christou: Dr. Belliveau, is it 
appropriate to treat rectal perfora­
tions without surgical intervention? 
Dr. Belliveau: Rectal injuries pres­
ent a difficult problem for the treat­
ing surgeon. The causes of these 
lesions include various surgical pro­
cedures, endoscopy, foreign bodies
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either ingested or inserted, blunt or 
penetrating trauma and stercoral 
perforation. Factors important in 
determining outcome include extent 
of soft-tissue trauma, presence of 
associated injury, delay in the onset 
of treatment, health and age of the 
patient, amount of fecal contamina­
tion and level of injury.
Barium enema complications are 
numerous; they include rectal per­
foration, rectal tear or extravasa­
tion, colonic perforation, barium 
peritonitis, barium submucosal gra­
nulomas, toxic megacolon, septice­
mia, venous barium embolism, ret­
rograde filling with vomiting and 
aspiration in infants. In this particu­
lar case, a colostomy was consid­
ered, but the surprising lack of 
rectal and general symptoms al­
lowed a more conservative approach 
to be used successfully. Any deteri­
oration would have necessitated a 
colostomy with presacral drainage 
from a posterior anal approach.
Management of rectal injuries in­
cludes early administration of 
broad-spectrum antibiotics, provid­
ing aerobic and anaerobic coverage, 
rectal examination, anoscopy and 
sigmoidoscopy. Barium enema 
should be avoided and, when in 
doubt, soluble contrast material 
should be used to demonstrate dis­
ruption of the rectal mucosa. In the 
management of important pelvic in­
juries with blunt pelviperineal trau­
ma, a colostomy with a distal wash­
out of the rectum has been pro­
posed by Kusminsky and col­
leagues.41’ They had a 42% death 
rate in 14 patients who had associ­
ated extensive injuries.
In the treatment of rectal trauma, 
classification according to the level 
of the injury has proven to be 
helpful. Injuries from penetrating 
trauma below the levator ani are 
treated by debridement, partial su­
ture, drainage and antibiotics. Teta­
nus prophylaxis is important in 
these patients as well as elemental
diet to reduce fecal output. In the 
management of patients with inju­
ries above the levator ani who are 
more at risk for pelvic sepsis, the 
use of a proximal sigmoid colosto­
my should be considered with divi­
sion of the bowel, dependent drain­
age using a posterior perianal inci­
sion, debridement and distal wash­
out of the rectum.
Controversy exists regarding mo­
bilization of the rectum and repair 
of the injury from an abdominal 
approach for high rectal injuries. 
Burch and associates,47 in 1986, 
reported on the treatment of 60 
patients with extraperitoneal pene­
trating injuries over a period of 6 
years. Fifty percent had irrigation 
of the distal rectal segment, 20% 
mobilization of the rectum and re­
pair of the extraperitoneal wound. 
The use of these two adjuncts did 
not appear to reduce the frequency 
of abdominal abscess, rectal fistula 
or pelvic cellulitis. For in- 
traperitoneal injuries of the rectum, 
the Hartmann procedure or sigmoid 
colostomy with closure of the rectal 
wound have been suggested, the 
latter being the simpler and associ­
ated with fewer complications. For 
posterior rectal wounds above the 
peritoneal reflection, the manage­
ment should include mobilization of 
the rectum with repair and proximal 
colostomy.
Antibiotic management in this 
patient was appropriate. Initially 
she received empiric broad-spec­
trum coverage with an aminoglyco­
side for the gram-negative aerobes 
plus clindamycin for the anaerobes 
and gram-positive cocci. Enterococ­
cus is not covered by this approach. 
Alternatively, monotherapy with a 
carbapenem or combination therapy 
with a third generation cephalos­
porin and metronidazole could have 
been used. The rationale for switch­
ing antibiotics to cefoperazone and 
metronidazole some days later is 
based on the need to cover possible
pathogens in the patient’s dilated 
common bile duct and prevent the 
development of ascending cholangi­
tis in its most virulent form (i.e., 
fever, chills, jaundice, hypotension 
and leukopenia). Cefoperazone is 
primarily excreted in the bile and 
can reach levels ranging from 50 to 
6000 fig/m l in bile depending on 
the degree of common-bile-duct ob­
struction. Ceftriaxone which has a 
dual route of excretion (i.e., kidney 
and liver) could have been an alter­
native third generation cephalos­
porin. Orally administered met­
ronidazole is appropriate for anaer­
obic coverage since this agent is 
absorbed from the gastrointestinal 
tract and is actively secreted in the 
large bowel; thus, it would have 
both local and systemic effects.
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Spontaneous Abortion
M.E. Boyd, MD, FRCSC
As a result of improved investigation and treatment techniques, understanding of all 
aspects of spontaneous abortion has improved. The term “threatened abortion” is 
often a misnomer, for the fate of the pregnancy is decided when bleeding occurs. A 
dilated cervix indicates that abortion is inevitable. If the cervix is not dilated, pelvic 
ultrasonography will usually show the following: a live fetus, an anembryonic 
pregnancy, incomplete abortion or missed abortion. If fetal heart movement is seen, 
no further treatment is needed and the prognosis is excellent (98% fetal survival). In 
other cases, the uterus must be evacuated, with a Karman catheter if the uterus is 
small, with a suction curette if the uterus is large. Forceful dilatation of the cervix is 
avoided through the use of Laminaria.
Comme consequence de l’amelioration des techniques d’examen et de traitement, nos 
connaissances de tous les aspects de l’avortement spontane se sont ameliorees. 
L’appellation “menace d’avortement” est souvent mal appropriee car le sort de la 
grossesse est deja decide quand l’hemorragie survient. Un col dilate signifie que 
1’avortement est inevitable. Quand le col n’est pas dilate, 1’echographie pelvienne 
revele habituellement les observations suivantes: un foetus vivant, une grossesse 
anembryonnaire, un avortement incomplet ou une retention foetale. Quand les 
mouvements du coeur foetal sont presents, aucun traitement n’est requis et le 
pronostic est excellent (98% de survie foetale). Autrement, l’uterus doit etre evacue 
avec un catheter Karman si l’uterus est petit, ou par curetage par aspiration si 
l’uterus est large. L’emploi de Laminaria evitera une dilatation vigoureuse.
I n 20% of all pregnancies the first trimester will be complicated by 
vaginal bleeding, and in half of 
these the fetus will spontaneously 
abort. The management of sponta­
neous abortion is therefore a com­
mon problem. It is important that 
the clinician have a clear idea of the 
nature of this condition and its 
treatment. The introduction of pel­
vic ultrasonography has given us 
new understanding of this process. 
The most important consequence of 
this is our ability now to forecast
outcome, which has eliminated the 
use of a variety of unnecessary, 
possibly dangerous, empiric reme­
dies for threatened abortion. The 
use of Laminaria to dilate the cervix 
and of suction curettage to empty 
the uterus have been notable ad­
vances. They have reduced need for 
mechanical dilatation of the cervix 
and sharp curettage of the uterus.
A number of patients abort with­
in a few days of conception,1 with 
few or no symptoms, so that the 
patient is usually unaware of the
pregnancy’s existence. In this paper 
I shall consider only the loss of a 
clinically apparent pregnancy.
Natural History
Fetal development is best under­
stood by relating it to ultrasono­
graphic findings. Pregnancy before 
5 to 6 weeks of amenorrhea does 
not have a unique ultrasonographic 
appearance, but at 5 to 6 weeks a 
small eccentrically located gesta­
tional sac is seen. At 6 to 7 weeks, 
the sac has enlarged and a fetal 
pole and active fetal heart are seen.
Most pregnancies that abort have 
not completed fetal development. 
The cause of the failure is common­
ly assumed to be a chromosomal 
anomaly, most often trisomy,2 but 
this is difficult to confirm because 
necrosis of the placental tissue 
often prevents karyotyping.3 If the 
insult causing abortion is both early 
and severe, there is no fetal devel­
opment, and ultrasonography will 
show an empty gestational sac, the 
so-called blighted ovum or anemb­
ryonic pregnancy. If the initial inju­
ry is less serious or occurs later, 
fetal development will proceed to a 
certain point and stop. In this in­
stance disorganized fetal parts will 
be seen within the gestational sac, 
with no fetal heart activity; this is 
called a missed abortion.
The initial failure of fetal devel­
opment or of continued fetal 
growth are asymptomatic and pass 
unnoticed. The clinical manifesta­
tions of this are seen, usually after 
7 to 10 weeks of amenorrhea, when
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painless vaginal bleeding occurs. 
Although the clinician will call this 
a threatened abortion, the fate of 
the pregnancy has been already 
decided. Painful uterine contrac­
tions ensue and cause the cervix to 
dilate (inevitable abortion); finally 
the placenta is expelled, either to­
tally (complete abortion) or partly 
(incomplete abortion).
The prognosis is completely dif­
ferent if ultrasonography demon­
strates fetal heart activity. Al­
though the vaginal bleeding is the 
same as that seen in patients with 
an anembryonic pregnancy or 
missed abortion, in this case 97.4% 
of pregnancies will continue with 
normal fetal development.4 The ori­
gin of the bleeding usually is not 
established, but in a few cases a 
second, empty gestational sac or an 
intrauterine hematoma are seen to 
explain the bleeding. The empty sac 
will gradually absorb, as will the 
hematoma, and the pregnancy con­
tinues without ill effect on the 
fetus.5
Diagnosis
The patient’s initial complaint is 
vaginal bleeding, the volume and 
nature of which are variable and 
cannot be used to predict the final 
outcome.6 If, on vaginal examina­
tion, the cervix is dilated, abortion 
is inevitable and the only decision 
to be made is the means of comple­
tion. If products of conception are 
found, the physician merely decides 
on the completeness of the process 
and the need for any surgery.
If the cervix is closed, the diag­
nosis is threatened abortion. Refine­
ments of this diagnosis require pel­
vic ultrasonography. The outcome 
and findings in patients who have 
ultrasonography at this stage have 
been reported:5 51% have a normal 
outcome, 15% an anembryonic 
pregnancy, 13% an ectopic preg­
nancy, 9% an incomplete abortion 
and 7% a missed abortion.
The ultrasonographer will have 
little difficulty in confirming that 
the fetus is alive or that the abor­
tion is missed or incomplete. In 
most instances anembryonic preg­
nancy is easily diagnosed (i.e., if the 
volume of the gestational sac is 
over 2.5 ml and no fetal parts are 
seen7). If a diagnosis of anembryon­
ic pregnancy is uncertain, ul­
trasonography should be repeated 1 
week later. In the series of Stabile 
and colleagues,5 this was necessary 
in 15% of referred cases.
The diagnosis of early intrauter­
ine pregnancy or ectopic pregnancy 
must be made if the urinary preg­
nancy test is positive but ul­
trasonography does not show an 
intrauterine pregnancy. The differ­
ential diagnosis will depend on the 
correlation of ultrasonographic 
findings with the quantitative levels 
of human chorionic gonadotropin 
(/3-HCG) and the selective use of 
culdocentesis. An intrauterine ges­
tational sac should be visible if the 
/3-HCG is over 6500 IU/L.8 If the 
diagnosis remains uncertain (/3-HCG 
less than 6500 IU/L), the /3-HCG is 
measured 2 days later. If a rise of at 
least 66% is not seen, the diagnosis 
is an abnormal intrauterine preg­
nancy or an ectopic pregnancy.9 A 
normal rise in /3-HCG level strongly 
suggests that the pregnancy is in­
trauterine and normal. Ultrasonog­
raphy should be repeated in 1 
week’s time, however, to identify 
the small percentage of ectopic 
pregnancies associated with a nor­
mal rise in quantitative /3-HCG.
T reatment
The typical patient with a sponta­
neous abortion is in good condition 
when first examined. It is unusual 
for such patients to bleed so much 
that hemorrhagic shock develops;
blood transfusion will rarely be re­
quired. If patients are found to have 
low blood pressure, the cause is 
likely to be dilatation of the cervix 
by retained placental tissue. Blood 
pressure will quickly be restored to 
normal by lifting the placental tis­
sue from the cervix with sponge 
forceps. Despite the infrequent need 
for transfusion, the patient’s blood 
group should be determined be­
cause Rh0 immunoglobulin D (50 
Mg) must be given to Rh-negative 
patients after abortion. An intrave­
nous line should be established and 
20 IU of oxytocin added to 1 L of 
solute.
Surgery is unnecessary if the 
abortion is complete, but the diag­
nosis should be confirmed by ul­
trasonography.10 Complete sponta­
neous evacuation of the uterus is 
less likely if the uterine size is that 
of 8 or more weeks’ gestation.
Patient and physician preference 
can be used with respect to the 
choice of anesthetic. General anes­
thesia is preferable if the uterus is 
large or the patient is anxious. On 
the other hand, local anesthesia 
with supplementary intravenous se­
dation, is safe and inexpensive. Li- 
docaine 1% with 1:200 000 epi­
nephrine is the drug of choice and a 
maximum of 20 ml should be used. 
The recommended sites are 12, 4 
and 8 o’clock at the cervical vaginal 
junction. The injection should be 
made just beneath the mucosa and 
cause the skin to “pop”.
Treatment varies between pa­
tients with a dilated cervix and 
those with a closed cervix, being 
further subdivided into those with 
early and those with late abortion.
Dilated Cervix
Early abortion (less than 8 
weeks). The standard surgical man­
agement today is suction curettage 
using the Karman suction cathe­
ter.11 The device consists of a 50-ml
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disposable syringe with a self-lock­
ing seal and attached cannula. Near 
the end of the cannula there is a 
side opening, which is used to 
scrape the uterine wall and take up 
the placental tissue.
Evacuation of the uterus with the 
Karman cannula is not painful but 
is unpleasant. The patient should be 
given intravenous sedation (Deme­
rol 50 mg and Valium 5.0 mg); no 
other anesthesia is needed. Follow­
ing bimanual examination, a bivalve 
vaginal speculum is inserted. The 
anterior lip of the cervix is grasped 
with a single-toothed tenaculum in 
the anterior-posterior direction and 
downward tension is applied to the 
cervix. The largest Karman cannula 
that can be easily inserted into the 
uterine cavity should be used (usu­
ally 5 to 6 mm diameter). After 
insertion of the cannula, the handle 
of the syringe is retracted, thereby 
giving negative suction to the appa­
ratus. The cannula is used in the 
same way as a uterine curet but is 
not removed from the uterus be­
tween strokes. The motion is longi­
tudinal and the uterine walls are 
systematically curetted. Completion 
is signalled by sensing the uterus 
clamp down on the cannula and 
feeling a gritty sensation on curet­
tage. The cannula is then removed 
from the uterus, cleared and rein­
serted for a final brief curettage.
A serious error is to curet the 
uterus of a patient with an ectopic 
pregnancy and then to discharge 
her with a diagnosis of an incom­
plete abortion. To prevent this, the 
physician must examine the tissue 
in the syringe and confirm that 
placental tissue has been aspirated. 
The diagnosis is straightforward if 
there is abundant placental tissue, 
but special measures must be taken 
if the curettings are scanty. In such 
cases the curetted material should 
be washed in water and the blood­
stained fluid decanted repeatedly 
until the water is clear. The sample
should then be examined under a 
good light. Chorionic villi of the 
placenta will be seen to have a light 
feathery border; their appearance is 
that of seaweed floating freely in 
water. In contrast, decidua is heavy 
and its edges are rough and shag­
gy. Diagnosis from gross examina­
tion as to the presence of chorionic 
villi is remarkably effective.12 If this 
differentiation is uncertain a frozen 
section of the curettings can be 
done. If chorionic villi are not seen, 
the diagnosis of an ectopic pregnan­
cy is likely but not certain. An 
intrauterine pregnancy may be pres­
ent despite the inability to identify 
chorionic villi on histologic exami­
nation.13 The clinician may try to 
confirm the diagnosis of an ectopic 
pregnancy by laparoscopy or decide 
to monitor the patient by quantita­
tive measurement of /3-HCG levels.
Late abortion (more than 8 
weeks). In these cases the surgeon 
can evacuate the uterus with the 
traditional sharp curet or a suction 
curet, but all evidence shows that 
evacuation is faster, with less blood 
loss and less need for further dila­
tion of the cervix if the suction 
curet is used.
The suction curet makes use of 
high negative pressures (600 mm 
Hg); for that reason, the tubing and 
the attached cannula are rigid. The 
rigidity makes the apparatus some­
what cumbersome and the operator 
will lose some of the “feel” of the 
traditional curet.
Bimanual examination is done to 
confirm the size and position of the 
uterus. If local anesthesia is chosen, 
a bivalve speculum is used and the 
cervix is grasped with a single­
toothed vulsellum or a sponge for­
ceps. The largest cannula that can 
comfortably pass the dilated cervix 
is inserted just beyond the internal 
os. The suction is then turned on 
and the opening on the cuff is 
occluded. The cannula need not be 
moved if evacuation of placental
tissue continues. If flow decreases, 
a rotary motion of the cannula is 
utilized. (The movement is rotary 
rather than longitudinal in these 
cases because the aperture of the 
suction cannula is at the distal end.) 
If flow stops, the vacuum seal 
should be broken and the cannula 
taken outside the uterus. The 
blocked aperture on the cannula 
should be cleared of placental tissue 
and the evacuation continued. Com­
pletion of the process is signalled 
by feeling the uterus clamp down 
on the cannula and seeing the aspi­
rate become frothy. A sharp curet is 
then used to confirm that the uter­
us is indeed empty, after which a 
second brief suction curettage is 
done.
If a general anesthetic has been 
given, much of the evacuation can 
be done at the time of the prelimi­
nary examination under anesthesia. 
At that time, the second finger of 
the examiner’s right hand should be 
inserted through the internal os 
into the uterine cavity. Exploration 
of the uterus with a digit is possible 
only if the second finger is used and 
if the left hand firmly pushes the 
uterus against the finger through 
the abdominal wall. The finger in 
the uterine cavity sweeps the pla­
cental fragments from the uterine 
wall with a rotary motion. This 
mobilization of the placenta is com­
pleted in a few moments and is 
completely atraumatic.
An Auvard speculum is next ins­
erted into the vagina. In most in­
stances, large amounts of placental 
tissue will be found there. The 
anterior lip of the cervix is then 
grasped with a sponge forceps. A 
second sponge forceps is inserted 
into the uterine cavity; the forceps 
are opened widely and then closed. 
The forceps will grasp the loosened 
placental tissue. This procedure is 
repeated a few times, but after 
reinsertion and before opening, the 
forceps are turned 90°. The largest
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sharp curet that can be easily ins­
erted through the cervix is then 
used to curet the uterus. It is 
important to use a large curet since 
this is much less likely to perforate 
the uterus and is more efficient in 
removing placental tissue. The need 
for a large curet is critical if the 
uterus is more than 12 weeks in 
size. Sharp curettage is done by 
gently inserting the curet to the 
uterine wall on the outstroke; the 
amount of force used is a matter of 
experience and the neophyte will 
use less than is necessary. The 
curettage should be systematic. The 
completion of curettage is indicated 
by the surgeon feeling the gritty, 
rather firm uterine wall and hear­
ing a different sound on curettage. 
In contrast, remaining placental 
tissue will give a “doughy” feel. 
Warnings of the danger of overcu­
rettage are traditionally given. The 
fear is of Asherman’s syndrome, 
which is a massive scarring of the 
endometrial cavity resulting from 
curettage that removes all of the 
lining of the uterine cavity. This is 
an unusual complication; it is more 
likely to occur when curettage is 
done on a recently pregnant patient.
After curettage is completed, the 
sponge forceps are removed from 
the cervix and the Auvard speculum 
from the vagina. The uterine cavity 
is again explored with the second 
finger. The uterine walls should feel 
remarkably smooth, save for the 
placental site which is roughened. 
Occasionally, placental tissue is pal­
pated and if so the curetting proc­
ess is repeated.
Closed Cervix
In the past, patients who present­
ed with vaginal bleeding but who 
were found to have a closed cervix 
were diagnosed as having a threat­
ened abortion. They were advised to 
“rest in bed and avoid intercourse” ,
and await the final outcome. The 
bleeding, pain and uncertainty as to 
the final result would persist, some­
times for weeks. The use of ul­
trasonography allows us to give 
more studied advice. If the fetus is 
shown to be alive, the prognosis for 
continuation of the pregnancy is 
excellent. The patient should be 
reassured and resumption of normal 
life encouraged. If diagnosis of a 
missed abortion or anembryonic 
pregnancy is made, treatment op­
tions are discussed. There is little 
risk that a missed abortion in the 
first trimester will cause either dis­
seminated intravascular coagulation 
or intrauterine infection. There is a 
small but significant risk associated 
with surgical evacuation of the 
uterus.14 Weighed against this is 
the psychological burden of contin­
uing to carry a pregnancy which 
will abort at some time in the 
future. After weighing treatment 
options, the majority of patients 
will opt for surgical evacuation of 
the uterus.
Complications of uterine evacua­
tion mostly relate to forceful dilata­
tion of the cervix. The use of 
excessive mechanical force to dilate 
the cervix is not only unacceptable 
but unnecessary. If the cervix is 
both undilated and uneffaced, eva­
cuation should not be attempted 
without the preoperative use of 
Laminaria. The means by which 
Laminaria causes dilatation of the 
cervix is unsettled. It is more com­
plex than the slow mechanical dila­
tation of the cervix as a result of 
Laminaria’s enlargement. Apparent­
ly Laminaria causes the cervical 
ground substance to change and 
the secretion of endogenous prosta­
glandins to increase. Laminaria use 
reduces cervical lacerations five­
fold15 and perforation of the uterus 
threefold.16 A recent variant is the 
substitution of the synthetic Lami- 
cel (Cooper Medical Devices Corp., 
Philadelphia, Pa) for the traditional
Laminaria. It acts more quickly, it 
can be inserted 1 hour before dilata­
tion and is less expensive.17
There is an intermediate group of 
patients who are seen early in the 
process of abortion, in whom the 
cervix may be effaced but incom­
pletely dilated. It is a matter of 
judgement as to whether immediate 
surgery is necessary or whether the 
patient’s condition should be moni­
tored. The physician should err on 
the side of conservatism and await 
cervical dilatation.
Bimanual examination confirms 
the size and position of the uterus. 
Hegar dilators should be inserted 
only to a depth of 5 cm. It is 
emphasized that dilatation must be 
easy and should be discontinued if 
more than minimal resistance is 
met. The aim is to dilate the cervix 
to a diameter slightly above that of 
the cannula chosen. Cannula size 
should approximate the size of the 
uterus in weeks. For example, a 
uterus 8 weeks in size should be 
evacuated with an 8-mm cannula, 
and will, therefore, require dilata­
tion of the cervix to a number 10 
Hegar.
Complications
Infection
The diagnosis of septic abortion 
is made when a patient who is 
aborting is found to be febrile. For 
the most part, septic abortion is 
caused by interference with the 
pregnancy. Treatment depends on 
evacuation of infected uterine con­
tents and the use of intravenous 
antibiotics. Evacuation should be 
prompt. It is not necessary to delay 
the evacuation while a prolonged 
course of antibiotics is given. The 
fear of septicemia at the time of 
curettage is unfounded. Clin­
damycin and gentamicin are chosen 
because of the polymicrobic nature
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of the infection. The response will 
be rewarding. Septic shock is an 
uncommon but possible complica­
tion. The patient’s pulse, blood 
pressure and urine output must be 
monitored.
Serious clostridial infections are 
rarely seen. At one time, hysterecto­
my was frequently advised as part 
of the treatment for this infection. 
This is no longer necessary, and 
finding Clostridium sp on Gram’s 
staining of the cervix or even seeing 
gas patterns in the uterine muscle 
on the pelvic x-ray film should not 
be taken as an indication for hyster­
ectomy. A satisfactory response to 
antibiotics (penicillin) should be an­
ticipated with most clostridial infec­
tions. Hysterectomy in this case is 
only indicated when there is evi­
dence of intravenous hemolysis.
Hemorrhage
Continuing vaginal hemorrhage 
after curettage usually relates to an 
incomplete evacuation of the uter­
us. In most instances the uterus 
should be recuretted. The possibili­
ty that the previous dilatation and 
curettage has injured the uterus or 
that a coagulation disorder has de­
veloped must be kept in mind.
Perforation
Perforation of the uterus with 
the suction curet may result in 
catastrophic injury to the intestine 
or its mesentery. The perforation is 
usually diagnosed by seeing the
intestine or fatty tissue in the aspi­
rate. In all such circumstances lapa­
rotomy must be done to confirm the 
extent of the injury. Perforation of 
the uterus by a sound or a dilator is 
not so serious. The abortion can be 
completed under laparoscopic guid­
ance.18
Follow-up
Spontaneous abortion is an inci­
dent in a woman’s life that will 
invariably be remembered. Patients 
often lay the blame for the abortion 
on chance happenings. They should 
be reassured that they are not re­
sponsible and that recurrent abor­
tion is most unlikely. Should re­
peated abortion occur (habitual 
abortion), specialist investigation 
will be required.
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Is Neomycin Necessary for Bowel 
Preparation in Surgery of the Colon? Oral 
Neomycin Plus Erythromycin Versus 
Erythromycin-Metronidazole
R.T. Lewis, MB, FRCSC, FACS;* R.G. Goodall, MD, FRCSC, FACS;t B. Marien, MD, FRCSC;$ 
W. Lloyd-Smith, MD, FRCSC, FACS;t M. Park, MD, FRCSC, FACS;$
F.M. Wiegand, MD, FRCSC, FACS$
In 132 patients who underwent elective surgery of the colon, the value of bowel 
preparation with a conventional oral antibiotic preparation of neomycin- 
erythromycin (N-E) was compared with erythromycin-metronidazole (E-M).
Of 125 patients who were available for assessment, 61 received N-E and 64 E-M. 
The two groups were evenly matched. Two wound infections occurred in patients 
receiving E-M, neither due to anaerobic bacteria, but seven wound infections 
developed in patients given N-E (p =  0.057), five of them caused by anaerobic 
bacteria. Anaerobic bacteria of the colon are the dominant cause of postoperative 
wound infection in elective surgery of the colon. Adequate antibiotic preparation 
directed against these bacteria makes the use of neomycin unnecessary.
On a compare, chez 132 patients qui ont subi une chirurgie non urgente du colon, 
l’efficacite de deux regimes prophylactiques: la preparation antibiotique orale 
classique constitute de neomycine et d’erythromycine (N-E) et une association 
erythromycine et metronidazole (E-M). Des 125 patients evaluables, 61 re?urent la 
N-E et 64 l’E-M. Les deux groupes etaient comparables. Deux infections de plaies 
sont survenues chez les patients qui avaient re?u l’E-M, ni une ni l’autre 
n’impliquant des bacteries anaerobies, alors qu’on compta sept infections de plaies 
chez les patients qui avaient eu la N-E (p =  0.057), dont cinq a bacteries anaerobies. 
Les bacteries anaerobies sont la cause predominate des infections de plaies 
postoperatoires lors des operations non urgentes du colon. Une antibiotherapie 
specifique adequate contre ces bacteries rend superflu l’usage de la neomycine.
N eomycin has long been the mainstay of oral antimicrobial 
prophylaxis for surgery of the colon 
because of its influence on coliform
organisms in the bowel lumen.1 Its 
efficacy was questioned as early as 
1953,2 and by 1974 it was clear 
that neomycin alone did not prevent
wound infection after bowel sur­
gery.34 Since the importance of 
anaerobic bacteria was recognized 
in the pathogenesis of infection 
after surgery of the large bowel,5 
neomycin has been used successful­
ly in combination with such agents 
as tetracycline, erythromycin and 
metronidazole.46-7 
Some surgeons have suggested 
that drugs such as metronidazole 
and lincomycin aimed at anaerobic 
bacteria provide effective bowel 
preparation on their own and there­
fore oral neomycin is unneces­
sary.8-9 Others claim that orally ad­
ministered metronidazole alone has 
no influence on microflora10 and is 
ineffective in preventing wound in­
fections after elective resection of 
the colon.11 The aim of this study 
was to assess whether oral neomy­
cin needs to be added to erythromy­
cin or to combinations of antibiotics 
aimed at anaerobic bacteria to pre­
vent sepsis after elective colonic 
resection.
Methods
Patients admitted into the study 
were scheduled for elective colorec­
tal operations at the Queen Eliza­
beth Hospital, Montreal. Patients 
were excluded if they had received 
antimicrobial therapy during the 
week before surgery or had a histo­
ry of allergy to any of the study 
antibiotics. Written informed con-
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sent was obtained from 132 pa­
tients. All had mechanical bowel 
preparation, consisting of dietary 
restriction, laxatives and enemas.12 
They were then randomized by hos­
pital pharmacists to receive one of 
two prophylactic antimicrobial regi­
mens. The “standard neomycin-ery­
thromycin regimen” (N-E) consisted 
of erythromycin base and neomycin 
sulfate, 1 g each by mouth at 1300 
hours, 1400 hours and 2200 hours 
on the day preceding operation.6 In 
the “ erythromycin-metronidazole 
regimen” (E-M), erythromycin base 
was given as above, but neomycin 
sulfate was replaced by met­
ronidazole orally, 750 mg three 
times daily for 2 days before opera­
tion. The pharmacist responsible for 
randomizing the patients and dis­
pensing the drugs did not partici­
pate further in assessment of the 
patients.
The age, sex, height and weight 
of each patient were recorded. At 
operation, the diagnosis, operative 
procedure and degree of wound 
contamination13 were noted. Speci­
mens were obtained for culture 
from the colon and subcutaneous 
fat of the wound before skin clo­
sure. Infection control personnel
examined the wound on days 5 and 
7 after operation, and thereafter as 
necessary for up to 1 month. A 
wound infection was diagnosed 
when pus drained from the 
wound;14 a sample of the discharge 
was then obtained for culture. 
Wounds that were red or tender 
were followed without antibiotic 
treatment until the problem re­
solved or the wound drained pus. 
An anastomotic leak was diagnosed 
when a fistula developed postopera- 
tively or at operation for postopera­
tive peritonitis. An intra-abdominal 
abscess was diagnosed by the usual 
clinical and radiologic criteria15 and 
confirmed by drainage. A blood­
stream infection was diagnosed 
when a blood culture, done because 
of a postoperative temperature of 
39°C or higher, was positive.
For each patient, a risk index of 
wound infection was calculated 
from the age, degree of wound 
contamination, duration of opera­
tion and results of subcutaneous fat 
cultures, as recommended by David­
son and associates.16 The preopera­
tive total leukocyte and differential 
counts, serum albumin and serum 
iron concentrations and iron-bind­
ing capacity (TIBC) were measured
by standard methods. The blood 
lymphocyte count was calculated as 
the product of the leukocyte count 
and percent lymphocytes, and the 
serum transferrin value was calcu­
lated from the TIBC.17
Statistical analysis was performed 
where necessary by Student’s t-test, 
Fisher’s exact test, and x2 analysis 
with Yates modification.
Results
Sixty-five patients were random­
ized to receive the N-E regimen and 
67 the E-M regimen. Four N-E and 
three E-M patients were excluded 
from further analysis because of the 
presence of overt infection at opera­
tion or for violation of the protocol 
(Table I). Thus, 125 patients 
formed the study group; 61 re­
ceived N-E and 64 E-M.
The two groups were evenly 
matched with respect to age, sex 
and percent actual of ideal weight 
for height. The mean risk index of 
wound infection was higher in the 
E-M group, but the groups were 
similar in wound class, preoperative 
blood lymphocyte count, and serum 
albumin and transferrin concentra­
tions (Table II). Table III compares 
the treatment groups with respect 
to the operative diagnosis and site 
in the large bowel. No differences 
were observed.
A wound infection was diagnosed 
in two patients receiving E-M, corn-
Table  1. R easons fo r  E xc lu d in g  P a tie n ts  fro m  Final A s s e s s m e n t
N eo m yc in -e ry th ro m yc in E ry th rom ycin -m etron idazo le
R e tro p e r ito n e a l abscess In tra -a b d o m in a l a b scess
S y s te m ic  a n tib io t ic s  fo r  m itra l s te n o s is Delayed w o u n d  c lo su re
P o r ta l v e in  th ro m b o s is  (d ied  p o s to p  da y  2) 
P e lv ic  a b s c e s s
A b d o m in a l w a ll a bscess
T a b le  II. C o m parison  o f P a tie n ts  R e ce iv ing  P re o p e ra tive  B ow el P repa ra tion  W ith  N e o m y c in -E ry th ro m y c in  (N -E ) o r E ry th ro m y c in -M e tro n id a z o le  (E -M ).
V a lues  A re M ean ±  SEM
F a c to r
Group
N-E E -M
S ign ificance  
(t va lu e )
A ge , y r 68  ± 2 6 7  ± 2 NS (0 .5 9 )
S e x , M /F 3 1 /3 0 3 2 /3 2 NS
W e ig h t,  % a c tu a l/id e a l 116  ±  3 1 1 5  ±  3 NS (0 .2 4 )
R is k  in d e x , % 31 ±  2 .6 4 2  ±  2 .5 p <  0 .01 (3 .0 6 )
W o u n d  co n ta m in a tio n  
(c o n ta m in a te d /c le a n -c o n ta m in a te d ) 1 1 /5 0 1 0 /5 4 NS
B lo o d  ly m p h o c y te s , X  10 9/L 1 .549  ± 0 .0 9 2 1 .4 4 4  ±  0 .0 7 8 NS (0 .8 7 )
S e ru m  a lb u m in , g /L 36 .8  ±  0 .0 7 3 6 .8  ±  0 .7 NS (0 .0 7 )
S e ru m  tra n s fe rr in , g /L 1.63 ± 0 .0 6 3 1 .7 5  ± 0 .0 7 1 NS (1 .2 5 )
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pared with seven patients receiving 
N-E (p =  0.057, Fisher’s exact 
test). Other postoperative complica­
tions were similar in the two groups 
(Table IV). Table V lists the bacteria 
causing wound infection. Anaerobic
bacteria were found in five of the 
seven wound infections in the N-E 
group, but were absent from in­
fected wounds of both E-M patients. 
Figure 1 shows the results o f in­
traoperative stool culture from the 
bowel lumen. Anaerobic bacteria 
were still present in significant 
numbers of patients who received 
N-E, whereas coliforms were domi­
nant in the E-M group.
Discussion
T a b le  II I .  C o m p a riso n  o f T re a tm e n t G rou p s -  O p e ra tive  D ia g n o s is  and S ite
D ia g n o s is /S ite N-E
Group
E -M S ig n ificance
D ia g n o s is
T u m o u r 45 41
In fla m m a tio n 14 19 NS
O the r 2 4
O p e ra tive  s ite
L e ft co lo n  o r  re c tu m 48 48
R ig h t o r  tra n sv e rse  co lo n 13 16 NS
T a b le  IV . C o m parison  o f P o s to p e ra tiv e  C o m p lic a tio n s
Group
C om plication N-E E -M
W o u n d  in fe c tio n 7 (1 1 .5 % ) 2 (3 .1% )
A n a s to m o tic  leak 1 2
In tra -a b d o m in a l a b scess 0 1
B lo o d s tre a m  in fe c tio n 1 0
T o ta l se p s is 7  (1 1 .5 % ) 3 (4 .7% )
T a b le  V. B ac te ria  C a us ing  In fe c tio n
Group N-E G roup E-M
No. of No. O f
B acteria patien ts B acteria p a tien ts
Escherichia coli + Escherichia coli +
Bacteroides fragilis 3 Streptococcus G roup  D 1
Clostridium sp /Peptococcus 1 Enterococcus 1
A n a e ro b ic  d ip th e ro id s /
Staphylococcus epidermidis 1
Staphylococcus aureus 1
Staphylococcus aureus +
Escherichia coli 1
N-E P E-M
Anaerobes 30 ? 001
Coliforms 25 0 . 0 0 1 3  jij:
50
Candida 16 0 . 0 0 8 : 6
No growth 10 0 .0 7 5 5
No. of patients
FIG. 1. Results of cultures taken intraoperatively from bowel lumen. N-E = 
neomycin-erythromycin, E-M = erythromycin-metronidazole.
Although the neomycin-ery­
thromycin preparation has been the 
“ gold standard”  of antibiotic prepa­
rations for elective colonic sur­
gery,18 there is still controversy 
about how it works and the reasons 
for its success in preventing postop­
erative infection.19 The current con­
sensus is that aerobic and anaerobic 
bacteria are both important in the 
pathogenesis of infection after elec­
tive colonic surgery and that antibi­
otics used for prophylaxis should be 
effective against both groups of 
bacteria.20 In the N-E preparation, 
neomycin is given to reduce the 
number of coliform bacteria in the 
large bowel and erythromycin is 
used to reduce the number of an­
aerobic bacteria. However, several 
questions arise.
First, is it necessary to reduce the 
number of coliform organisms in 
the bowel lumen by giving neomy­
cin orally? This question arises be­
cause neomycin fails to prevent 
wound infection when used alone, 
but it works well when combined 
with antibiotics that kill intestinal 
anaerobic bacteria (Table VI3'4'6-7'21- 
24). We have shown that neomycin 
is not necessary. Indeed, the regi­
men that excluded neomycin was 
marginally more successful, and 
most failures of N-E were caused by 
intestinal anaerobes, not coliforms; 
E-M prevented these infections de­
spite persistence o f coliforms in the
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colon. Arabi and associates10 and 
Vallance and colleagues11 found a 
neomycin-metronidazole prepara­
tion more effective than met­
ronidazole alone, but they gave 
only a small dose of metronidazole. 
Our findings agree with those of 
most other workers.8'9 25-28 Neomy­
cin is not necessary for bowel prep­
aration; and, when given alone, neo­
mycin fails because it is ineffective 
against the dominant anaerobic bac­
teria of the colon.
Second, does neomycin also fail 
because it is not absorbed from the 
bowel? This raises the larger ques­
tion of whether the dominant effect 
of oral antibiotic prophylaxis in 
colonic surgery is systemic (destroy­
ing bacteria in blood and con­
taminated tissues) or luminal (re­
ducing the number of bacteria in 
the colon). Our study did not exam­
ine this question, but others sug­
gest a primary systemic29-30 and sec­
ondary luminal effect.101131
Keighley and colleagues29 com­
pared oral with intravenous ka- 
namycin and metronidazole in pa­
tients having colonic operations. 
The oral preparations did not pro­
duce substantial blood levels of the 
antibiotics, but did reduce the num­
ber of bacteria in the bowel. Wound 
sepsis was high (36%). On the other 
hand, the intravenous agents did 
not change the fecal microflora but 
produced high blood levels of anti­
biotics and a low rate of wound 
infection (6.5%). Using a higher 
dose of oral metronidazole, Dion 
and coworkers30 compared oral with 
intravenous neomycin and met­
ronidazole. Bacterial counts in the 
colon were low and blood levels of 
metronidazole were high with both 
regimens, and in both the rate of 
wound sepsis was low. Taken in 
conjunction, these studies show 
that the main effect of the oral 
antibiotics is systemic: when blood 
concentrations of appropriate anti­
biotics are high, the wound infec­
tion rate is low, even in the pres­
ence of normal colonic microflora; 
when blood concentrations of the 
antibiotics are low, the wound infec­
tion rate is high, despite effective 
reduction of bacterial counts in the 
colon.
Other studies suggest a lesser 
luminal effect for oral antimicrobi­
als in bowel preparation. Thus, 
Arabi and colleagues10 and Vallance 
and colleagues11 found that low- 
dose metronidazole alone had no 
effect on colonic microflora, and 
allowed wound infections to develop 
in 51% of patients having elective 
colonic surgery. Neomycin alone 
reduced the number of coliform 
bacteria in the bowel but had no 
effect on colonic anaerobes. When 
given together, neomycin and met­
ronidazole profoundly reduced both 
aerobic and anaerobic bacteria in 
the colon, and reduced the inci­
dence of wound infection to 22%. 
Similarly, Finegold31 has suggested 
that in the N-E preparation, eryth­
romycin acts to prevent the over­
growth of anaerobic bacteria that 
occurs when neomycin alone is 
used.
Third, are agents that are effec­
tive only against anaerobic bacteria 
adequate for oral antibiotic prepara­
tion of the colon? Our study shows 
that erythromycin-metronidazole is 
effective; and Keighley and associ­
ates32 found lincomycin, a macrolide 
antibiotic related to erythromycin, 
effective when given intravenously.
Most workers9-26-28-33 report that 
metronidazole alone provides good 
prophylaxis, but, as noted above, 
Vallance and associates11 found low- 
dose oral metronidazole ineffective.
Would erythromycin alone be 
sufficient? This question has not 
been studied. However, we can spe­
culate that it would be no better 
than low-dose metronidazole, since 
oral erythromycin in the N-E prepa­
ration has only a marginal systemic 
effect against intestinal anaerobes. 
Approximately 50% of the oral dose 
is absorbed,34 but wide variations 
occur.35 So although the mean peak 
blood concentration of erythromy­
cin, 3.4 to 6.5 Atg/ml,35-40 is suffi­
cient to inhibit many anaerobic bac­
teria, including 60% to 90% of 
isolates of Bacteroides fragilis,3B 
blood concentrations vary widely in 
individual patients. Therefore oral 
erythromycin alone probably has an 
unreliable systemic effect against 
anaerobic bacteria of the colon; and 
this may explain some of the report­
ed failures of the N-E prepara­
tion.40-41 Certainly, in the present 
study, the failure of the N-E prepa­
ration was a failure of erythromy­
cin, since anaerobic bacteria were 
dominant in most infections in the 
N-E group. Unfortunately, blood 
concentrations of erythromycin 
were not measured. We have report­
ed similar findings before.42
We can also speculate that neo­
mycin contributes to the usual suc­
cess of the N-E preparation by
T a b le  V I. R eported  R esu lts  U s in g  N e o m y c in  O ra lly  in B ow e l P repara tion
S erie s
W ound infection, no. (% )
N eom ycin Controls
N eom ycin  +  
antib io tic  aga inst 
anaerob ic  bacteria
R ubbo  and co lle a g u e s, 1 9 6 5 3 11 (2 8 ) 1 9 (4 8 )
H ughes , 196722 35  (3 7 ) 38  (48 )
W a s h in g to n  and co lle a g u e s, 1 9 7 4 4 28  (4 1 ) 27 (43 ) 3 (4 .6 )
C la rke  and co lleagues, 1 9 7 7 6 21 (35 ) 5 (8 .9 )
K han and N ixon, 1 9 7 8 23 9 ( 6 0 ) 3 (2 0 )
M a th e s o n  and co lle a g u e s , 1 9 7 8 7 25  (4 2 .3 ) 9 (1 7 .6 )
M o lin  and R ieger, 1 9 7 9 21 41 (62 ) 9 (1 2 )
Ja g e lm a n  and co lle a g u e s , 1 9 8 5 24 8 (2 2 ) 0 ( 0 )
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synergy with erythromycin. This ef­
fect may be similar to that observed 
with low-dose metronidazole.1011 In 
the present study, we chose instead 
to augment the power of antimicro­
bial preparation against anaerobes 
by giving metronidazole orally in a 
dose sufficient to inhibit and de­
stroy intestinal anaerobic bacte­
ria. 12-30'43 Our study confirms the 
efficacy of this regimen directed 
only against the anaerobic bacteria 
of the colon.
Finally, is oral neomycin poten­
tially harmful when used for antibi­
otic preparation of the colon? The 
main risk is from the emergence of 
resistant organisms. As early as 
1953, Poth2 noted overgrowth of 
Candida in patients on a 3-day 
neomycin preparation. Nichols and 
colleagues1 found no evidence of 
Candida overgrowth when a short 
(19-hour) neomycin-erythromycin 
preparation was used, but Weaver 
recently questioned this finding.37 
We observed some overgrowth of 
Candida in the N-E group, but no 
clinical problem resulted from this.
It appears, then, that oral neomy­
cin is not necessary for antibiotic 
preparation of the colon when ade­
quate prophylaxis against anaerobic 
bacteria is provided. It remains to 
be seen whether systemic antibiot­
ics effective against coliforms can 
produce a further reduction in post­
operative wound infection.
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University of Toronto — 
Continuing Education
A symposium on ischemia/reperfusion 
injury in skeletal muscle will be held 
Sept. 10, 1989 in Toronto. For further 
information contact: Continuing Educa­
tion, Faculty of Medicine, University of 
Toronto, Medical Sciences Building, To­
ronto, Ont. M5S 1A8; (416) 978-2718.
American Association for Hand 
Surgery
The 19th annual meeting of the Ameri­
can Association for Hand Surgery will 
be held in San Francisco, Calif., Oct. 
26-29, 1989. The program’s goal is to 
provide those attending with state-of- 
the-art information on hand surgery 
through panel discussions, mini-courses 
and “ask-the-expert” sessions. Write to 
Myra Josephson, Central Office Manag­
er, American Association for Hand Sur­
gery, Ste. 210, 2934 Fish Hatchery 
Rd., Madison, WI, 53713 for informa­
tion or call (608) 273-8940.
Bone and Soft-Tissue Tumours
A conference on the diagnostic modali­
ties, pathologic features and treatment 
of bone and soft-tissue tumours will be 
held Nov. 3 -5 , 1989 in Sacramento, 
Calif., which will also be the setting for 
a symposium on anesthesiology Nov. 
17-19. Information on both of these 
events can be obtained from the Office 
of Continuing Medical Education, UC 
Davis School of Medicine, 2701 Stock- 
ton Blvd., Sacramento, CA 95817; 
(916) 453-5390.
American Back Society
The American Back Society Fall Sym­
posium on Back Pain will be held from 
Nov. 30 to Dec. 3, 1989 in Las Vegas. 
The course chairman is Dr. Vert Moo­
ney. The course provides 18 hours of 
CME credit. For further information 
contact: American Back Society, 2647 
East 14th Street, Ste. 401, Oakland, 
CA 94601, or phone (415) 536-9929.
SESAP VI Critique
Item 300
Prolonged total parenteral nutrition (TPN) can produce significant liver 
abnormalities, including fatty infiltration of the liver, particularly when 
the glucose to nitrogen calorie ratio is high. The resultant hepatocellu­
lar damage occurs to the various enzyme systems in the hepatocytes, 
and these changes occur long before the hepatocyte damage leads to a 
bile leak into the vascular spaces. Liver enzymes should be monitored in 
any patient receiving TPN. Monitoring reveals abnormalities in the 
various transaminases, the alkaline phosphatase, and gammaglutamyl 
transferase long before hyperbilirubinemia occurs. If one waits until the 
patient becomes clinically jaundiced or simply follows the bilirubin as an 
indicator of liver damage, hepatic damage would be much greater than 
if enzymes are used for monitoring.
cu
References
300/1. Fischer JE: Metabolism in surgical patients; Protein, carbohy­
drate, and fat utilization by oral and parenteral routes, in Sabiston DC 
Jr (ed): Textbook of Surgery. The Biological Basis of Modern Surgical 
Practice, ed 13. Philadelphia, WB Saunders Co, 1986, p 142 
300/2 . Fischer JE: Surgical Nutrition. Boston, Little Brown & Co, 
1983
270 CJS, VOL. 32, NO. 4, JULY 1989
ORIGINAL ARTICLES
Patent Ductus Venosus: Problems in 
Assessment and Management
M.F. Barsky, MD, FRCPC;* R.N. Rankin, MB, ChB, FRCPC;* W.J. Wall, MD, FRCSC;t 
C.N. Ghent, MD, FRCPC;* B. Garcia, MD, FRCPC§
A congenitally patent ductus venosus is the rarest form of portosystemic shunt. 
Although it occurs in the absence of serious parenchymal liver disease, it may be 
associated with hepatic encephalopathy. This case report describes a 49-year-old 
man with a patent ductus venosus who presented with recurrent bouts of 
encephalopathy but few other features of chronic liver disease. Ligation of the shunt 
was followed by life-threatening complications. The portal venous system must be 
carefully assessed before closure of a patent ductus venosus is attempted.
La persistance du canal veineux represente la forme la plus rare d’anastomose 
congenitale systemo-porte. Bien qu’elle survienne en l’absence d’atteinte grave du 
parenchyme hepatique, elle peut etre associee a une encephalopathie hepatique. On 
fait la description du cas d’un homme de 49 ans presentant une persistance du canal 
veineux et qui a ete vu souffrant d’acces d’encephalopathie a repetition, en l’absence 
d’autres signes d’hepatite chronique. La ligature de l’anastomose fut suivie de 
complications qui mirent en peril la vie du patient. Le systeme veineux porte doit 
etre soigneusement evalue avant de tenter la fermeture du canal veineux.
Portosystemic encephalopathy is a well-recognized complication 
of surgically created portosystemic 
shunts, performed to relieve portal 
hypertension. Bypassing blood from 
the normal detoxification processes 
within the liver can result in neuro­
logic disturbances manifested in 
many ways.1 Congenital portosys­
temic shunts are rare, but have also 
been associated with encephalopa­
thy.1-6 We recently treated a man 
suffering from recurrent episodes of 
encephalopathy, in whom a diagno­
sis of hepatoportal sclerosis had 
been made by liver biopsy. A patent 
ductus venosus was demonstrated
Accepted for publication Aug. 30, 1988
by ultrasonography and angiogra­
phy. There have been a few in­
stances in which surgical ligation or 
resection of a portosystemic shunt 
has led to clinical improvement and 
correction of encephalopathy.2-5 
This report describes a serious com­
plication resulting from attempted 
closure of the shunt and reviews 
the literature relating to congenital 
portosystemic shunts.
Case Report
A 49-year-old man was admitted 
to the University Hospital in Lon­
don, Ont., for assessment for a liver 
transplant. In 1979, recurrent he­
patic encephalopathy secondary to 
portal vein occlusion had been diag­
nosed. The patient was born prema­
turely, his intelligence quotient was 
borderline and milestones of devel­
opment were delayed; he required 
special education classes. He was, 
however, functional, was married 
and held several jobs. He was first 
seen after repeated episodes of con­
fusion, inappropriate behaviour and 
tremulousness that began around 
1974. There was no history of drug 
or alcohol abuse or hepatitis. In 
1979, abdominal angiography, in­
cluding selective celiac and superior 
mesenteric artery injection, demon­
strated tortuous hepatic arteries. 
The venous phase demonstrated a 
markedly dilated portal vein (5 cm). 
Splenoportography showed an ap­
parent portal vein obstruction at the 
porta hepatis, but no collaterals 
were seen. No esophageal varices 
were seen on endoscopy. A percuta­
neous liver needle biopsy showed 
changes of hepatoportal sclerosis 
with a striking absence of visible 
venules in the portal areas.
Over the next few years, the 
patient was admitted to hospital on 
numerous occasions with recurrent 
episodes of hepatic encephalopathy. 
Serum ammonia levels were variably 
elevated, as high as 176 /umol/L 
(normal 11 to 35 /umol/L), with 
normal liver enzymes, slightly de­
creased albumin and mildly elevated 
serum bilirubin levels. He initially 
responded well to therapy, which
From the *Department o f  Radiology, fDepartment o f Surgery, f  Department o f  Medicine and 
§Department o f  Pathology, University Hospital, University o f Western Ontario, London, Ont.
Reprint requests to: Dr. Richard N. Rankin, Radiology Department, University Hospital, 339 
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included lactulose, neomycin and a 
low protein diet. However, progres­
sive physical and mental deteriora­
tion led to his admission to a nurs­
ing home in 1986.
At that time he was inattentive, 
agitated and had a resting tremor 
and athetosis. There was one spider 
nevus and testicular atrophy, but 
no other signs of chronic liver dis­
ease. Results of cerebellar function 
tests were abnormal, reflexes were 
brisk and Babinski’s reflex was pos­
itive. There were no Kayser- 
Fleischer rings. Laboratory tests 
showed mildly abnormal liver en­
zyme levels and tests of synthetic 
function gave the following results: 
serum alanine aminotransferase 43 
U/L (normal 5 to 30 U/L), aspar­
tate aminotransferase 36 U/L (nor­
mal 10 to 30 U/L), 7-glutamyl 
transferase 40 U /L  (normal 0 to 30 
U/L), alkaline phosphatase 135 
U/L (normal 18 to 113 U/L), pro­
tein 54.3 g /L  (normal 60 to 80 
g/L), albumin 26.4 g /L  (normal 
29 to 49 g/L), total bilirubin 22.8 
/umol/L (normal 3.4 to 17.1 
^mol/L). The serum ammonia level 
was 39 ij.mol/L (normal 11 to 35 
jumol/L) and the serum copper was 
10.7 junol/L (normal 11 to 22 
jiimol/L).
Ultrasonography demonstrated a 
large tortuous vessel originating 
from the portal vein and communi­
cating with the inferior vena cava 
(Fig. 1). Celiac angiography con­
firmed the abnormal communication 
between the inferior vena cava and 
the proximal left branch of the 
portal vein. This was catheterized 
through the inferior vena cava, and 
retrograde injection demonstrated 
patent portal, splenic and superior 
mesenteric veins (Fig. 2). Small, 
tortuous portal branches to the 
right lobe, with a deficient branch­
ing pattern, were also seen (Fig. 3).
The patient was operated on to 
close the patent ductus venosus in 
the expectation that the portosys­
temic encephalopathy would be 
cured by redirecting portal flow to 
the liver. Division and closure of the 
patent ductus as it entered the 
retrohepatic cava was performed 
without difficulty, but following clo­
sure of the shunt, the bowel became 
edematous and engorged. Portal 
vein pressure changed from 18 cm 
H20  before ligation to 31 cm H20 
after. Postoperatively, there was an 
increase in abdominal girth, oliguria 
and acidosis and a rise in the serum 
inorganic phosphate level. Because 
of the clinical findings, laparotomy 
was carried out 12 hours later, 
revealing dusky, engorged, edema­
tous intestine, ascites and clot with­
in the portal vein. An end-to-side 
portacaval shunt was performed. 
Bowel colour immediately improved 
and adequate urine output was re­
stored. The patient required a third 
operation 2 days later to ligate a 
bleeding artery adjacent to the por­
tal vein dissection. At that time, the 
intestine was normal.
The patient recovered from the 
surgery but his mental status re­
mained poor. While awaiting place­
ment in a nursing home 7 months 
later, pneumonia developed and he 
died.
At autopsy, the liver appeared 
small; it weighed 650 g. There was 
micronodular scarring, particularly 
in the periportal regions, but with­
out regenerative nodules. Within
FIG. 1. Portal region demonstrates 
large communication (arrow) between 
portal vein and inferior vena cava.
the periportal hepatocytes there 
were a-1-antitrypsin globules.
Discussion
Previous reports of congenital 
portosystemic anastomoses have de­
scribed a variety of connections. 
Raskin and associates2 described a 
patient with multiple connections
FIG. 2. Anteroposterior (top) and lat­
eral (bottom) views showing catheter­
ization of shunt vessel via inferior 
vena cava. Patent splenic vein and 
proximal left portal vein are seen with 
antegrade flow of contrast up inferior 
vena cava.
\
\
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between portal and hepatic veins. 
Kerlan and colleagues3 reported a 
patient who had an extrahepatic 
communication between portal vein 
and inferior vena cava. Ohtomo and 
colleagues4 found multiple in- 
trahepatic channels between 
branches of the portal and hepatic 
veins in their patient. Chagnon’s 
group5 reported on two patients, 
one with an aneurysmal communi­
cation between left portal and left 
hepatic veins and another with mul­
tiple connections between right por­
tal vein and an accessory right 
hepatic vein. Mori and associates6 
presented a patient who had multi­
ple peripheral portohepatic shunts 
through the liver. All these patients 
had encephalopathy.
Wittich and associates7 described 
a shunt between a right portal vein 
branch and the middle hepatic vein, 
in a patient who was asymptomatic. 
A right portal vein to right hepatic 
vein shunt was observed also in an 
asymptomatic patient by Charn- 
sangavej and colleagues.8 Mori and 
associates9 had two patients with 
membranous obstruction of the in­
ferior vena cava; one had a connec­
tion between the left portal vein and
FIG. 3. Selective catheterization of 
right portal vein by way of shunt 
vessel demonstrates small but patent 
right portal vein with incomplete, 
slightly bizarre branching pattern.
the inferior vena cava and the other 
was between the right portal vein 
and right hepatic vein. A patent 
ductus venosus was reported by 
Ohnishi and colleagues10 in a pa­
tient with alcohol-induced cirrhosis 
and encephalopathy. To the best of 
our knowledge, this is the first 
report of a patent ductus venosus in 
a patient who had minimal signs of 
liver disease.
Surgical intervention, carried out 
in three of the symptomatic cases, 
included resection of the involved 
area of liver or ligation of the shunt 
vessel.235 In another case,4 several 
channels were closed by coil emboli­
zation. The encephalopathy was im­
proved in all patients, apart from 
Raskin’s, who died 2 days postoper- 
atively of prolonged hypotension, 
renal failure and pneumonia. Our 
case is unique in that ligation of the 
shunt resulted in acute portal ve­
nous congestion and bowel isch­
emia requiring decompression of 
the portal vein by an emergency 
portacaval shunt.
Our patient was reported previ­
ously11 as a case of occult portal 
vein occlusion, neuropsychiatric 
disturbances being the presenting 
feature. At that time, the nature of 
the portosystemic shunt was not 
appreciated. This may be because of 
the limited injection of contrast 
material used in performing spleno­
portography and superimposition of 
the dilated portal vein over the 
ductus. Clearly, the shunt must 
have been present in view of the 
apparent portal vein occlusion with­
out variceal collaterals.
Pathologically, a diagnosis of he- 
patoportal sclerosis was made. The 
pathogenesis of this condition is 
uncertain. Phlebosclerosis may be 
secondary to thrombosis within the 
portal venous system, but a primary 
phlebosclerosis or congenital failure 
of normal development of the portal 
venous system are possible 
causes.12 The extent of liver in­
volvement may vary and liver biopsy 
may not reflect the degree of portal 
venous obstruction.13 We believe 
that our patient’s hepatoportal scle­
rosis reflects congenital failure of 
the ductus venosus to close togeth­
er with hypoplasia of intrahepatic 
portal venous radicals. No precipi­
tating events could be established. 
The onset of neurologic symptoms 
in late adulthood is consistent with 
previously reported cases;1"5 en­
cephalopathy may be due to in­
creasing sensitivity of an aging 
brain to toxic materials. The patient 
was determined to be heterozygous 
for a-l-antitrypsin deficiency; 
whether this condition played an 
additive or separate role is unclear. 
However, the portal venous branch­
ing pattern was not typical of that 
seen in cirrhosis.14
Although previous reports have 
shown good results after interrup­
tion of portosystemic connections 
in noncirrhotic patients, in our case 
the result was life-threatening be­
cause the intrahepatic portal venous 
system could not accommodate sud­
den restoration of the normal portal 
blood flow. Detailed angiography of 
the portal system, including visual­
ization of intrahepatic portal radi­
cals, is suggested as a prerequisite 
to operation on these patients. The 
integrity of the portal system must 
be established if ligation of a por­
tosystemic collateral is planned. Ap­
preciation of the venous intrahepat­
ic anatomy in our case could have 
warned of this problem and deter­
mined the need for an alternative 
surgical strategy.
We thank Dr. S.N. Sullivan for allowing 
us to review his files on this patient.
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"CIPRO"
Ciprofloxacin Hydrochloride 
THERAPEUTIC CLASSIFICATION
Antibacterial Agent
PRESCRIBING INFORMATION 
ACTIONS
Ciprofloxacin, a synthetic fluoroquinolone, has a bactericidal mode of action. This actli 
achieved through inhibition of DNA gyrase, an essential component of the bacterial _ . 
replication system, inhibition of the alpha subunit of the DNA gyrase Mocks the reseating of 
the nicks on the DNA strands induced oy this alpha subunit, leading to the degradation ofthe  
DNA by exonucleases. This bactericidal activity persists not only during the multiplication 
phase, but also during the resting phase of the Bacterium.
Ciprofloxacin retained some of its  bactericidal activity after inttibitfoh of RNA and protein 
synthesis by rifamycin and chloramphenicol, respectively. These observations suggest 
ciprofloxacin may possess two bactericidal mechanisms, one mechanism resulting from 
the inhibition of DNA gyfase and a second mechanism which may be independent on RNA 
and protein synthesis,
INDICATIONS AND CLINICAL USES
CIPRO* (CtoroflQxacm Hydrochloride Monohydratei may be indicated tot the treatment of patients 
with the following infections caused by susceptible strains of the indicated microorganisms' 
RESPIRATORY TRACT INFECTIONS:
Acute bronchitis and acute pneumonia caused by '  ... .
Enterobacter cloacae mmgumtgmmmm/fc’ Proteus mirabilis 
Escherichia cnii Pseudomonas aeruginosa
Haemophilus in f im m  Staphylococcus aureus
Klebsiella pneumoniae Streptococcus pneumoniae
Due to the nature of the undeflying conditions which usually predispose patients to 
Pseudomonas infections of the respiratory tract, bacterial eradications may not be achieved 
in patients who display clinical improvement despite evidence of in vitro sensitivity. In 
patients requiring subsequent courses of therapy, CIPRO* should be used alternately with 
other anti; pseudomonal agents. Some strains of Pseudomonas aeruginosa may develop 
"uring treatment. Therefore, susceptibility testing should be performed period
DNA
therapy to detect the 
CT INFECTIONS:
o f  bacterial resistance.
Upper and lower urinaryry tract infections, such as complicated and uncomplicated cystitis, 
pyelonephritis, and pyefitis, caused by:
Citrobacter diversus 
Citrobacter treundn 
Enterobacter cloacae 
Escherichia coli 
Klebsiella pneumoniae 
Klebsiella oxytoca 
Morganeiia morganii 
SKIN AND SOFT TISSUE INFECTIONS: 
caused by:
Enterobacter cloacae 
Escherichia coli 
Klebsiella pneumoniae 
Proteus vulgaris 
Proteus mirabilis 
BONE AND JOINT INFECTIONS: 
caused by:
Enterobacter cloacae 
Pseudomonas aeruginosa
INFECTIOUS DIARRHEA: (When antibacterial therapy is indicated) 
caused by:
Escherichia coli (enterotoxigenic strains) Shigella flexneri
Campylobacterjejuni Shigella sonnei
Moieus
Pseudomonas aeruginos. 
Serntia marcescens 
Staphylococcus aureus 
Staphylococcus epidermidis 
Streptococcus taecalis * j
Pseudomonas aeruginosa 
Streptococcus pyogenes 
Staphylococcus aureus 
Staphylococcus epidermidis
Serntia marcescens 
Staphylococcus aureus
. . . Therapy with CIPRO* may L . ______________________
these tests are known. However, modification of this treatment may be required once results 
become available or if there is no clinical improvement. Culture and susceptibility testing 
performed periodically during therapy will provide information on the possible emergence or 
bacterial resistance.
CONTRAINDICATIONS
CIPRO* (Ciprofloxacin Hydrochloride Monohydrate) is contraindicated in patients who have 
shown hypersensitivity to ciprofloxacin or other quinolone antibacterial agents.
WARNINGS
Children
The safety of CIPRO* (Ciprofloxacin Hydrochloride Monohydrate) in children has not yet 
been established. Damage to juvenile weight-bearing joints and lameness were observed 
both in rat and dog studies but not in weaned piglets (see Product Monograph: TOXI­
COLOGY). Histopatnological examination ot the weight-bearing jo in ts  of immature dogs 
revealed permanent lesions of the cartilage. Consequently, CIPRO* should not be used in 
prepubertal patients.
Pregnancy
The safety of CIPRO* in the treatment of infections in pregnant women has not yet been 
established (see PRECAUTIONS).
PRECAUTIONS
General
Anaphylactic reactions including cardiovascular collapse have occurred rarely in patients 
receiving therapy with CIPRO* (Ciprofloxacin Hydrochloride Monohydrate). These reactions 
have occurred within the first 30 minutes following the first dose and may require epineph­
rine and other emergency measures.
CIPRO* may cause central nervous system (CNS) stimulation which may lead to tremor, 
restlessness, light-headedness, confusion, and very rarely to hallucinations or convulsive 
seizures. Therefore, CIPRO® should be used with caution in patients with CNS disorders, 
such as severe cerebral arteriosclerosis or epilepsy. Patients with known convulsive seizure 
disorders should only be treated with CIPRO* if anticonvulsive therapy has been initiated. 
Crystalluria related to ciprofloxacin has been reported only rarely in man because human 
urine is usually acidic. Patients receiving ciprofloxacin should be well hydrated and alkalinity 
of the urine should be avoided. The recommended daily dose should not be exceeded. 
Crystals of ciprofloxacin have been observed rarely in the urine of human subjects but more 
frequently in the urine of laboratory animals.
Prolonged use of CIPRO" may result in the overgrowth of nonsusceptible organisms. Careful 
observation of the patient is therefore essential, and if superinfection should occur during 
therapy, appropriate measures should be taken.
Pregnancy
The safety of CIPRO * in pregnancy has not yet been established. CIPRO* should not be used 
by pregnant women unless tne likely benefits outweigh the possible risk to the fetus. CIPRO" 
has been shown to be non-embryotoxic and non-teratogemc in animal studies.
Nursing Mothers
It is not known whether ciprofloxacin is excreted in human milk. However, it is known that 
cipiQtlgxacin is. excreted in the milk of lactating rats and that other drugs ot this class are 
excreted in human milk. A decision should be made to discontinue nursing or to discontinue 
the administration of CIPRO* , taking into account the importance of the drug to the mother 
and the possible risk to the infant.
Drug Interactions
Concurrent administration of ciprofloxacin with theophylline may lead to an elevated plasma 
concentration and prolongation ot elimination h a lf-ti '----------  1.....  _ ..... ife of theophylline. This may result in
ted adverse reactions. It concomitant use cannot be 
theophylline should be monitored and dosage adjust-
increased risk of fheophyll, .
avoided, plasma concentrations 
ments made as appropriate 
Ciprofloxacin has been shown to interfere with the metabolism and pharmacokinetics of 
caffeine. Excessive caffeine intake should be avoided.
Probenecid blocks renal tubular secretion of ciprofloxacin and has been shown to produce an 
increase in the level of ciprofloxacin in the serum.
Concomitant administration of a nonsteroidal anti-inflammatory drug with ciprofloxacin has 
been reported to increase the risk of CNS stimulation and convulsive seizures.
Antacids containing aluminum or magnesium hydroxide have been shown to reduce the 
absorption of ciprofloxacin. Concurrent administration with these agents should be avoided. 
Renal Impairment
Since ciprofloxacin is eliminated primarily by the kidney, CIPRO* should be used with 
caution and^areduced dosage in patients with impaired renal function (see DOSAGE AND
ADVERSE REACTIONS
CIPRO" (Ciprofloxacin Hydrochloride Monohydratei is generally well tolerated. During worldwide 
clinical investigation, 8,861 courses of ciprofloxacin treatment were evaluated for drug 
safety. (Included in this evaluation were data from 283 patients who received ciprofloxacin 
only intravenously and 169 patients who received sequential intravenous/oral ciprofloxacin 
therapy.)
Adverse events, whether drug-related or not. occurred in 10.2% of patients These adverse 
events occurred in the following frequencies: Gastrointestinal System (5.0%). Central 
Nervous System f t  .6%). Skirr/Hypersensitivity (1.4%), and Adverse Laboratory Changes
(5.6%). J M
The most frequently reported events, drug-related ofjnot, were nausea jl ,6%) and diarrhea
Additional events that occurred in less than 1% of ciprofloxacin courses are listed below:
Gastrointestinal vomiting, dyspepsia, abdominal pain, anorexia
Central Nervous System: dizziness, light-headedness, headabhe, nervousness, anxiety,
agitation, restlessness, tremor, lethargy, drowsiness, somnolence
Skin/Hypersensitivity: rash, pruritus, local edema, urticaria, increased perspiration,
photosensitivity
Most of the adverse events were described as only mild or moderate in severity.
There have been 9 reports of arthropathy associated with CIPRO®. Three of these reports 
involved children. Arthralgia was usually the first symptom which led to rapid assessment 
and withdrawal of the drug. No irreversible arthropathies have been observed.
Adverse Laboratory Changes
Changes in laboratory parameters listed as adverse events without regard to drug relationship (5.6%): 
Hepatic: Elevations of: SGPT (1.3%), SGOT (1.4%),
^ kHal(iSe3^ferStma^ ,S r°u^|b^,amyl tranSpep,idaSe
Hematologic: Eosinophilia (0.6%), leukopenia (0.2%)
Renal: Elevations of: Serum creatinine (0.3%), BUN (0.3%)
Other changes occurring in less than 0.1% of courses were: elevated uric acid elevated 
cholesterol, increase in Blood platelets, monocytes, and leukocytes 
SYMPTOMS AND TREATMENT OF OVERDOSE
Overdose has not yet been reported with CIPRO® (Ciprofloxacin Hydrochloride Mono­
hydrate). In the event of acute overdosage, the stomach should be emptied by inducing 
vomiting or by gastric lavage. The patient should be carefully observed and aiven sup­
portive treatment.
DOSAGE AND ADMINISTRATION
The determination of dosage for any particular patient must take into consideration the 
severity and nature of the infection, the susceptibility of the causative organism and the 
status of renal (unction.
CIPRO® (Ciprofloxacin Hydrochloride Monohydrate) may be taken before or after meals 
Absorption is faster on an empty stomach. Patients should be advised to drink fluids liberally 
and not take antacids containing magnesium or aluminum.
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Adult 
The recommended dosages of CIPRO~· are: DOSAGE FORMS Avallablltty 
Location of Unll Fre- Dally 
CIPRO® 250-each tablet contains ciprofloxacin hydrochloride monohydrate 
equivalent to 250 mg c1pro1Joxacin. 
Infection Type/Severity Dose quency Dose CIPRO® 500-each tablet contains ciprofloxacin hydrochloride monohydrate equivalent to 500 mg c1profloxacin. 
Urinary Tract Mild/Moderate 250 mg 
Severe/Complicated 500mg 
q 12h 
q 12h 
500 mg 
1000 mg 
CIPRO® 750-each tablet contains ciprofloxacin hydrochloride monohydrate 
equivalent to 750 mg c1profloxacin. 
STORE BELOW 30° C (B6° F). 
Lower Respiratory Mild/Moderate 500mg 
Tract Severe/Complicated* 750 mg 
Bone & Joint 
Skin & Soft Tissue 
Infectious Diarrhea Mild/Moderate/Severe 500 mg 
* e.g. hospital-acquired pneumonia, osteomyelitis. 
q 12h 
q 12h 
1000mg 
1500 mg 
q 12h 1000 mg Bottles of 50 
Unit Dose Package of 100 
References: 
Str11ngth 
250mg 
500mg 
750mg 
500mg 
750mg 
Tablet 
Jdenllflcatlon 
Miles 512 
Miles513 
Miles 514 
Miles 513 
Miles 514 Depending on the severity of the infections, as well as the clinical and bacteriological responses, the average treatment period should be approximately 7 to 14 days. Generally, 
treatment should last 3 days beyond the disappearance ol clinical symptoms or until 
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Importance of Magnetic Resonance 
Imaging in Osteoid Osteoma: a Case 
Report 
R.S. Bell, MD, FRCSC; G.D. O'Connor, MD; J.P. Waddell, MD, FRCSC 
A 23-year-old man presented with a femoral osteoid osteoma, which, because of its 
small calcified nidus and extensive osteoblastic response, could not be localized on 
bone scanning, computed tomography or angiography. Magnetic resonance imaging 
clearly defined the nidus and permitted excision with minimal morbidity. 
Un homrne de 23 ans a ete recu souffrant d'un osteDide-osteome qui, a cause d'un 
foyer calcifie de petite taille et d'une osteol>lastose reactionnelle importante, n'a pu 
etre localise par scintigraphie osseuse, par tomodensitometrie ou par angiographie. 
La resonance magnetique nuclfaire definit clairement le foyer et en permit ]'excision 
avec un minimum de rnorbidite. 
T he surgical treatment of oste-oid osteoma depends on the 
localization and excision of the os-
teoid nidus that is characteristic of 
this benign bone tumour.1.2 We 
present a case of osteoid osteoma 
with an extensive osteoblastic re-
sponse and emphasize the difficulty 
in identifying the nidus within this 
marked sclerotic reaction. Magnetic 
resonance imaging (MRI) proved to 
be the only imaging technique capa-
ble of demonstrating the osteoid 
nidus. 
Case Report 
~-·' 
A 23-year-old man was admitted 
for investigation of pain in the 
distal, medial left thigh. The pain, 
present for several months, was 
continuous, not activity related, 
worse at night and partially relieved 
by acetylsalicylic acid. There was 
no history of trauma or infection. 
Physical examination revealed a dif-
fuse, firm expansion of the left 
femur, limited to the distal portion 
of the thigh and accompanied by 
moderate muscle wasting. Labora-
tory investigations, including com-
plete blood count, determination of 
the erythrocyte sedimentation rate, 
serum calcium, phosphorus and al-
kaline phosphatase levels gave nor-
mal results. X-ray films and com-
puted tomography showed an ex-
tensive osteoblastic lesion involving 
12.5 cm of the distal diaphysis of 
the femur (Fig. 1). A techneti-
um-99m bone scan demonstrated 
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marked, diffuse, increased uptake 
of tracer throughout the sclerotic 
process (Fig. 2). Computed tomog-
raphy showed that the lesion was 
circumferential, not involving the 
medullary canal and with no evi-
dence of a soft-tissue mass (Fig. 3). 
No nidus was identified. The differ-
ential diagnosis included parosteal 
osteosarcoma, so the patient under-
went incisional biopsy through the 
vastus medialis• muscle. Extensive 
sampling of the sclerotic process 
demonstrated organized, lamellar 
periosteal new bone formation over-
lying normal cortex. Based on the 
investigations, we thought the pa-
tient had a healing stress fracture 
and advised him to limit his activity. 
FIG. 1. Anteroposterior view of scle-
rotic femoral lesion. 
MRI IN OSTEOID OSTEOMA
;
Six months later, he was referred 
to the Orthopaedic Oncology Ser­
vice at St. Michael’s Hospital in 
Toronto with increasing pain in the 
distal, medial left thigh. Results of 
roentgenography, conventional to­
mography and technetium bone 
scanning, undertaken with collima- 
tion over the distal femur, were
unchanged from the previous re­
sults. Angiography, concentrating 
on the late arterial phase to evalu­
ate the possible presence of a vascu­
lar nidus within the sclerotic bone, 
showed no abnormality. A contrast- 
enhanced computed tomogram 
showed the previous biopsy site but 
was otherwise unchanged. Magnetic
resonance imaging, using a repeti­
tion time of 1800 ms and an echo 
time of 30 ms finally identified a 
small intracortical nidus in the mid­
dle portion of the sclerotic reaction 
within the lateral femoral cortex 
(Fig. 4). Excision of the nidus was 
accomplished by removing overly­
ing periosteal new bone until a 
6-mm lesion Filled with calcified, 
reddish brown tissue was encoun­
tered within the femoral cortex. 
The affected site was curetted and 
filled with bone graft, using the 
surrounding reactive new bone. Mi­
croscopic review of the specimen 
showed osteoid and fibrovascular 
granulation tissue, typical of oste­
oid osteoma. Cultures taken in- 
traoperatively showed no evidence 
of infection. Postoperatively, the 
pain resolved and the patient was 
free of symptoms at 18-month fol­
low-up.
Discussion
This case is remarkable for the 
extent of reactive bone formation in 
response to a single nidus of oste­
oid osteoma and for the difficulty 
experienced in localizing this nidus. 
Since Jaffe’s original description3 of 
osteoid osteoma, there have been 
many reports on its clinical presen-
FIG. 2. Technetium-99m scan, anterior and left-lateral views. There was diffuse, 
intense uptake of technetium on delayed bone scan. No nidus was seen on early or 
late phases.
FIG. 3. Computed tomogram shows circumferential cortical thickening throughout 
lesion but no nidus.
FIG. 4. Magnetic resonance imaging 
clearly shows small intracortical nidus 
on proton density image.
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tation and pathophysiology,1'2-4"20 
but little has been written about the 
extent of the periosteal reaction 
that may be produced by the tu­
mour. In reviewing the radiologic 
features of osteoid osteoma, Karls- 
berg and Kittleson13 and Wilner21 
commented that the sclerotic reac­
tion may extend for several cen­
timetres from the central nidus; 
however, both the extent (12.5 cm) 
and the circumferential nature of 
the periosteal reaction in our case 
are unusual. The location of the 
nidus and the age of the patient 
may be important in determining 
the subsequent osteoblastic re­
sponse. Wilner21 suggested that the 
intracortical nidus elicits a greater 
local blastic response than one aris­
ing in cancellous bone and that the 
sclerotic reaction is greater in pa­
tients younger than 5 years. The 
blastic reaction may also be en­
hanced in the unusual case with 
more than one nidus.10
Localization of the nidus may be 
difficult if the lesion is surrounded 
by extensive new bone formation; 
the nidus is generally recognized by 
its uptake of tracer on the techneti- 
um-99m bone scan and, indeed, 
intraoperative scanning has been 
used to identify occult lesions.22 
The increased uptake associated 
with the reactive bone in our case 
presumably masked the uptake in 
the nidus, the small size and calcific 
density of which prevented detec­
tion on either angiography or com­
puted tomography. Magnetic reso­
nance imaging, however, provided 
excellent resolution of the interface 
between the abnormal osteoid of
the nidus and the reactive bone, 
thus permitting excision of the le­
sion with minimal disruption of the 
surrounding bony architecture.
Demonstration of the nidus on 
computed tomography depends on 
finding osteoid within the lesion 
that is more or less calcified than 
surrounding bone.23 Magnetic reso­
nance imaging may be more sensi­
tive since it may detect the vascular, 
abnormal tissue within the nidus, 
even when it has a radiologic densi­
ty similar to the surrounding 
bone.23
We thank Mrs. Krista Sereno for her 
help in preparing and editing this 
manuscript.
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Immunohistologic Diagnosis of Multiple 
Carcinomas. The Role of Monoclonal 
Antibodies Against Carcinoembryonic 
Antigen
Marie-Christine Guiot, MD;*J Robert Sawka, BSc;* Jonathan L. Meakins, MD, DSc, FRCSC;t 
Serge Jothy, MD, PhD, FRCPC*
The occurrence of multiple malignant lesions in the same patient requires that 
management decisions be made from an accurate pathological identification of the 
tumours. The authors describe five patients who had colorectal adenocarcinoma 
preceded or followed by adenocarcinomas in other organs. Definitive identification 
could not be established from routine histopathologic findings. The use of 
immunohistochemistry helped to clarify the relationship between the various 
tumours; in particular, a monoclonal antibody (D14) directed against 
carcinoembryonic antigen (CEA) made a notable contribution. Because of the 
increasing number of monoclonal antibodies with well-defined tumour specificities, 
their use in the documentation of multiple malignant tumours has great clinical 
potential.
Une identification anatomo-pathologique precise est necessaire dans les cas de 
tumeurs malignes multiples a cause de l’impact sur le traitement. Les auteurs 
decrivent cinq patients atteints d’adenocarcinomes colorectaux, precedes ou suivis 
d’adenocarcinomes dans d’autres organes. L’histopathologie de routine n’a pas 
permis d’etablir de diagnostic definitif. L’emploi de l’immunohistochimie a aide a 
clarifier la relation entre les differentes tumeurs. Un anticorps monoclonal (D14) 
dirige contre l’antigene carcinoembryonnaire (ACE) a apporte en particulier une 
contribution significative. Etant donne que l’on peut obtenir un nombre croissant 
d’anticorps monoclonaux dont la specificite tumorale est bien definie, il apparait 
judicieux de les utiliser dans l’identification de tumeurs malignes multiples.
The occurrence of synchronous or metachronous carcinomas in 
the same patient is uncommon.
These patients present serious man­
agement problems, such as deter­
mining whether a second tumour
represents a new and different pri­
mary malignant lesion or metastatic 
spread, or whether one of the multi­
ple tumours can be treated by adju­
vant methods. Routine histopa­
thologic examination of the tumour 
tissues is often inconclusive when 
the second tumour involves a differ­
ent organ, especially the lung. How­
ever, the demonstration of tumour 
markers might help to clarify these 
diagnostic problems. We1’2 and oth­
ers3 have shown that some poly­
clonal and monoclonal antibodies 
possess enough tissue specificity to 
distinguish different types of solid 
tumours. We report here on five 
patients who had carcinoma of the 
colon and a synchronous or meta­
chronous malignant tumour at a 
distant site and in whom the use of 
monoclonal antibodies to carcino­
embryonic antigen (CEA) helped to 
identify the relation between the 
two tumours.
Material and Methods
Immunohistochemical Studies
Tissue was obtained from each 
patient and fixed in formalin. In 
addition to routine histopathologic 
examination of the tissue, each pa­
tient was tested for the presence of 
CEA using polyclonal and mono-
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clonal antibodies. Rabbit anti-CEA 
(Dakopatts, Glostrup, Denmark) 
was used as a source of polyclonal 
antibody. Like most polyclonal anti- 
CEA reagents, it reacts not only 
with colonic adenocarcinomas but 
also with many extracolonic car­
cinomas. The monoclonal antibody 
used was the mouse D14 (E-Z-EM 
Co., Westbury, NY), known to be 
more specific for colonic carcinoma 
than polyclonal anti-CEA reagents. 
The D14 is one of the monoclonal 
antibodies to CEA that have been 
produced and fully characterized 
previously.4 Its tumour specificity 
has been extensively documented.2
Paraffin sections of the tumours 
were immunostained with the poly­
clonal antibody using a peroxidase- 
antiperoxidase technique.5 D14 an­
ti-CEA monoclonal antibody im- 
munostaining was performed using 
a three-layer double peroxidase 
technique.6
The immunohistochemical reac­
tions were reported positive when 
5% or more of the tumour cells 
were immunostained. Normal rabbit 
serum and mouse myeloma super­
natant were used as negative con­
trols.
In addition to staining for the 
presence of CEA, the tumour tis­
sues were tested for the presence of 
one or more of the following mark­
ers, depending on the case: pros­
tate-specific antigen (PSA), cytoke- 
ratin, tissue polypeptide antigen 
(TPA), protein S-100 and pancreatic 
cancer-associated antigen (Bl).
Case Reports
Case 1
A 76-year-old man presented with 
signs and symptoms of carcinoma 
of the ascending colon, confirmed 
by biopsy. He had a history of stage 
I prostatic adenocarcinoma, which 
had been treated by transurethral 
prostatic resection 9 years earlier. 
He underwent a right hemicolecto­
my which revealed a Dukes’ class C 
tumour.
Eleven months later, the patient 
was readmitted with a history of 
bilateral leg swelling and heavy pro­
teinuria. A kidney biopsy showed 
membranous nephropathy. A liver 
scan showed a single filling defect 
in the liver. The serum CEA level 
was 38 ng/ml. A right hemihepa- 
tectomy was performed. It showed a 
metastatic adenocarcinoma with 
histologic features consistent with a 
colonic origin, although a metasta­
sis from the prostatic carcinoma 
could not be ruled out. Postopera- 
tively, a right hemothorax devel­
oped, accompanied by respiratory 
failure, septicemia and renal failure. 
Autopsy showed that the patient 
had residual adenocarcinoma of the 
prostate. The pelvic and periaortic 
lymph nodes were enlarged. The 
partial hepatectomy specimen and 
the lymph nodes were examined by 
immunohistochemistry. The results 
showed that the liver contained me- 
tastases from the colonic carcinoma 
and the periaortic lymph nodes con­
tained metastases from the prostatic 
cancer (Table I).
Case 2
A 64-year-old woman was admit-
Table I. Results of Immunohistochemistry in Subsequent Malignant Tumours
Immunohistochemical findings
Sites of Histopathology Carcinoembryonic antigen
Patient subsequent of second Polyclonal D14 monoclonal Diagnosis of
no. First tumour tumours tumour antibody antibody Other markers second tumour
1 Prostatic AD Ascending colon AD (liver) Liver + Liver + Liver Liver metastasis from
Liver Cytokeratin + colonic carcinoma
LN
Aortic Aortic
PSA -
Aortic LN PSA + Periaortic LN
LN - LN - metastasis from 
prostatic carcinoma
2 Breast carcinoma, Sigmoid colon AD (colon) Liver metastasis from
Dukes' stage I Liver AD (liver) Liver + Liver + colonic carcinoma
3 Transverse colonic Lung AD Lung + Lung + Cytokeratin + Lung metastasis from
AD TPA -  
B1 -
colonic carcinoma
4 Rectal AD Lung AD Lung + Lung + Cytokeratin + Lung metastasis from
TPA + colonic AD
5 Sigmoid colon AD Lung AD Lung - Lung - Lung Primary lung AD
Cytokeratin +  
Protein S-100 — 
'PSA -
AD =  adenocarcinoma, LN =  lymph nodes, +  =  reactive, -  =  nonreactive, PSA =  prostate-specific antigen, TPA =  tissue polypeptide antigen, B1 =  
pancreatic cancer-associated antigen.
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ted because she had signs and 
symptoms of cancer of the sigmoid 
colon. She had undergone a mastec­
tomy for a right breast carcinoma 
25 years previously. At that time, 
the axillary lymph nodes were free 
of metastases. A segmental resec­
tion of the sigmoid colon was per­
formed and two lymph nodes were 
found to contain metastatic foci. In 
addition, a single, large, hepatic 
tumour nodule was discovered and 
a biopsy was done. The serum CEA 
level was greater than 50 ng/ml. 
The histopathologic changes in the 
liver tumour were compatible with 
either a colonic or a breast origin. 
When immunohistochemical studies 
were performed, the hepatic lesion 
was found to be of colonic origin. 
Two months later she underwent a 
right hemihepatectomy which
FIG. 1. Case 3. Tissue section of lung 
tumour immunostained with D14 anti- 
CEA monoclonal antibody. There is 
evidence of dark CEA-staining of lumi­
nal border of neoplastic glands (arrow­
heads) and moderate staining of cyto­
plasm. Positively stained single cells 
are also present scattered through 
stroma (arrows). This staining pattern 
indicates that this lung tumour is 
metastasis from colonic carcinoma (im- 
munoperoxidase stain for CEA, origi­
nal magnification X 330).
showed histopathologic changes si­
milar to the previous liver biopsy. 
After 1 year, follow-up studies doc­
umented the presence of tumour in 
the pelvis. She died 2 years after 
hepatectomy of widespread colonic 
carcinoma.
Case 3
This 67-year-old woman, a non- 
smoker, first presented with signs 
of rectal bleeding. Colonoscopy 
demonstrated an adenocarcinoma of 
the colon at the splenic flexure. The 
tumour was resected. It involved 
only the superficial layers of the 
muscularis propria; the mesenteric 
lymph nodes were free of disease. 
Six years later a routine chest x-ray 
film showed a nodular opacity in 
the left upper lobe, with hilar 
lymph-node involvement. A trans­
thoracic needle aspirate showed an 
adenocarcinoma. The serum CEA 
level was within the normal range. 
A lobectomy was performed. The 
histopathologic findings suggested 
a metastasis from the colon, al­
though a primary lung adenocarci­
noma could not be ruled out. The 
patient received radiation therapy 
to the chest. Immunohistochemical 
studies performed later on the lung 
tumour demonstrated that it was a 
metastasis from the colonic carcino­
ma. During the following year, liver 
and cerebellar metastases devel­
oped. The patient’s condition deteri­
orated progressively and she died of 
widely disseminated carcinomatosis.
Case 4
This 61-year-old man was found 
to have a Dukes’ class C adenocar­
cinoma of the rectum. It was treat­
ed by abdominoperineal resection. 
Radiotherapy was given postopera- 
tively. Three years later, he was 
found to have an opacity in the left 
lower lung lobe. The serum CEA 
level was not elevated. A clinical
diagnosis of a primary lung tumour 
was made and a lobectomy was 
performed. An adenocarcinoma was 
documented on histologic examina­
tion of the specimen, and had some 
features of the previously resected 
rectal tumour. The lung tumour 
was tested immunohistochemically 
and found to be a metastasis from 
colorectal carcinoma. The patient 
died 1 year later of disseminated 
carcinomatosis.
Case 5
A 71-year-old alcoholic was ad­
mitted because of neurologic symp­
toms after a fall. While in hospital 
he was found to have a Dukes’ class 
B adenocarcinoma of the sigmoid 
colon, which was resected. His post­
operative course was complicated 
by sepsis and he died 2 weeks after 
surgery. At autopsy, an adenocarci­
noma was found in the right upper 
pulmonary lobe, without metastasis 
to the hilar lymph nodes. Im­
munohistochemical studies showed 
an immunophenotype consistent 
with a primary adenocarcinoma of 
the lung.
Results and Discussion
The results are summarized in 
Table I and one case is illustrated in 
Fig. 1.
In each of our patients there was 
a problem identifying the second 
tumour. Specifically, a search was 
made to determine if the second 
tumour was a separate malignant 
lesion requiring a specific treatment 
or a metastasis from the colonic 
carcinoma. In each case immunohis­
tochemical testing of the tumour 
specimens contributed diagnostic 
information which, when combined 
with clinical data, helped in estab­
lishing the relation between the two 
tumours. Although it is not always 
difficult to establish metastatic or
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nonmetastatic relationships between 
two asynchronous malignant tu­
mours, the first four cases present­
ed here illustrate that problems do 
arise. For instance, patient 1 had 
residual prostatic carcinoma at the 
time of autopsy and, thus, shortly 
before when his liver tumour was 
discovered. Prostatic carcinoma can 
metastasize to the liver and, fur­
thermore, even when disseminated 
it is known to respond to medical 
treatment. Therefore, it was impor­
tant to document whether the liver 
tumour was a metastasis from the 
prostatic or the colonic carcinoma.
With respect to patient 2, it was 
important to determine whether the 
hepatic tumour was a metastasis 
from the breast or from the colonic 
carcinoma, the former being more 
likely to respond to chemotherapy 
and the latter to resection.
The second malignant tumour in 
the two last cases presented as a 
lung parenchymal mass with evi­
dence of involved mediastinal and 
hilar lymph nodes. These findings 
were interpreted as indicating that 
the lung tumours were new primary 
carcinomas and with this rationale 
patient 3 was treated with radio­
therapy to the chest.
In patient 5, the second tumour, 
which was a primary lung carcino­
ma, was discovered only at autopsy; 
if it had been discovered earlier, the 
patient’s management might have 
been different. In all cases, the 
regular histopathologic features of 
the subsequent tumours showed ad­
enocarcinoma. Although some fea­
tures were typical of a colonic pri­
mary, the pathologists did not be­
lieve it was reliable or appropriate 
to make a final diagnosis without 
the help of immunohistochemical 
studies.
When the second tumours were 
tested, most were shown to react
positively with a polyclonal anti­
body to CEA. This finding by itself 
is not specific of colonic origin 
because polyclonal antibodies to 
CEA react with most carcinomas 
regardless of origin.2 By contrast, 
the reactivity of tumours with the 
D14 anti-CEA monoclonal antibody 
is highly suggestive of a colonic 
origin because this reagent is high­
ly specific for colonic cancer.2 Our 
patients had a history of carcinoma 
of the prostate or breast in addition 
to the colonic cancer, and subse­
quently had liver or lung tumours. 
The rate of positive staining with a 
polyclonal anti-CEA antibody is 
close to 100% for breast, liver or 
lung cancers. By contrast, D14 
staining is positive in primary 
breast, liver or lung carcinoma in 
only 9%, 20% and 8% of cases 
respectively. Therefore, the high se­
lectivity of D14 for colonic cancer 
indicates that this monoclonal anti­
body helps substantially in deter­
mining tumour origin.
It should be noted, however, that 
the specificity of D14 for colonic 
cancer, although much higher than 
that of polyclonal antibodies, is not 
100%. This lack of absolute speci­
ficity is found with all the mono­
clonal antibodies that have been 
generated so far against CEA or 
other tumour markers. From the 
various monoclonal antibodies di­
rected against markers of colonic 
cancer, those against CEA are still 
the most specific.3 Consequently, 
the immunohistopathologic diagno­
sis of tumours depends not only on 
the use of the most specific marker 
but also on other markers that 
complement the pattern of reactivi­
ty. For instance, the association of 
a negative staining of PSA and 
positive staining of D14, as was 
found in patient 1, was a clear 
indication that a tumour originated
from colonic epithelium and exclud­
ed a prostatic origin.
In conclusion, the immunohisto­
chemical testing of tumours with 
nonoclonal antibodies greatly facili­
tates the identification of multiple 
malignant tumours occurring in the 
same patient. The use of monoclon­
al antibodies in these tests has 
significantly increased the value of 
this approach. When combined with 
operative findings, regular patho­
logic changes and electron micros­
copy, the use of monoclonal anti­
bodies in immunohistochemistry 
has the potential of diagnosing cor­
rectly a large number of these tu­
mours with a high degree of accu­
racy, thereby facilitating appropri­
ate multimodal therapy.
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ORIGINAL ARTICLES
Cecal Diverticulitis
Andrew Luoma, MD, FRCSC; Alex G. Nagy, MD, FRCSC
Cecal diverticulitis is an uncommon entity. Its operative treatment represents 0.2% 
of procedures performed for an acute abdomen. The clinical presentation is often 
indistinguishable from acute appendicitis. At operation, it may be confused with 
cecal carcinoma. The surgeon must be aware of this condition and be prepared to 
choose the most appropriate treatment. Local excision has been advocated as the 
treatment of choice. The authors review 18 cases seen over a 10-year period. In no 
case was the correct diagnosis made preoperatively. Intraoperatively, a correct 
diagnosis was made in 12 of the 18. Carcinoma was the next most frequent 
intraoperative diagnosis (four cases). Twelve of the 18 patients were treated by 
standard or limited right hemicolectomy. One patient died early in the series of 
sepsis caused by a perforated diverticulum and one patient had a life-threatening 
complication. Right hemicolectomy appears to be a safe and effective treatment 
option for cecal diverticulitis.
La diverticulite caecale est une affection rare. Son traitement chirurgical represente 
0.2% de toutes les operations pratiquees pour abdomen aigu. II est parfois 
impossible de distinguer son tableau clinique de celui d’une appendicite aigue. A 
l’operation, elle peut etre prise pour un carcinome du caecum. Le chirurgien doit 
tenir compte de cette affection et etre pret a choisir le traitement approprie. 
L’excision locale a ete proposee comme traitement de premier choix. Les auteurs 
passent en revue 18 cas qu’ils ont vu au cours d’une periode de 10 ans. Jamais, le 
bon diagnostic n’avait ete pose en preoperatoire. A i’operation, le diagnostic 
approprie fut pose 12 fois sur 18. Le second diagnostic le plus frequemment evoque, 
fut celui de carcinome (quatre fois). Douze des 18 patients furent traites par une 
hemicolectomie droite conventionnelle ou limitee. Un patient est decede tot dans 
cette serie d’une sepsie consecutive a une perforation du diverticule, alors qu’un 
autre patient subissait une complication qui mit sa vie en danger. L’hemicolectomie 
droite paralt etre un traitement sur et efficace de la diverticulite caecale.
Acute cecal diverticulitis is an uncommon condition. Since 
Potier1 reported the first case in 
1912, just over 500 cases have 
been reported in the literature. The 
largest modern series from a single 
institution totals only 33 cases,2 so 
an individual surgeon is unlikely to
have much experience with this 
condition. Cecal diverticulitis pres­
ents problems both in diagnosis and 
management. Since it is often an 
unexpected finding at laparotomy, 
every surgeon must be prepared to 
make decisions intraoperatively to 
treat this disease effectively. The
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principles of emergency surgery in­
volving the right colon have evolved 
considerably in recent decades. Our 
experience and the controversies 
surrounding cecal diverticulitis 
prompted this review.
Clinical Material
The records of the Vancouver 
General Hospital, a major teaching 
institution affiliated with the Uni­
versity of British Columbia, provid­
ed material for this study. The 
charts of 18 consecutive patients 
(13 men, 5 women) assigned a 
diagnosis of cecal diverticulitis over 
10 years were reviewed. The salient 
features of clinical presentation, 
laboratory data, preoperative, in­
traoperative and postoperative 
course, outcome and histologic 
findings, where available, were re­
corded for each patient.
Findings
The mean age of the 18 patients 
was 44 years (range from 23 to 70 
years). Eleven patients were Cauca­
sian, 6 oriental and 1 was of Philip­
pine extraction.
The chief complaints on admis­
sion included right lower quadrant 
pain in 17 patients, anorexia in 17 
and nausea in 13. Central abdomi­
nal pain, vomiting, diarrhea and 
fever were less frequent. The aver­
age duration of symptoms was 53 
hours (range from 12 to 168 
hours). On physical examination at 
the time of admission, abdominal
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tenderness was present in all pa­
tients and was characteristic of ap­
pendicitis in 14. A lower abdominal 
mass was palpable in four patients. 
Two patients had previously under­
gone appendectomy.
Investigation revealed an average 
leukocyte count of 12.3 X 109/L  
(range from 6.7 to 18.0 X 109/L). 
Plain x-ray films of the abdomen 
were obtained in 14 patients. One 
showed free intraperitoneal air, two 
a mass effect and two showed loc­
alized air fluid levels in the lower 
abdomen. Other investigations in­
cluded barium enema in one and 
abdominal ultrasonography in 
three. No other useful diagnostic 
information was obtained from 
these tests. Two patients, both men, 
underwent laparoscopy before lapa­
rotomy, but no useful diagnostic 
information was obtained aside 
from confirmation of an inflamma­
tory process in the region of the 
cecum.
The preoperative diagnosis was 
acute appendicitis in 15 patients 
and perforated appendicitis in 1; 4 
of them were noted to have “atypi­
cal” presentations. Ovarian tumour 
was suspected in one patient as was 
acute sigmoid diverticulitis. Both 
these patients had previously under­
gone appendectomy.
Fifteen patients underwent emer­
gency laparotomy. Operation was 
delayed for several days in three 
patients; two of these underwent 
mechanical bowel preparation be­
fore laparotomy. The incisions used 
were grid iron in seven patients, 
muscle-cutting in six and paramedi­
an in seven patients (two patients 
had more than one incision). The 
operative procedures varied (Table 
I), but 11 patients had a standard or 
limited right hemicolectomy. All but 
one of these had a primary anasto­
mosis.
One elderly patient with a free 
perforation died of complications of 
sepsis. One patient had bleeding at
the anastomosis and required reop­
eration, which led to a prolonged 
stay in the intensive care unit and 
delayed recovery. Three had wound 
infections. The average hospital 
stay was 16 days (range from 6 to 
70 days).
Examination of the operative 
specimens showed inflammation in 
only eight, localized perforation in 
seven and free perforation in one. 
Two patients had no resection of 
the diverticulum. Pathologic exami­
nation combined with operative 
findings revealed that the diverticuli 
were nearly equally distributed 
around the circumference of the 
cecum. In one case the diverticulum 
arose from the mesenteric aspect of 
the terminal ileum. No comment 
regarding the presence of muscula- 
ris in the wall of the diverticulum 
was made in any case. The inflamed 
diverticula were solitary in seven 
cases and made up one of multiple 
cecal diverticula in five cases. This 
information could not be ascer­
tained from the charts in six cases.
Discussion
Cecal diverticula are classified as 
true or false. True cecal diverticula 
are usually solitary, involve all lay­
ers of the colon and are thought to 
be congenital.3
In contrast, false cecal diverticula 
are multiple, most often associated 
in continuity with left-sided diver- 
ticulosis, do not contain muscle and 
are typical, acquired, pulsion diver­
ticula.4 In studies of cecal diverticu­
litis, it is often difficult to document 
the true pathologic appearance of a 
pre-existing diverticulum, possibly 
because of the inflammatory re­
sponse,5 and controversy persists 
concerning the origins of cecal di­
verticula. Cecal diverticulitis does 
tend to affect younger patients than 
typical sigmoid diverticulitis.46
These diverticula are not particu­
larly rare. Hughes,7 in a study of 
200 cadavers, found diverticula of 
the cecum in 24. In 10 of these, the 
cecum was involved alone or dis- 
continuously with left-sided diver- 
ticulosis. Williams8 identified cecal 
diverticulosis in 5% of patients who 
had barium enema examination.
Cecal diverticula usually cause 
disease through inflammation. 
Much more rarely they may bleed910 
or undergo torsion.11 Greaney and 
Snyder12 reported 14 cases of cecal 
diverticulitis among 6781 emergen­
cy laparotomies performed over 8 
years. We found 18 cases over 10 
years. Over the same period, ap­
proximately 400 cases of appendici­
tis have been diagnosed annually in 
our hospital for a ratio of cecal 
diverticulitis to acute appendicitis of 
1:220. The condition may be more 
common in orientals.2
Lauridsen and Ross4 emphasized 
that most cases of acute cecal diver­
ticulitis are misdiagnosed at presen­
tation as acute appendicitis or ap­
pendiceal abscess. Anderson,13 in a 
review of the world literature, re­
ported that the correct diagnosis 
was made in only 6% of cases. In 
each of these cases, appendectomy 
had been carried out previously. 
Appendicitis was the preoperative 
diagnosis in 84%.13 In our series, 
appendicitis was the tentative diag­
nosis at presentation in all but two 
patients and both of these had 
already undergone appendectomy.
T a b le  1. Operative Procedures Performed 
for Cecal Diverticulitis
O peration
No. ol 
patien ts
Right hemicolectomy 5
Limited right hemicolectomy 5
Right hemicolectomy, ileostomy 1
Diverticulectomy,
appendectomy 3
Appendectomy, cecostomy 1
Appendectomy, drainage 2
Laparotomy and closure. 
Reoperation with right 
hemicolectomy after bowel
preparation. 1
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Of the alternative diagnoses, diver­
ticulitis, carcinoma of the cecum, 
bowel obstruction and cholecystitis 
are assigned much less frequently 
at presentation.13
Recently, Crist and colleagues14 
reported the use of computed to­
mography in seven patients with 
cecal diverticulitis. Three had un­
dergone appendectomy earlier. At 
present we do not recommend com­
puted tomography as a method of 
diagnosing cecal diverticulitis, be­
cause other pathologic processes — 
perforated neoplasms, Crohn’s dis­
ease and other inflammatory cecal 
changes — may mimic the findings 
of acute cecal diverticulitis. Lapa­
roscopy also is sometimes per­
formed in an attempt to find the 
cause of atypical right lower quad­
rant abdominal pain. It is of little 
help in diagnosing cecal diverticuli­
tis since the gross findings may be 
nonspecific for a number of cecal 
inflammatory conditions, including 
perforated neoplasms of the cecum.
Accepting that the diagnosis will 
rarely be correctly made preopera- 
tively, the surgeon must consider 
the diagnosis at the time of laparot­
omy if a normal appendix is found. 
Greaney and Snyder,12 in their re­
view, found that it was possible in 
over half the cases to identify an 
obvious diverticulum at laparotomy. 
Less commonly, it was possible only 
to identify a mass within the bowel 
wall. They referred to this as the 
hidden diverticulum.
Several maneuvers have been ad­
vocated to help make a correct 
diagnosis intraoperatively. Trans­
mural palpation of the ostium of 
the diverticulum for a possible feca- 
lith has been suggested.4 However, 
this is not reliable because a malig­
nant ulcer can feel quite similar.15 
Similarly, colotomy with visualiza­
tion of the lesion16 is unreliable and 
exposes the patient to the unneces­
sary risk of spillage of bowel con­
tent. Biopsy of the lesion is associ­
ated with a risk of false-negative 
results due to sampling error and is 
associated with a risk of spillage of 
malignant cells.17 Lymph-node biop­
sy has similar limitations. The re­
sults of these maneuvers ultimately 
will not affect operative decisions in 
most instances and, since they are 
unreliable, they are contraindicated.
Recommended treatment varies 
widely. Anderson13 and Cutajar18 
have advocated appendectomy with 
drainage and administration of anti­
biotics. Based on the death rates 
reported by Lauridsen and Ross,4 
the most commonly recommended 
treatment is diverticulectomy. The 
death rate associated with diver­
ticulectomy was 1.4% versus 7.3% 
for right hemicolectomy.4 Cecosto- 
my drainage as an adjunct in diffi­
cult cases has been recommended;5 
however, rarely does cecostomy re­
sult in adequate decompression of 
the cecum. More recently, a review 
of several series collected from the 
literature since 1958 by Schuler 
and Bayley5 reported a 1.4% cumu­
lative death rate for right hemico­
lectomy and no deaths with diver­
ticulectomy. In the single largest 
series in the modern literature, Ar­
rington and Judd2 reported no 
deaths among 31 patients treated 
by right hemicolectomy or cececto- 
my out of a total of 33 patients 
treated for cecal diverticulitis.
Resection and primary anastomo­
sis of the right colon with unpre­
pared bowel is now recognized to be 
safe in the emergency situation.19 
Primary anastomosis may be per­
formed if no contraindications, such 
as gross peritonitis,20 free perfora­
tion or gross spillage of bowel con­
tent preclude it. Resection with 
ileostomy and staged anastomosis is 
preferred in this instance.21 Modern 
operative technique and periopera­
tive antibiotic prophylaxis have 
made this approach safe. The single 
death in our series occurred after 
resection and ileostomy of a free
perforation of a cecal diverticulum. 
The possibility of complications 
such as this preclude conservative 
treatment of cecal diverticulitis.
We believe that the treatment of 
cecal diverticulitis should be individ­
ualized, but basic surgical princi­
ples should be followed. If the in­
traoperative diagnosis is certain, the 
diverticulum is small and excision 
will not compromise bowel function 
or blood supply or expose puru- 
lence, then simple excision is ade­
quate. More commonly in our expe­
rience, however, these conditions 
are not satisfied. In this case, right 
hemicolectomy or limited right he­
micolectomy with primary anasto­
mosis is safe and effective for both 
diagnosis and treatment. Where 
conditions preclude primary anasto­
mosis, resection with staged anasto­
mosis is preferable.
Conclusions
Cecal diverticulitis is an uncom­
mon condition which is usually mis­
diagnosed as appendicitis at presen­
tation. At laparotomy it must be 
treated as an unexpected finding. 
Free perforation is uncommon but 
occurs with sufficient frequency to 
preclude treatment by drainage and 
administration of antibiotics. When 
the diagnosis is uncertain at lapa­
rotomy, right hemicolectomy or 
limited right hemicolectomy is pre­
ferred. Primary anastomosis may be 
performed if no contraindications 
exist.
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BOOK REVIEW S
continued from page 237
Mohs micrographic surgery, 4 on der­
matologic laser surgery and 21 chapters 
on cosmetic and reconstructive derma­
tologic surgery.
The text is indexed, and, although 
many of the clinical photographs are 
overexposed, in general the photo­
graphs are adequate. The line drawings 
of surgical techniques seem to be quite 
good.
The chapters on surgical treatment 
of skin disease, such as those on prema- 
lignant lesions and basal cell carcinoma, 
are merely brief reviews of standard 
dermatologic knowledge. All of this 
material is more completely covered in 
any standard dermatologic text.
To whom is the book addressed and 
to whom might it be useful? Most 
surgeons learn by doing, not by study­
ing how-to-do-it sketches, and any der­
matologist worth his salt will know all 
the nonsurgical material in this book. 
As a general overall review of the 
surgical procedures that are performed 
on the skin, it is satisfactory.
In the preface the authors state “our 
goal is to help define dermatologic 
surgery” , but, unfortunately, no defini­
tions are given. There are some com­
ments on the fluid dermatologic surgery 
situation in the United States. The 
difficulty that dermatology is having
competing with plastic surgery and oto­
laryngology is outlined. The question is 
asked, should dermatologists be per­
forming liposuction and lipoaugmenta- 
tion? I admit to the rather old-fashioned 
bias that dermatologists should diag­
nose and surgeons do surgery. If der­
matologists wish to do extensive sur­
gery, they should become surgeons. 
There is no way that in a 3-year period 
a resident can learn to be both a 
dermatologist and a surgeon. One diffi­
culty I have with mixed training pro­
grams is that the diagnostic acumen of 
dermatologists will be lost. No one else 
has this knowledge — but there are 
many others who can do dermatologic 
surgery!
Nowhere in this book is there men­
tion of the financial aspect of dermato­
logic surgery. Apparently, surveys in 
the United States show that there is a 
virtually unlimited demand for cosmetic 
dermatologic surgical procedures. To 
fill this demand, dermatology and other 
surgical specialties are obviously ex­
panding.
Robert Jackson, MD 
Ste. 508,
1081 Carling Ave.,
Ottawa, Ont.
K1Y 4G2
DECISION MAKING IN SURGERY 
OF THE CHEST. Edited by Laurens R. 
Pickard. 168 pp. Iliust. W .B. Saunders 
Company Canada Limited. Toronto, 
1989 . $10 7 .9 5 . ISBN 0-7216-1168-0 .
This excellent text, containing the con­
tributions of 70 recognized authorities 
in the field, uses a new, effective ap­
proach to promote logical thinking and 
accurate problem-solving in cardio- 
thoracic surgery. More than 80 specific 
problems are presented in easy-to- 
understand algorithms, each giving a 
logical, systemic, step by step overview 
of patient management for each condi­
tion.
On the page facing each “decision­
making tree” is an up-to-date explana­
tion of the thinking behind the algo­
rithm; this explanation expresses the 
diagnosis and principles of treatment, 
which justify the algorithm.
The book is not meant to encompass 
every area of cardiothoracic surgery, 
but all of the common conditions a 
cardiothoracic surgeon would see are 
covered. It includes the important top­
ics of congenital and acquired diseases 
of the heart and great vessels, the 
pericardium and cardiac rhythm distur-
continued on page 289
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Transrectal Fine-Needle Aspiration and 
Truecut Needle Biopsy of the Prostate: a 
Blinded Comparison of Accuracy
L.H. Klotz, MD, FRCSC;* P.A. Shaw, MD, FRCPC;t J.R. Srigley, MD, FRCPCf
Transrectal needle aspiration biopsy and core biopsy of the prostate were performed 
simultaneously on 88 men with prostatic nodules. Cytologic and histologic 
assessments were made in a blinded, independent fashion, and the results were 
compared. All patients with positive findings on aspiration also had positive 
findings on core biopsy, for a positive predictive value for aspiration of 100%. 
However, five negative and six “insufficient” results obtained by aspiration were 
positive on core biopsy, for a negative predictive value for aspiration of 88%. This 
experience supports the use of needle aspiration as an initial diagnostic maneuver in 
the assessment of prostatic nodules.
Une ponction-biopsie transrectale a l’aiguille et une biopsie du centre de la prostate 
ont ete pratiquees simultanement chez 88 hommes souffrant de nodules prostati- 
ques. Les examens cytologiques et histologiques ont ete faits a l’aveugle et les 
resultats ont ete compares. Tous les patients qui ont presente une ponction-biopsie 
positive avaient aussi une biopsie centrale positive, ce qui donne une valeur 
previsionnelle positive de 100% pour la technique par aspiration. Neanmoins, cinq 
resultats negatifs et six resultats “insatisfaisants” obtenus par aspiration etaient 
positifs a la biopsie reguliere, ce qui donne une valeur previsionnelle negative de 
88% pour la ponction-biopsie. Cette experience valide l’utilisation de la ponction- 
biopsie comme technique diagnostique initiale dans 1’evaluation des nodules 
prostatiques.
Localized carcinoma of the pros­tate is suspected by the family 
practitioner when a prostatic nodule 
or induration is palpated on digital 
rectal examination. The ability to 
screen such patients by a simple 
diagnostic procedure is desirable. 
As early as 1930, Ferguson1 at­
tempted to perform cytologic exam­
ination of transrectally aspirated 
prostatic tissue. The specimens 
were not satisfactory. In 1960, 
Franzen and colleagues2 introduced 
a technically simple procedure for 
cytologic diagnosis of prostatic can­
cer. This technique has been used 
extensively in Europe,34 but until 
recently it had few adherents in 
North America.5
The advantages of fine-needle as­
piration (FNA) are as follows:
•  The intervention can be per­
formed quickly, without anesthesia, 
on out-patients.
•  The needle guide permits pre­
cise positioning and biopsy of ex­
tremely small nodules.
•  Fan-like aspiration captures 
cells from different areas of the 
prostate for analysis.
•  The complication rate is ex­
tremely low.
•  The procedure may be repeat­
ed at short intervals when the index 
of suspicion is high, without caus­
ing the patient undue discomfort.
•  The low morbidity of the pro­
cedure makes it applicable to other 
clinical scenarios, including obtain­
ing culture material in patients with 
resistant prostatitis.
The accuracy of the procedure is 
variable. In general, it can be com­
pared to core biopsy as the “gold 
standard” . Because of its ability to 
sample multiple sites, FNA may be 
more accurate than core biopsy.
Patients and Methods
Between 1985 and 1988, simul­
taneous FNA and transrectal core 
biopsy (TCB) were performed on 88 
patients at Sunnybrook Medical 
Centre, Toronto. All procedures 
were performed on out-patients 
using urethral xylocaine anesthesia 
only. In all patients prostatic cancer 
was suspected because the gland 
was abnormal to palpation. All pa­
tients received antibiotic prophylax­
is — Flagyl orally and tobramycin 
intramuscularly — and a Fleet 
enema the night before the proce­
dure. Aspiration biopsy was per­
formed according to the technique 
of Franzen and colleagues,2 using a 
0.6-mm aspiration needle. Tissue 
was aspirated from one to three 
sites, smeared on slides, fixed with 
cytostat and stained according to 
Papanicolaou’s technique. When no 
fluid was obtained, the technique
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was performed a second time. Pa­
tients continued to receive Flagyl 
for 5 days postoperatively. The cy­
tologic and core biopsy specimens 
were reviewed by independent pa­
thologists with no knowledge of the 
results of the corresponding speci­
men.
Criteria for Cytologic 
Evaluation
The criteria used for assessment 
of FNA are well described in the 
literature.5 Specimens were reported 
as negative, positive or insufficient. 
Benign prostatic epithelium ap­
peared in cohesive uniform groups, 
often with a honeycomb arrange­
ment (Fig. 1). In addition to benign 
prostatic epithelium, mesenchymal 
elements were noted, and squamous 
metaplasia was seen in association 
with prostatitis. Seminal vesicle epi­
thelium and colonic mucosa not 
infrequently accompanied the pros­
tatic elements. Malignant aspirates 
were more cellular, with dissolution 
and disarray of the epithelial groups 
(Fig. 2). The usual cytologic criteria 
for malignancy were applied.
Results
The accuracy of aspiration biopsy 
relative to core biopsy was high 
when no carcinoma was identified 
by core biopsy (Tables I and II). All 
positive FNAs had a positive TCB 
(specificity 100%). Twenty-four per­
cent of the FNAs contained insuffi­
cient cells for analysis.
Excluding the insufficient sam­
ples from the calculations, the sen­
sitivity of aspiration was 83%. Neg­
ative and positive predictive values 
were 88% and 100% respectively.
Morbidity
Four (5%) of 88 patients had
urosepsis requiring hospitalization 
and intravenous administration of 
aminoglycosides. All four responded 
promptly to therapy; there was no 
long-term morbidity. This frequency 
of urosepsis undoubtedly reflects 
the impact of two simultaneous 
procedures, and would be lower 
with FNA alone.
Comment
Fine-needle aspiration is easily 
performed in an out-patient setting; 
the procedure is well tolerated and 
associated morbidity and discomfort 
are minimal.
A positive FNA indicates carcino­
ma of prostate with a high degree
FIG. 1. Benign prostatic epithelium appears in cohesive uniform groups, often with 
honeycomb arrangement (Papanicolaou stain, original magnification X 400).
FIG. 2. Malignant aspirates are more cellular than benign ones. They show 
dissolution and disarray of epithelial groups, and nuclear pleomorphism (Papanico­
laou stain, original magnification X 400).
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of reliability (100% in our experi­
ence). However, even with experi­
ence, 24% of FNAs have given 
insufficient material for examina­
tion. This rate is higher than that 
reported elsewhere.4 It likely re­
flects a more conservative approach 
to obtaining an excellent aspirate 
because of the planned core biopsy 
performed immediately afterwards
Table 1. Yields From the Two Biopsy 
Techniques
Result FNA TCB
Insufficient material 21 0
Positive 24 35
Negative 44 51
Totals 89 86
FNA =  fine-needle aspiration biopsy, TCB
=  transrectal core biopsy.
in this cohort. Generally, we made 
only a single pass of the aspirate 
needle and did not attempt to sweep 
the needle through the prostate. If 
aspiration is being performed as a 
sole maneuver (i.e., without a core 
biopsy), a more aggressive ap­
proach, including two or more pass­
es and a sweeping technique, would 
undoubtedly improve the number of 
adequate samples and this might 
also reduce the false-negative rate.
From a negative FNA one cannot 
conclude unequivocally that carci­
noma is not present (p =  92% ±  
9%). Accordingly, FNA cannot re­
place conventional biopsy complete­
ly, even though it is associated with 
less discomfort and morbidity.
Transrectal needle aspiration bi­
opsy is a reasonable initial approach 
to prostatic nodules. If the cytolog­
ic interpretation is “negative” , “in­
sufficient material” , “atypia” or 
“suggestive” , aspiration should be 
repeated or a core needle biopsy 
performed. This is particularly im­
portant in the “learning phase” of 
the technique.
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con tinued  from  page 286
bances; in the area of thoracic surgery, 
important subjects concerning the 
lungs and major airways, mediastinum, 
pleura, chest wall, diaphragm and 
esophagus are discussed. It also looks 
at practical problems in trauma of the 
chest and in pre- and postoperative 
care.
This text, therefore, is an important 
acquisition for the library of cardio- 
thoracic surgeons and residents, who 
would enjoy and benefit from browsing 
through the text. It is an important 
reference and guide to decision-making 
for any problem with which a patient
presents. It has the additional excellent 
feature of being an ideal reference for 
preparing clinical problem-solving ses­
sions for residents and students, a pre­
sentation on an individual patient prob­
lem, and even lectures. As a text for the 
medical student, it is too overwhelming.
In summary, this book is highly 
recommended. It has an excellent prob­
lem-solving format, showing and ex­
plaining practical steps for approaching 
patient problems in cardiothoracic sur­
gery. The algorithm (deductive) format 
makes it a most valuable and practical 
adjunct to the library of every cardio­
thoracic surgeon and resident. It does 
not replace the usual formal text which 
includes extensive references. Rather, it 
is a practical “how-to” book for day-to- 
day use in the management of patients 
and the preparation of teaching ses­
sions.
Edward J.P. Charrette, FRCSC
P rofessor o f  Surgery,
Queen's U nivers ity .
R ichardson House.
102 S tu a rt St.
K ings ton . Ont.
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^PRIMAXIN®
(imipenem and cilastatin sodium 
for injection)
Antibiotic
CNS adverse experiences such as myoclonic 
activity, confusional states, or seizures have 
been reported with PRIMAXIN® especially when 
recommended dosages based on renal function 
and body weight were exceeded. These expe­
riences have occurred most commonly in patients 
with CNS disorders (e.g., brain lesions or 
history of seizures) and/or who have compro­
mised renal function. However, there were rare 
reports in which there was no recognized or 
documented underlying CNS disorder. Close 
adherence to recommended dosage schedules 
is urged, especially in patients with known 
factors that predispose to seizures.
ACTION
Imipenem exerts a bactericidal action by inhibiting 
cell wall synthesis in aerobic and anaerobic gram­
positive and gram-negative bacteria.
PRIM AXIN® consists o f tw o com ponents: 
(1) im ipenem, a derivative of thienamycin, a 
carbapenem antibiotic; and (2) cilastatin sodium, a 
specific inhibitor of dehydropeptidase-l a renal 
enzyme w h ich  metabolizes and inactivates 
imipenem. Cilastatin blocks the metabolism of 
imipenem in the kidney, so that concomitant 
administration of imipenem and cilastatin allows 
antibacterial levels of imipenem to be attained in the 
urine.
Inhibition of cell-wall synthesis is achieved in gram­
negative bacteria by the binding of imipenem to 
penicillin binding proteins (PBPs). In the case of 
E s c h e r ic h ia  c o li and se lec ted  s tra in s  o f 
Pseudomonas aeruginosa, imipenem has been 
shown to have highest affinity for PBP-2, PBP-1a 
and PBP-1 b, with lower activity against PBP-3. The 
preferential binding of imipenem on PBP-2 and 
PBP-1 b leads to direct conversion of the individual 
cell to a spheroplast resulting in rapid lysis and cell 
death without filament formation. When imipenem 
is removed prior to complete killing of gram­
negative species, the remaining viable cells show a 
measurable lag, termed a "post-antibiotic effect” 
(PAE), prior to resumption of new growth.
INDICATIONS AND CLINICAL USE
PRIMAXIN® (imipenem and cilastatin sodium for 
injection) may be indicated in the treatment of 
serious infections when caused by sensitive strains 
of bacteria Where considered necessary, therapy 
may be initiated on the basis of clinical judgment 
before results of sensitivity testings are available. 
Continuation of therapy should be reevaluated on 
the basis of bacteriological findings and of the 
patient's clinical condition.
Imipenem is active in vitro against a wide range of 
gram-positive and gram-negative aerobic and 
anaerobic bacteria, including most strains which 
are beta-lactamase producing. Patients have 
responded while under treatment with PRIMAXIN® 
for single or mixed infections of the following body 
systems, when they were associated with a number 
of pathogenic species and strains of the genera 
listed:
1. Lower Respiratory Tract Infections
2. Urinary Tract Infections
3. Intra-Abdominal Infections
4. Gynecological Infections
5. Septicemia
6. Endocarditis caused by Staphylococcus 
aureus
7. Bone and Joint Infections
8. Skin Structure Infections
Gram-positive Aerobes
•  Listeria monocytogenes
•  Nocardia asteroides
•  Staphylococcus (excluding many strains 
which are methicillin resistant)
•  Streptococcus (excluding S. taecium)
Gram-negative Aerobes
•  Acinetobacter
•  Citrobacter
•  Enterobacter
•  Escherichia coli
•  Haemophilus influenzae
•  Haemophilus parainfluenzae
•  Klebsiella
•  Morganella morganii
•  Neisseria
•  Proteus (indole positive and indole negative 
strains)
•  Providencia
•  Pseudomonas aeruginosa
•  Serratia marcescens
Gram-positive Anaerobes
•  Clostridium (excluding C. difficile)
•  Peptococcus
•  Peptostreptoccus
Gram-negative Anaerobes
•  Bacteroides fragilis
•  Bacteroides (non-fragilis)
CONTRAINDICATIONS
PRIMAXIN® (imipenem and cilastatin sodium for 
injection) is contraindicated in patients who have 
shown hypersensitivity to either component of this 
product.
WARNINGS
PRIMAXIN® (imipenem and cilastatin sodium for 
in jec tion ) SHOULD BE ADMINISTERED WITH 
CAUTION TO ANY PATIENT WHO HAS DEMONS­
TRATED SOME FORM OF ALLERGY, PARTICULARLY 
TO STRUCTURALLY-RELATED DRUGS. IF AN 
ALLERGIC REACTION TO PRIMAXIN® OCCURS, 
DISCONTINUE THE DRUG. SERIOUS HYPER­
SEN SITIVITY REACTIONS MAY REQUIRE 
EPINEPHRINE AND OTHER EMERGENCY 
MEASURES.
Pseudomembranous colitis
Pseudomembranous colitis has been reported with 
the use of PRIMAXIN®. Therefore it is important to 
consider this diagnosis in patients who develop 
diarrhea during or after therapy. This colitis may 
range from mild to life threatening in severity.
Mild cases of pseudomembranous colitis may 
respond to drug discontinuance alone. In more 
severe cases, m anagem ent may in c lu d e  
sigm oidoscopy, appropriate bacte rio log ica l 
studies, fluid, electrolyte and protein supple­
mentation, and the use of a drug such as oral 
vancomycin, as indicated. Other causes of colitis 
should also be considered.
PRECAUTIONS
General
Prolonged use of PRIMAXIN® (imipenem and 
cilastatin sodium for injection) may result in 
overgrowth of resistant organisms. Repeated 
evaluation of the patient’s condition is essential. If 
superinfection occurs during therapy, appropriate 
measures should be taken.
CNS adverse experiences such as myoclonic 
activity, confusional states, or seizures have been 
reported with PRIMAXIN® especially when recom­
mended dosages based on renal function and body 
weight were exceeded. These experiences have 
occurred most commonly in patients with CNS 
disorders (e.g., brain lesions or history of seizures) 
and/or who have compromised renal function. 
However, there were rare reports in which there was 
no recognized or documented underlying CNS 
disorder. Close adherence to recommended dosage 
schedules is urged especially in patients with 
known factors that predispose to seizures (see 
DOSAGE AND A D M IN IS TR A TIO N ). A n t i­
convulsant therapy should be continued in patients 
with a known seizure disorder If focal tremors, 
myoclonus, or seizures occur, patients should be 
evaluated neurologically and placed on anti­
convulsant therapy if not already instituted. If CNS 
symptoms continue, the dosage of PRIMAXIN® 
should be decreased or discontinued.
Use in Patients with Impaired Renal Function
Dosage in patients with impaired renal function is 
based on the severity of infection but the maximum 
daily dose varies with the degree of renal functional 
im pa irm ent (see DOSAGE AND A D M IN IS ­
TRATION - Dosage in Patients w ith  Renal 
Insufficiency),
Use in Pregnancy
The use of PRIMAXIN® in pregnant women has not 
been studied, therefore, PRIMAXIN® should be 
used during pregnancy only if clearly needed. Use 
of this drug in women of childbearing potential 
requires that the anticipated benefits be weighed 
against possible hazards.
Reproduction studies with bolus I.V. doses suggest 
an apparent intolerance to PRIMAXIN® (including
emesis, inappetence, body weight loss, diarrhea 
and death) at doses equivalent to the average 
human dose in pregnant rabbits and cynomolgus 
monkeys that is not seen in non-pregnant animals in 
these or other species. In other studies, PRIMAXIN® 
was well tolerated in equivalent or higher doses (up 
to 11 times the average human dose) in pregnant 
rats and mice (see REPRODUCTION STUDIES 
under TOXICOLOGY in the complete monograph).
Nursing Mothers
It is not known whether PRIMAXIN® is excreted in 
milk. If the use of PRIMAXIN® is deemed essential, 
the patient should stop nursing.
Pediatric Use
Efficacy and tolerability in infants under the age of 
3 months have not yet been established; therefore, 
PRIMAXIN® is not recommended in the pediatric 
age group below the age of 3 months.
Drug Interactions
Concomitant administration of PRIMAXIN® and 
probenecid results in only minimal increases in 
plasma levels of imipenem and plasma half-life. It is 
not recommended that probenecid be given with 
PRIMAXIN®.
PRIMAXIN® should not be mixed with or physically 
added to other antibiotics. PRIMAXIN® has been 
administered concomitantly with some antibiotics, 
such as aminoglycosides.
There is no evidence to suggest that association of 
PRIMAXIN® with any other beta-lactam antibiotics 
has any therapeutic advantage.
ADVERSE REACTIONS
PRIMAXIN® (imipenem and cilastatin sodium for 
injection) is generally well tolerated. The following 
adverse reactions were reported on 1,723 patients 
treated in clinical trials. Many of these patients were 
severely ill and had multiple background diseases 
and physiological impairments, making it difficult to 
determine causal relationship of adverse ex­
periences to therapy with PRIMAXIN®.
Local Adverse Reactions
Adverse local clinical reactions that were reported 
as possibly, probably or definitely related to therapy 
with PRIMAXIN® were:
Incidence (%)
Phlebitis/thrombophlebitis 1.7
Infused vein pain 0.6
Vein induration 0.2
Infused vein infection 0.1
Systemic Adverse Reactions
Adverse clinical reactions that were reported as 
possib ly, probably, or de fin ite ly  related to 
PRIMAXIN® were:
Gastrointestinal
Incidence (%)
nausea 2.0
diarrhea 1.7
vomiting 1.6
tongue papillar hypertrophy 
pseudomembranous colitis
0.2
(see WARNINGS) 0.1
hemorrhagic colitis <0.1
gastroenteritis <0.1
abdominal pain <0.1
glossitis <0.1
heartburn <0.1
pharyngeal pain <0.1
increased salivation <0.1
CNS
fever 0.4
dizziness 0.3
seizures
(see PRECAUTIONS)
0.2
somnolence 0.2
confusion 0.2
myoclonus 0.1
vertigo 0.1
headache 0.1
encephalopathy <0.1
paresthesia 
Special Senses
<0.1
transient hearing loss in
patients with impaired hearing <0.1
tinnitus <0.1
Respiratory
dyspnea 0.1
hyperventilation <0.1
thoracic spine pain <0.1
Cardiovascular
hypotension 0.4
palpitations 0.1
tachycardia <0.1
Renal
oliguria/anuria <0.1
polyuria <0.1
Skin
rash 0.9
pruritus 0.3
urticaria 0.2
skin texture changes 0.1
candidiasis 0.1
erythema multiforme <0.1
facial edema <0.1
flushing <0.1
cyanosis <0.1
hyperhidrosis <0.1
pruritus vulvae <0.1
Body as a whole
polyarthralgia <0.1
asthenia/weakness <0.1
Adverse Laboratory Changes
Adverse laboratory changes, without regard to drug 
relationship, that were reported during clinical trials 
were:
Hepatic: Increased SGPT, SGOT, alkaline phospha­
tase, bilirubin and LDH.
Hemic: Increased eosinophils, positive Coombs 
test, decreased WBC and neutrophils, increased 
WBC, increased platelets, decreased platelets, 
decreased hemoglobin and hematocrit, increased 
monocytes, abnormal prothrombin time, increased 
lymphocytes, increased basophils.
Electrolytes: Decreased serum sodium, indreased 
potassium, increased chloride.
Renal: Increased BUN, creatinine.
Urinalysis: Presence of urine protein, urine red 
blood cells, urine white blood cells, urine casts, 
urine bilirubin, and urine urobilinogen.
TREATMENT OF OVERDOSAGE
There are no data available on overdosage.
PRIMAXIN® (imipenem and cilastatin sodium for 
injection) is cleared by hemodialysis.
DOSAGE AND ADMINISTRATION
The dosage recommendations for PRIMAXIN® 
(imipenem and cilastatin sodium for injection) 
represent the quantity of imipenem to be ad­
ministered by I.V. infusion only. An equivalent 
amount of cilastatin is also present in the solution.
The dosage of PRIMAXIN® should be determined 
by the severity of the infection, renal function, body 
weight, the antibiotic susceptibility of the causative 
organism(s) and the condition of the patient. Doses 
cited are based on body weight of 70 kilos.
The median duration of treatment with PRIMAXIN® 
in clinical trials for infections of the various body 
systems ranged from 6 to 10 days except for 
endocarditis and bone and joint infections for which 
the median duration of treatment was 4 weeks.
Dosage in Adults
The recommended daily dose is 1 to 2 g adminis­
tered in equally divided doses every 6 to 8 hours 
(see Table 1).
TABLE 1
ADULT DOSAGE OF PRIMAXIN®
I .V . A d m in is tra t io n
S e v e rity  
o f in fe c tio n
D o s e
(m g  o f  im ip e n e m )
D o s a g e
In te rv a l
D a ily
D o s e
Mild 250 mg 6 h 1.0 g
Moderate 500 mg 8 h 1.5 g
Severe (fully 
susceptible)
500 mg 6 h 2.0 g
Severe* infections 
due to less 
susceptible 
organisms 
or life threatening 
conditions
1000 mg 
1000 mg
8 h 
6 h
3.0 g
4.0 g
x Primarily some strains of Ps. aeruginosa.
The maximum daily dose should not exceed 4 g or 
50 mg/kg, which ever is less.
Dosage In Elderly Patients
The recommended dosage of PRIMAXIN® in elderly 
patients with normal renal function is the same as 
given for adults above. Renal status o f elderly 
patients may not be accurately portrayed by 
measurement of BUN or creatinine alone. Deter­
mination of creatinine clearance is suggested to 
provide guidance for dosing in such patients.
Dosage in Patients with Renal Insufficiency
P a tie n ts  w ith  c re a t in in e  c le a ra n c e s  of 
<5 mL/min/1.73m2 «0 .08 mL/s/1.73m2) should 
not receive PRIMAXIN® unless hemodialysis is 
instituted within 48 hours. Both imipenem and 
cilastatin are cleared from the circulation during 
hem odia lys is . The p a tien t should receive 
PRIMAXIN® after hemodialysis and at 12 hour 
intervals timed from the end of that hemodialysis 
session. Dialysis patients, especially those with 
background CNS disease, should be carefully 
m o n ito re d ; fo r  pa tien ts  on hem od ia lys is , 
PRIMAXIN® is recommended only when the benefit 
outweighs the potential risk of seizures (see 
PRECAUTIONS). Currently, there are inadequate 
data to recommend the use of PRIMAXIN® in 
patients undergoing peritoneal dialysis.
TABLE 2
MAXIMUM DOSAGE OF PRIMAXIN®
IN RELATION TO RENAL FUNCTION
RENAL
FUNCTION
CREATININE
CLEARANCE
mL/mln/1.73 m2 
(mL/»/1.73 m2)
DOSE
(9)
DOSAGE
INTERVAL
(h)
M AXIM UM
TOTAL
DAILY
DOSAGE
(9)
Mild
impairment 31-70
(0.52-1.17)
0.5 6-8 1.5-2
Moderate
impairment 21-30 
(0.35 - 0.50)
0.5 8-12 1-1.5
Severe*
impairment 0-20
(0-0.33)
0.25 - 0.5 12 0.5-1.0**
* Patients w ith  crea tin ine  clearance of 6 to 
20 mL/min/1.73 m2 (0.1 -0.3 mL/s/1.73 m2) should 
be treated with 250 mg (or 3.5 mg/kg whichever is 
lower) every 12 hours for most pathogens. When 
the 500 mg dose is used in these patients, there may 
be an increased risk of seizures.
* *  The highest dose is only recommended fo r 
infections due to less susceptible organisms 
primarily some strains of Ps. aeruginosa.
When only the serum creatinine level is available, 
the following formula (based on sex, weight, and 
age of the patient) may be used to convert this value 
into creatinine clearance (mL/min). The serum 
creatinine should represent a steady state of renal 
function.
Males: Weight (kg) x (140 - age)
72 x serum creatinine (mg/100 mL) 
Females: 0.85 x above value.
When using the International System of units (SI), 
the estimated creatinine clearance (mL/s) in males 
can be calculated as follows:
(lean body weight, kg) x (140 - age, years) x 1.4736 
(72) x (serum creatinine concentration, //mol/L)
and in females the estimated creatinine clearance 
(mL/s) is:
(lean body weight, kg) x (140 - age, years) x 1.2526 
(72) x (serum creatinine concentration, ^imol/L)
PRIMAXIN® is cleared by hemodialysis. After each 
dialysis session the dosage schedule should be 
restarted.
Each reconstituted 250 mg or 500 mg dose should 
be given by intravenous infusion over twenty to 
th irty  minutes. Each 1000 mg dose should be 
infused over 40 to 60 minutes. In patients who 
develop nausea during the infusion, the rate of 
infusion may be slowed.
RECONSTITUTION
Contents of the vials must be suspended and 
transferred to 100 mL of an appropriate infusion 
solution.
A suggested procedure is to transfer approximately 
10 mL from the 100 mL of the appropriate infusion 
solution to the vial (see list of diluents under 
COMPATIBILITY AND STABILITY). Shake well. 
Return the resulting 10 mL of suspension to the 
remaining 90 mL of the infusion solution.
Repeat, using 10 mL of the diluted suspension, to 
ensure complete transfer of the contents of the vial 
to the infusion solution.
CAUTION: CONTENTS OF VIALS NOT FOR 
DIRECT INFUSION.
COMPATIBILITY AND STABILITY
List of diluents
0.9% Sodium Chloride Injection 
5% or 10% Dextrose Injection 
5% Dextrose Injection with 0.02% sodium 
bicarbonate solution
5% Dextrose and 0.9% Sodium  C h lo ride  
Injection
5% Dextrose Injection with 0.225% or 0.45% 
saline solution 
NORMOSOL-M in D5-W 
5% Dextrose Injection with 0.15% potassium 
chloride solution 
Mannitol 2.5%, 5% and 10%
Reconstituted solutions
Solutions of PRIMAXIN® range from colourless to 
yellow. Variations of colour within this range do not 
affect the potency of the product.
PRIMAXIN®, as supplied in vials and reconstituted 
as above maintains satisfactory potency for four 
hours at room temperature and for 24 hours under 
refrigeration (4°C). PRIMAXIN® has been found to 
be stable in 0.9% Sodium Chloride Injection for 
10 hours at room temperature and 48 hours under 
refrigeration.
DOSAGE FORMS 
AVAILABILITY
PRIMAXIN® is supplied as a sterile powder mixture 
in vials containing im ipenem anhydrous and 
cilastatin sodium as follows:
3514 Ca - 250 mg imipenem equivalent and 250 mg 
cilastatin equivalent in vials.
3516 Ca - 500 mg imipenem equivalent and 500 mg 
cilastatin equivalent in vials.
STORAGE
The dry powder should be stored at a temperature 
below 30° C.
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Dosage In Infants and Children
The recom m ended to ta l da ily dosage of 
PRIMAXIN® in children and infants 3 months of age 
and older is 60 to 100 mg/kg of body weight divided 
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Hepatic Artery Aneurysm Presenting as 
Abdominal Pain and Hemoperitoneum
Gordon E. Searles, OD, MD;* James L. Wellington, MD, FACS, FRCSCt
Rupture of a hepatic artery aneurysm is one of the commonest causes of 
hemoperitoneum, second only to abdominal aortic rupture. The authors illustrate 
the difficulties of diagnosis and therapy in their description of the case of a 
65-year-old man with a ruptured hepatic artery aneurysm. There are no 
pathognomonic features, and definitive diagnosis requires selective angiography of 
the hepatic artery. Early intervention by ligation or reconstruction may improve 
outcome but is associated with a high death rate. Selective embolization under 
fluoroscopic control may be preferable.
La rupture d’un anevrisme de l’artere hepatique est une des causes les plus 
frequentes de l’hemoperitoine, deuxieme seulement derriere la rupture d’un 
anevrisme de l’aorte abdominale. Les auteurs illustrent les difficulties de diagnostic 
et de traitement en decrivant le cas d’un homme de 65 ans qui subit une rupture 
d’un anevrisme de l’artere hepatique. II n’existe pas de caracteristique pathognomo- 
nique et le diagnostic definitif necessite une angiographie selective de l’artere 
hepatique. Une intervention rapide par ligature ou reconstruction peut ameliorer le 
resultat mais elle s’accompagne d’un haut taux de mortality. II peut etre preferable 
de recourir a une embolisation sous surveillance fluoroscopique.
S udden cardiovascular instability associated with clinical findings 
of hemoperitoneum usually necessi­
tates urgent surgical exploration. 
Although ruptured aortic aneurysm 
is the commonest cause of such 
bleeding in adults, the surgeon 
should be aware of other possible 
sources of bleeding within the 
splanchnic circulation. We present 
a case of a ruptured hepatic aneu­
rysm presenting as hemoperito­
neum.
Case Report
A 65-year-old man presented to a 
local hospital complaining of epi­
gastric pain and vomiting for 1 day. 
Four days previously he had experi­
enced a constant nonradiating chest 
pain without syncope, peripheral 
numbness or dyspnea. He had a 
history of stable exertional angina.
On examination, he had mild 
right upper quadrant tenderness 
with guarding. Ultrasonography re­
vealed a cystic lesion in the right 
hepatic lobe and a normal gallblad­
der. His physical discomfort com­
bined with increased abdominal wall 
thickness required us to apply mod­
erate pressure with the ultrasound 
probe. During the examination, he 
became hypotensive and required 
resuscitation. On repeat ultrasonog­
raphy, the cystic lesion had disap­
peared and there was free fluid in 
the peritoneal cavity.
Laparotomy revealed a bleeding 
3-cm defect in the right hepatic 
lobe, which was interpreted as a 
bleeding hepatic tumour. A wedge 
resection was performed and the 
base was electrocauterized. Estimat­
ed blood loss was 3 L. Postopera- 
tively, acute renal failure developed, 
so he was transferred to the Ottawa 
General Hospital for hemodialysis.
Results of laboratory investiga­
tions indicated a blood urea nitro­
gen level of 25.5 mmol/L urea 
(normal 3.5 to 9.0 mmol/L urea), a 
serum creatinine level of 680 
Mmol/L (normal 70 to 130 
Mmol/L), serum aspartate amino­
transferase level of 837 U/L (nor­
mal 7 to 40 U/L), serum alanine 
aminotransferase of 2358 U/L 
(normal 7 to 40 U/L) and a serum 
alkaline phosphatase 272 U/L (nor­
mal 30 to 110 U/L). The serum 
creatine kinase level was also ab­
normal (680 U/L), but the MB frac­
tion was only just detectable. A 
chest x-ray film showed right lower 
lobe atelectasis with a small pleural 
effusion.
Computed tomography of the ab-
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domen revealed a fluid-filled lesion 
7 cm in diameter in the right hepat­
ic lobe, and peripheral calcification. 
Needle aspiration yielded no fluid. 
Hepatic angiography revealed an 
aneurysm of the main right hepatic 
artery, 7 cm in diameter, and a 
smaller aneurysm from a medial 
branch (Fig. 1). Selective intra-arte­
rial embolization was performed.
Several days later, the activated 
partial thromboplastin time became 
prolonged. Hematemesis developed 
and endoscopy showed a possible 
small gastric ulcer at the cardia. 
There was no mention of blood 
coming from the region of the 
ampulla of Vater, which would sug­
gest hematobilia. Liver function test 
findings became progressively ab­
normal, the platelet count fell and 
hypovolemic shock developed.
Continued bleeding made laparot­
omy mandatory. Exploration re­
vealed a large amount of blood in 
the left upper quadrant from a small 
splenic laceration, which may have 
been iatrogenic. Splenectomy was 
performed. The stomach was dis­
tended with fresh organized clot. 
The small ulcer at the cardia was 
oversewn, and vagotomy, pyloro­
plasty and feeding jejunostomy 
were performed. The right hepatic 
lobe was encased with fibrin and 
was adherent to the diaphragm, but 
there was no active bleeding. The 
patient remained hemodynamically 
unstable throughout the procedure 
despite the administration of ino­
tropic drugs.
He was transferred to the inten­
sive care unit but suffered a cardiac 
arrest and died 7 hours postopera- 
tively.
Autopsy revealed two large hem­
orrhagic cysts in the right hepatic 
lobe measuring 11 X 8 X 8 cm and 
extensive surrounding liver necro­
sis. The cystic regions correlated 
anatomically with the location of 
the aneurysms (Fig. 2). No evidence 
of hepatic adenoma was found on 
microscopic review. Evidence of a 
massive gastrointestinal hemorrh­
age was found, but no site of 
ulceration was detected.
Discussion
Aneurysms of the hepatic circula­
tion account for about 20% of all 
visceral arterial aneurysms, but they 
have the highest reported rate of 
rupture (44%).1
The mean age of patients with 
hepatic artery aneurysms is 40 
years, with a male to female ratio of 
2:1.2 There is no pathognomonic 
physical finding. The classic presen­
tation triad of Quinke (abdominal 
pain, hematobilia and obstructive
FIG. 1. Angiogram of hepatic circulation revealing two aneurysmal cavities 
(arrows) in right hepatic lobe.
FIG. 2. Cross-section showing aneurysm cavities in right hepatic lobe. Note 
thrombus inside cavities created after selective arterial embolization.
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jaundice) is seen in less than one- 
third of cases. Ultrasonography, 
computed tomography or percuta­
neous transhepatic cholangiogra­
phy suggests the diagnosis, but 
definitive diagnosis requires selec­
tive angiography of the hepatic ar­
tery.3
Chronic inflammatory infections 
such as syphilis and tuberculosis 
were once the cause of hepatic 
artery aneurysms but are now rare. 
Zachary and colleagues1 stated that 
trauma to the hepatic circulation 
was responsible for an increasing 
number of cases.
Erskine4 reported the surgical re­
sults in 61 patients. Of 38 who had 
an extrahepatic hepatic artery aneu­
rysm, ligation and excision were 
carried out in 23; the remaining 15 
had reconstruction. Of the 23 pa­
tients who had intrahepatic artery 
aneurysms, successful correction of 
an intrahepatic aneurysm was re­
ported in only 2. The remainder 
died of intraperitoneal hemorrhage, 
hemobilia or portal hypertension 
with variceal hemorrhage.
Several approaches have been ad­
vocated. If the aneurysm is located 
proximal to the gastroduodenal ar­
tery, the artery can be ligated with 
or without excision.3 Aneurysms lo­
cated distal to the gastroduodenal 
artery can be ligated and excised, 
and reconstruction carried out to 
reinstate the blood supply.3 Recon­
struction may not be necessary if 
the liver colour does not change on 
clamping the distal end of the ar­
tery before ligation.1
Liver synthesis of vitamin In­
dependent coagulation factors can 
be substantially impaired with dear- 
terialization leading to prolonged 
prothrombin and partial thrombo­
plastin times. It was not reported if 
vitamin K supplementation correct­
ed this deficiency.5
Hepatic artery aneurysm is un­
common. It presents typically with 
hemodynamic collapse, hemoperito-
neum or upper gastrointestinal he­
morrhage. Clinical suspicion, early 
examination by ultrasonography or 
angiography will lead to the correct 
diagnosis. Early control of the an­
eurysm by ligation or reconstruc­
tion can result in a favourable out­
come. The surgical death rate from 
ruptured intrahepatic artery aneu­
rysms remains high, and treatment 
by embolization may be preferable.
We thank Drs. P. Rasuli and B. Olberg 
for their assistance.
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Editor’s Note
This case report highlights the 
ever-present hazard of diagnostic sys­
tems. Ultrasonography, a widely used 
noninvasive technique, is generally ac­
cepted as being without risk. The dra­
matic events recorded here apparently 
began during the examination — proba­
bly not so much from the ultrasonic 
waves as from aggressive manipulation 
of the instrument. — CBM.
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Giant Salivary Calculi: an Orocervical 
Fistula Caused by a Submandibular Gland 
Calculus
Sami K. Asfar, MD, FRCS(Edin), FACS; Mustafa R. Steitiyeh, MB, ChB, FRCS(Edin); Raad Abdul-Amir, 
DDS, MSc
Large calculi of the salivary glands are rare. They may go undetected for many 
years. The authors report three cases of giant submandibular gland calculi. In one 
patient, the calculus was an incidental finding. In all patients, the mass was in the 
substance of the gland; in one, the configuration of the mass was unusual and it had 
eroded through the floor of the buccal cavity forming an orocervical fistula (the first 
such report) and in another the mass occupied a small portion of Wharton’s duct. 
The histopathologic findings in all three cases were of nonspecific chronic 
inflammation. All the patients made a smooth recovery and had no complaints at 
follow-up.
Les gros calculs des glandes salivaires sont rares. Ils peuvent demeurer non detectes 
pendant plusieurs annees. Les auteurs decrivent trois cas de calculs geants de la 
glande sous-mandibulaire. Chez un patient, le calcul fut une decouverte fortuite. 
Dans tous les cas, la masse se trouvait dans le corps de la glande; dans un cas, la 
masse etait de forme inhabituelle et elle avait erode le plancher de la cavite buccale, 
formant une fistule orocervicale (le premier cas a etre signale) et, dans un autre cas, 
la masse occupait une petite partie du canal de Wharton. Dans les trois cas, les 
observations histopathologiques etaient compatibles avec une inflammation chroni- 
que non specifique. Tous les patients ont fait une guerison sans histoire et n’ont 
signale aucun symptome a l’examen de rappel.
G iant salivary gland calculi are rare. We report three cases, 
seen over 7 years, one of which 
presented as an orocervical fistula. 
We believe this is the first report of 
an orocervical fistula caused by a 
salivary gland calculus.
Case Reports
Case 1
A 55-year-old man presented with 
a painful lump in the right subman­
dibular region and discharging si­
nuses in the same side of the neck. 
These had been present for 1 year.
He appeared healthy and was not 
hypertensive or diabetic. The ten­
der, firm mass appeared to be an 
enlarged right submandibular sali­
vary gland (Fig. 1). The two dis­
charging sinuses in the right upper 
cervical region just below the en­
larged gland were discharging clear 
fluid.
Inspection of the buccal cavity 
revealed a 2.0 X 1 cm defect in the 
floor of the mouth medial to the 
right molar and premolar teeth. 
Through this protruded a dark- 
brown, hard calculus. A plain later­
al x-ray film of the neck showed a 
very large calculus in the region of
the right submandibular salivary 
gland (Fig. 2).
Hematologic and biochemical 
blood test results were normal.
The diagnosis was orocervical fis­
tula caused by a right submandibu­
lar gland calculus.
Under general anesthesia and an­
tibiotic cover (Ampiclox, 1 g intra­
venously with premedication, then 
500 mg every 6 hours for 3 days 
postoperatively), a transverse ellipti­
cal incision was made to include the
FIG. 1. Case 1. Lateral view showing 
right submandibular swelling and cer­
vical sinuses.
FIG. 2. Case 1. Right lateral x-ray film 
of neck and submandibular region 
showing submandibular gland calcu­
lus.
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fistulous openings. The skin flaps 
were dissected around the fistulous 
tracts, and the right submandibular 
salivary gland together with the 
contained calculus was excised after 
ligation of Wharton’s duct. The 
defect in the floor of the mouth was 
closed with 2-0 chromic catgut. 
There were no calculi in the duct. A 
vacuum drain was left in place and 
brought out through a separate 
stab wound.
The drain was removed on post­
operative day 2 and the patient was 
discharged home on day 4.
The gross specimen showed an 
enlarged, chronically inflamed gland 
with a giant calculus occupying the 
gland substance and eroding its 
superior surface. The calculus was 
in the shape of a question mark and 
measured 3.8 X 2.5 cm. Histopa­
thologic examination of the gland 
showed nonspecific chronic inflam­
mation.
At follow-up 7 years later, the 
patient had no complaints and clini­
cal examination revealed no abnor-
FIG. 3. Case 2. Occlusive x-ray film of 
left submandibular region showing ir­
regularly round calculus.
FIG. 4. Case 3. Left lateral oblique film 
showing cylindrical calculus (arrows).
mality except for a hardly visible 
scar in the neck.
Case 2
A 43-year-old man with hyperten­
sion, ischemic heart disease and 
severe angina was admitted for 
work-up in the cardiology unit in 
preparation for coronary artery by­
pass grafting. A tender lump was 
noted in the left submandibular re­
gion. An occlusive left submandibu­
lar x-ray film revealed a large calci­
fied shadow in the region of the 
submandibular salivary gland (Fig. 
3). Blood biochemical profile and 
hematologic test results were nor­
mal. The submandibular gland was 
excised through a curved incision in 
the left submandibular region 
(along Langer’s lines). The stone 
was not in Wharton’s duct but 
within the gland substance; it had 
an irregular round shape and mea­
sured 1.6 X 2.0 cm. Histopatholog­
ic findings were chronic nonspecific 
inflammation. The patient made a 
smooth recovery and was dis­
charged on postoperative day 3. At 
2-week follow-up he was well and 
had no complaints.
Case 3
A 75-year-old man presented to 
the surgical outpatient department 
complaining of a painful swelling in 
the left submandibular region which 
increased in size during mastica­
tion. He was receiving treatment for 
mild hypertension. Hematologic test 
results and the blood biochemical 
profile were normal. A left lateral 
oblique x-ray film of the subman­
dibular region revealed an oblong 
calcular shadow in the region of the 
left submandibular salivary gland 
(Fig. 4). The gland was excised. 
The oblong, slightly curved calcu­
lus was partly in Wharton’s duct 
but mainly within the gland tissue. 
It measured approximately 2.8 X
0. 7 .cm. As in case 2, the excised 
gland showed chronic nonspecific 
inflammation. Recovery was smooth 
and at 2-week follow-up the patient 
was well.
Discussion
Small calculi in Wharton’s duct 
or in the submandibular salivary 
gland are fairly common, but large 
calculi are rare.1 The probable rea­
son for this is that the discomfort 
caused by the small calculi forces 
the patient to seek medical advice 
early. Large calculi may remain un­
noticed for up to 50 years.2 All 
three patients reported here delayed 
in seeking medical advice. In fact in 
case 2 it was found incidentally.
Very large calculi in the subman­
dibular duct or gland are extremely 
rare.1 The largest reported stone in 
the submandibular duct was a 
3.6-cm long cylindrical calculus.2 
The largest reported stone in the 
submandibular gland was 4 X 2.5 
cm in diameter.3
The first of our three cases was 
an unusual gigantic calculus in the 
shape of a question mark, which 
occupied the gland substance and 
eroded through the floor of the 
buccal cavity causing an orocervical 
fistula. As far as we are aware, this 
is the first report of an orocervical 
fistula caused by a submandibular 
salivary gland calculus and the sec­
ond report in the world literature of 
a giant calculus in the submandibu­
lar gland with such an unusual 
configuration.
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Hepatic Portal Venous Gas in Adults: 
Importance of Ultrasonography in Early 
Diagnosis and Survival
S. McFadden, MD;* W.E. Dunlop, MD
Hepatic portal venous gas (HPVG) is an ominous radiologic sign and indicates the 
need for urgent surgical intervention. The causes are varied, but the commonest 
and most serious is infarcted bowel. Because HPVG is difficult to detect on plain 
abdominal x-ray films, more reliable methods have been sought. The authors 
describe the case of a 31-year-old man to illustrate the need for and benefit of early 
detection of HPVG using ultrasonography, which was instrumental in the survival 
of the patient.
La presence de gaz dans la veine porte hepatique (GVPH) est un signe radiologique 
de mauvais presage. Elle indique la necessite d’une intervention chirurgicale 
urgente. Les causes varient, mais la plus frequente et la plus serieuse est l’infarctus 
de l’intestin. Comme le GVPH est difficile a detecter sur une radiographie simple de 
l’abdomen, on a recherche des techniques plus fiables. Les auteurs decrivent le cas 
d’un homme de 31 ans pour illustrer la necessite et les avantages de detecter tot le 
GVPH a l’aide de l’echographie, cette technique ayant contribue a sauver le patient.
H epatic portal venous gas (HPVG) was first reported in 
1955 in children who had necrotiz­
ing enterocolitis.1 In 1960, the first 
cases were reported in adults,2 but 
not until 1965 were there reports of 
survivors in this age group.3-5 In 
adults, HPVG usually indicates an 
intra-abdominal catastrophe requir­
ing urgent laparotomy.6-9 We de­
scribe the case of an adult who had 
HPVG and in whom ultrasonogra­
phy was used for early detection.
Case Report
A 31-year-old white man was 
admitted to the Calgary General
Hospital with a 3-day history of 
severe epigastric pain radiating 
through to his back associated with 
nausea and vomiting. He was a 
known heavy drinker and drug 
abuser. He had undergone 37 oper­
ations, beginning with an appendec­
tomy, cholecystectomy and vagoto­
my and pyloroplasty. No previous 
operations involved a biliary-enteric 
anastomosis. Results of physical ex­
amination and initial laboratory 
tests were in keeping with a diagno­
sis of acute pancreatitis. Three 
views of the abdomen showed only 
nonspecific air fluid levels in the 
small and large intestine, in keeping 
with an ileus.
The patient was started on intra­
venous fluids and antibiotics. His 
condition worsened and after 24 
hours ultrasonography was done. 
This revealed evidence of hepatic 
portal venous gas (Fig. 1).
At operation, the terminal small 
bowel was found to be infarcted 
through to the mid-transverse co­
lon. The bowel was resected and an 
ileostomy established. A pathologic 
cause for the infarction was never 
determined. He recovered after a 
prolonged hospital course.
Discussion
This case demonstrates many
FIG. 1. Two sonograms of liver show­
ing air (arrows) in portal venous sys­
tem. This has characteristic bright 
area of reflection and echo shadowing 
distal to it.
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characteristic findings associated 
with detection of HPVG — a mori­
bund patient,3 -7-8 a septic focus, 
most often necrotic bowel, 5 -9  and 
the need for urgent laparotomy. 9 It 
also demonstrates the many prob­
lems of detection by conventional 
methods. The plain abdominal x-ray 
films in this case showed evidence 
of HPVG only in retrospect, after 
the ultrasonography was done. We 
have presented this case to illus­
trate the need for early detection of 
HPVG using adjunctive radiologic 
techniques, mainly ultrasonogra­
phy. In the past, computed tomog­
raphy has been used, 10 but this 
method is expensive. One earlier 
report of HPVG (in adults) , 11 indi­
cated a need to determine if HPVG 
could be detected by ultrasonogra­
phy early enough to affect the
outcome. The case presented here 
clearly indicates that ultrasonogra­
phy is a reliable method and can 
detect HPVG early enough to affect 
treatment and outcome.
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MANAGEMENT OF PYOGENIC LIVER ABSCESSES IN THE CT 
ERA. C.J. Swallow, O.D. Rotstein. Department of Surgery, Toronto 
General Hospital, Toronto, Ont.
The advent of CT and U /S imaging has facilitated earlier diagnosis and 
management of pyogenic liver abscesses. To determine the management 
and outcome of pyogenic liver abscess in the CT era, the charts of 
patients with this diagnosis seen at a Toronto hospital between 1982 
and 1987 were reviewed. Forty patients ranging in age from 20 to 91 
years (median 63 years) were identified. Twenty-one patients (53%) had 
single abscesses and 19 (47%) multiple abscesses. In four patients, 
diagnosis was made at autopsy, and in six it was incidentally made at 
laparotomy. In the other 30, diagnosis was made radiologically and 
confirmed by needle aspiration. All patients received intravenous 
antibiotics. Results: Overall mortality rate was 9 /4 0  (23%). In treated 
patients (i.e., not diagnosed at autopsy), mortality was 5 /36  (14%). 
Success was defined as clinical and radiologic improvement followed by 
hospital discharge.
Treatment N Success rate Mortality
IV antibiotics only 5 80% (4/5) 20% (1/5)
Percutaneous drainage (PCD) 16 75% (12/16) 13% (2/16)
Operative drainage (OD) 
i) as initial therapy 15 87% (13/15) 13% (2/15)
ii) following PCD failure 2 100% (2/2) 0% (0/2)
Mortality was no different for single or multiple abscesses (14% 
versus 11%). Of abscesses treated by PCD. success rate was 7 /8  (88%) 
for single abscesses and 5 /8  (63%) for multiple abscesses. For OD, 
success rate for single abscesses was 9 /10  (90%) and 6 /7  (86%) for 
multiple abscesses. Two patients who failed PCD subsequently under­
went successful OD. In summary, PCD was equally effective as OD for 
solitary pyogenic liver abscesses. For multiple abscesses, PCD had a > 
60% success rate, and failures were amenable to OD.
R246
DECREASED BETA STIMULATED LIPOLYSIS WITH ENDOTOX- 
EMIA. S. Meterissian, D. Saint-Vil, A. Alaud-din, R.A. Forse. Depart­
ment of Surgery, Royal Victoria Hospital, McGill University, Montre­
al, PQ
Lipid is a major fuel in trauma and sepsis. Previous studies have 
demonstrated increased betai adrenergic stimulated lipolysis in trauma 
patients. With sepsis, as with in-vitro studies using Escherichia coli 
endotoxin, a decrease in betai stimulated lipolysis occurs. The aim of 
this project was to study the effect of endotoxin on lipolysis in vivo. 
Eleven swine had operative placement of carotid artery and bilateral 
internal jugular catheters. On a separate day the animal was infused 
with 14C-palmitate and then with either isoproterenol (0.75 jug/min) or 
endotoxin (0.3 mg/kg). Plasma samples were obtained during the 
infusion for the determination,, of free fatty acid (FFA) levels, specific 
activity (SA) and turnover (TR). Adipose tissue was obtained pre and 
post infusion. Betai stimulated lipolysis, using varying concentrations of 
isoproterenol (10 s to 10_8M), was assayed in vitro with a dual isotope
technique and the result expressed as the lipolysis factor (LF). The 
results (with *p < 0.01, tp  < 0.05) are:
FFA ±  SEM, SA ± SEM, TR (X 103 ±  SEM), 
mmol CPM//umol /xmol/min
Isoproterenol
infusion
Pre-inf 0.63 ±  0.23 37.3 ±  7.0 18.4 ±  9.4
Post-inf 0.95 ±  0.34* 16.6 ±  4.5* 40.9 ±  15.4*
(adipose tissue stimulation)
Iso (M) 10-5 10“6 10~7 1(T8
Pre-inf 82 ±  15 142 ± 1 3  113 ± 2 1 35 ± 6.4
Post-inf 101 ±  20* 64 ±  14* 49 ±  15* 14 ±  5.7*
Endotoxin
infusion
Pre-inf 0.46 ±0.11 24.2 ± 6 .5  18.1 ± 4 .6
Post-inf 0.28 ±  0.08t 49.9 ±  12.0* 9.4 ±  3.4 t
(adipose tissue stimulation)
Iso (M) 10“5 10“6 1(T7 10~8
Pre-inf 47 ±  14 67 ± 18 52 ± 16 4 ± 6.6
Post-inf 151 ±  33* 143 ±  20* 70 ±  25 59 ± 37
The isoproterenol infusion increased in-vivo lipolysis as FFA-SA 
decreased and the TR doubled. The adipose tissue LF decreased, 
indicating decreased betai receptor responsiveness in vitro which 
supports increased betai stimulated lipolysis in vivo. The endotoxin 
infusion decreased in-vivo lipolysis as SA increased and the TR 
decreased. The adipose tissue LF increased indicating increased betai 
receptor responsiveness in vitro which supports decreased betai stimu­
lated lipolysis in vivo. This study indicates that endotoxemia produces a 
decrease in betai stimulated lipolysis and may play a significant role in 
the decreased betai stimulated lipolysis in the septic patient.
R247
FIBRINOLYSIS USING TISSUE PLASMINOGEN ACTIVATOR (t- 
PA) PREVENTS INTRA-ABDOMINAL ABSCESS FORMATION. D.I. 
McRitchie, O.D. Rotstein. Department of Surgery, University of 
Toronto, Toronto, Ont.
Fibrin deposition in response to intraperitoneal infection has been 
shown to serve as a nidus for abscess formation. We previously showed 
that t-PA administered intraperitoneally simultaneously with the infect­
ing inoculum prevented abscess formation. However, in the clinical 
setting, intervention is delayed following the onset of peritonitis. The 
purpose of these studies was to examine the effect of delayed t-PA 
administration on abscess formation. Wistar rats were inoculated 
intraperitoneally with Bacteroides fragilis enmeshed within fibrin. At t = 
0, 2, 6 and 18 hours, the abdomen was openly lavaged with HBSS or 
t-PA. Animals were assessed on day 5.
Time o f adm inistra tion
0  h o u rs 2 hours 6 hours 18 h o u rs
R ate  W t. g Rate W t. g Rate W t. g Rate W t. g
HBSS 1 2 / 1 2  0 .3 5  (0 .04 ) 1 0 /1 2  0 .4 1 (0 .0 2 ) 1 5 /1 5  0 .33  (0.03) 9 / 9 0 .4 3  (0 .05)
t-PA .01 0 / 1 2 8 / 1 2  0.07  (0.02)* 1 5 /1 5  0 .1 8  (0 .02)b 9 / 9 0 .3 6  (0 .04 )
t-P A .l ND NI) 0 /9 * 1 /6 *  0 .19 9 / 9 0 .2 4  (0 .04 )b
a: p < 0.001 vs H B S S  b: p < 0 .0 5  v s  HBSS. All values: m ean (SEM)
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At t = 0, t-PA (0.01 mg/ml) obviated abscess formation. It had no 
effect on abscess rate but reduced abscess size at 2 and 6 hours. Since 
fibrin clots dehydrate in vivo, we hypothesized that a higher concentra­
tion of t-PA might be necessary. Indeed, high-dose t-PA prevented 
abscess formation and reduced mean weight when administered follow­
ing a 2- and 6-hour delay. Tissue plasminogen activator after an 
18-hour delay lowered abscess size but not rate, indicating partial 
fibrinolysis. These studies suggest the clinical efficacy of t-PA when 
administered after a bacterial insult. Its use combined with antibiotics 
and appropriate surgical intervention may improve outcome in patients 
with diffuse fibrinopurulent peritonitis.
R248
ASCENDING CHOLANGITIS: SURGERY VERSUS ENDOSCOPIC 
OR PERCUTANEOUS DRAINAGE OF THE COMMON BILE DUCT. 
T. Lindsay, H.S. Himal. Department of Surgery, Toronto Western 
Hospital, Toronto, Ont.
Ascending cholangitis has traditionally been considered a surgical 
emergency. Recently, endoscopic or percutaneous drainage of the 
common bile duct has been suggested as alternative therapy. To 
determine whether nonsurgical therapy leads to decreased mortality, the 
charts of 55 patients admitted to hospital with ascending cholangitis 
were reviewed. The mean age in the surgical group (32 patients) was 72 
years and 69 years in the nonsurgical group (23 patients). In the 
surgical group, 8 patients presented in shock (< 80 mm Hg) and 15 
patients had positive blood cultures. Twenty-seven patients underwent 
cholecystectomy and common-bile-duct exploration and 5 patients 
underwent only common-bile-duct exploration. Operative mortality was 
6% (two patients). In the nonsurgical group, 4 patients presented in 
shock and 10 patients had positive blood cultures. Thirteen patients 
underwent endoscopic drainage, 1 underwent percutaneous drainage 
and 9 patients had both procedures. Eight patients also had surgery 
because of continuing sepsis. In the nonsurgical group the mortality 
was 34% (eight patients). We conclude that surgical intervention 
remains the treatment of choice for ascending cholangitis.
R249
INTESTINAL PERMEABILITY AND BACTERIAL TRANSLOCA­
TION FOLLOWING ORTHOTOPIC INTESTINAL TRANSPLANTA­
TION IN THE RAT. D. Hurlbut, R. Zhong, P. Wang, H. Chen, D. 
Lamont, R. Behme, B. Garcia, C. Stiller, J. Duff, D. Grant. University 
of Western Ontario, London, Ont.
Intestinal permeability was measured after orthotopic intestinal trans­
plantation (IT) in Lewis rats with Lewis X Brown Norway-Fl allografts 
(group 1). Lewis rats with isografts (group 2) and Lewis X Brown 
Norway-Fl allografts treated with cyclosporine, 6 m g/kg daily, (group 
3) served as controls. Pathological examination at the time of sacrifice 
on the 7th postoperative day showed advanced rejection in the 
untreated allografts and normal histology in the controls. Data on 
intestinal permeability, measured by the % urinary clearance of 10 nC'\ 
of oral 51Cr-EDTA, and the mean ± SEM log of the bacteria plated from 
tissue homogenates of donor mesenteric lymph nodes (MLN), liver (LIV) 
and spleen (SPL) are presented below:
51C r-ED TA  
u p ta k e . % B ac t MLN B a c t LIV B ac t S P L
G R P  1 (n =  6) 
G R P  2  (n =  6) 
G R P  3  (n =  6)
10.66 ±  1.47*  
4 .47  ±  0 .5 5  
4 .03  ±  0 .7 1
3 .6 7  ±  0 .2 1 1 
1 .3 2  ±  0 .3 7  
2 .5 0  ±  0 .2 2
3 .3 1  ±  0 .9 1  
1 .1 5  ±  0 .7 1  
1 .0 7  ±  0 .6 6
3 .6 5  ±  0 .3 8 +  
0 .9 6  ±  0 .6 6  
2 .0 4  ±  0 .3 3
*p <  0 .0 1 .  t p  <  0 .0 5
Rejection of the rat orthotopic intestinal transplant leads to increased 
intestinal permeability to 51Cr-EDTA, with bacterial translocation to the 
host’s reticuloendothelial system. Treatment with cyclosporine prevents 
these complications. Changes in intestinal permeability may contribute 
to the frequent occurrence of sepsis after clinical intestinal transplanta­
tion.
R250
IN-VITRO CULTURE OF ISOLATED RAT PANCREATIC ISLETS 
DEPLETES DONOR ANTIGEN PRESENTING CELLS AND PRO­
LONGS ISLET ALLOGRAFT SURVIVAL. E.D. Skarsgard, R.M. 
Meloche. Division of General Surgery, Department of Surgery, 
University of British Columbia, Vancouver, BC
The purpose of this study was to assess the ability of tissue culture to 
deplete antigen presenting cells (APCs, characterized by surface expres­
sion of major histocompatibility [MHC] class II antigen) from rat 
pancreatic islets and to compare the duration of culture required for 
APC depletion with that necessary to achieve successful islet allotran­
splantation. Sprague Dawley (RTla) rat islets were isolated using a 
collagenase digestion and dextran density gradient purification. Islets, 
either freshly isolated or after 4 to 14 days of culture in supplemented 
Ham's F-12 medium at 37°C in 5% C02/room air, were snap frozen, 
cryostat sectioned and indirectly immunostained with a monoclonal 
antibody (OX-6), directed against MHC class II antigen. Fresh and 
cultured islets were transplanted under the renal capsule of both 
syngeneic (control) and allogeneic (Wistar Furth -  RT1U) recipients. 
Twelve days later the grafts were harvested, paraffin imbedded, 
sectioned and stained with hematoxylin and eosin to determine the 
duration of culture necessary to permit histologically successful islet 
allografting. The results of these studies are summarized in the 
following table:
Duration of islet culture, d
0 4 7 10 14
Presence of MHC class 11 + cells 
Allogeneic graft (Wistar Furth)
yes yes yes no no
islet integrity 0 0 0 0 +4
mononuclear infiltrate +4 +4 +4 +4 + 1
As confirmation of in-vivo allograft function, 6 to 800 14-day 
cultured, transplanted islets were shown to reverse, indefinitely, hyper­
glycemia in recipients rendered diabetic by treatment with intravenous 
streptozotocin (50 mg/kg). In conclusion, tissue culture of isolated rat 
pancreatic islets results in the depletion of MHC class II positive 
“antigen presenting cells”, as determined by immunostaining. The 
temporal disparity that exists between duration of culture required for 
APC depletion and that which allows successful allografting, suggests 
that tissue culture may impose some additional tissue alteration that 
results in diminished graft immunogenicity.
R251
THE ROLE OF CLARK’S MEASUREMENT AS A PROGNOSTIC 
INDICATOR IN THIN MELANOMA. L.A. Pontikes, W.J. Temple, S. 
Cassar, S. Huchcroft, M. Jerry, R. Lafreniere. University of Calgary/ 
Tom Baker Cancer Centre, Calgary, Alta.
Previous literature has shown that Breslow’s measurement of primary 
melanoma depth may be more important than Clark’s level of melanoma 
invasion in predicting risk of recurrence. Our study attempts to
300 CJS, VOL. 32. NO. 4, JU LY 1989
CAGS
determine the influence of these two parameters on recurrence risk in 
the subgroup of thin melanomas (i.e., less than or equal to 1.0 mm).
We studied 215 cases of stage 1 melanoma of tumour depth less than 
or equal to 1.0 mm. In each of these cases, both Clark’s level and 
Breslow’s tumour thickness could be determined. Mean follow-up time 
was 41 months.
Each case was categorized by level (II to V), depth (from 0 to 1 mm in 
0.25-mm increments), site (head and neck, trunk or extremities) and by 
sex. Recurrence and metastases were documented and correlated to 
these variables.
Overall recurrence rate was 10.7% (23 cases). Risk of recurrence was 
influenced by each of the variables of level (p < 0.002), site (p < 0.04) 
and depth (p < 0.02) of the primary tumour. Discriminant function 
analysis showed that Clark’s level was the single most predictive 
variable and that the additive interaction of level with site was the best 
prognostic indicator of risk of recurrence. The interactive effect of level 
and head and neck location of the primary tumour gave the highest risk 
of recurrence. After the effects of level and site, Breslow’s depth failed 
to add predictive power.
It appears that measurement of Clark’s levels is an important 
prognostic indicator in thin melanoma for identifying a subgroup of 
high-risk patients in whom further therapy may be appropriate.
R252
IMMUNE RESPONSES IN SMALL INTESTINAL TRANSPLANTA­
TION (SIT). P. Kim, Z. Cohen, M. Craig, G. Levy. Department of 
Surgery, University of Toronto, Toronto, Ont.
Monocyte procoagulant activity (PCA) has been shown in our laboratory 
to be a sensitive marker of rejection in rat SIT. We have now studied 
PCA changes in peripheral blood mononuclear cells (PBMs), graft 
mesenteric nodes (GM) and graft intraepithelial lymphoid cells (IEC) in 
rat SIT in order to study the sequence of this immune response during 
rejection. Group 1 consisted of 32 syngeneic transplants (Lew grafts- 
Lew hosts). Group 2 consisted of 32 allogeneic transplants using a 
unidirectional rejection model of rat SIT (Lew hosts-Lew X BN Fi 
graft). Sixteen rats in each group were treated and 16 received 
cyclosporine (CsA) 10 m g/kg daily subcutaneously for 7 days. Rats 
were serially sacrificed, and complete necropsies performed. Blood, 
mesenteric nodes and graft intestine were harvested, and lymphoid cells 
from each were isolated and assayed for PCA in a one-stage clotting 
assay. In group 1 (syngeneic grafts) PCA levels were not significantly 
different for treated and untreated animals. In group 2 untreated 
allogeneic transplants, statistically significant changes in PCA occurred 
initially in the graft nodes to 278.3 ± 51.3 mU/106 isolated cells on 
day 4-5 followed by 3- and 10-fold increases of PCA to 302.3 ± 122 
and 1720.0 ±  540 mU/106 isolated cells in PBM and IEC on day 7-8 
respectively (p < 0.01 as compared to CsA treated group 2 allogeneic 
transplants). Cyclosporine fully suppressed PCA in group 2 allografts to 
levels comparable to group 1 syngeneic transplants. In conclusion, (a) 
an early rise in PCA level in the graft mesenteric lymph nodes marks the 
onset of immune response in intestinal allograft rejection and has a 
predictive value for incipient rejection, (b) PCA is a sensitive and 
accurate marker of immune response closely correlating with clinical 
and histopathological changes of rejection, and (c) CsA fully suppresses 
alloantigen activation of PCA in vivo.
R253
THE ROLE OF DEXTRAN-40 AND POTASSIUM IN LUNG PRES­
ERVATION FOR TRANSPLANTATION. S.H. Keshavjee, F. Yamaza- 
ki, H. Yokomise, P. Cardoso, J.B.M. Mullen, A.S. Slutsky, G.A. 
Patterson. Department of Surgery, University of Toronto, Toronto, 
Ont.
We have previously demonstrated that a low potassium dextran solution
(LPD, K+ = 4 mmol/L, Dextran-40 =  20 g /L ) is capable of providing 
superior immediate lung function compared with the commonly used 
Euro-Collins solution following preservation for 12 hours. High potassi­
um concentrations cause pulmonary vasospasm and have been implicat­
ed in cellular injury during hypothermic storage. Dextran-40 has been 
shown to improve microvascular flow under various conditions. This 
study was designed to determine the contribution of a low potassium 
concentration and dextran to the improved preservation seen with LPD. 
The function of canine left lung allografts stored for 12 hours following 
pulmonary artery (PA) flush preservation was studied in a randomized, 
blinded study. Animals were assigned to groups according to the 
composition of the flush solution: I: LPD (n =  6); II: LP - low potassium 
(4 mmol/L) without dextran (n =  6); and III: HPD - high potassium 
(123 mmol/L) dextran (n = 6).
The LPD solution provided significantly better immediate gas ex­
change by the transplanted lung (P02: 519 ±  12 mm Hg, mean ±  SEM, 
F ^  = 1.0) than the LP (P02: 243 ±  78 mm Hg, p < 0.05) and the HPD 
(P02: 176 ± 79 mm Hg, p < 0.01) solutions. There were two early 
postoperative deaths in group III related to poor preservation. The P02 
was excellent for all animals on day 3. Pulmonary vascular resistance 
and PCO2 were not different among the groups immediately or at day 3. 
On histopathological examination, 9 /1 0  airways in the dextran-contain- 
ing groups (LPD, HPD) were viable, whereas only 2 /6  in the LP group 
were viable. These results confirm our hypothesis that Dextran-40 and a 
low potassium concentration contribute significantly to the uniformly 
excellent function of a transplanted lung preserved for 12 hours with 
LPD.
R254
GENERAL SURGICAL PROCEDURES AFTER HEART TRANS­
PLANTATION. J. Yee, D. Petsikas, M.A. Ricci, A. Guerraty. McGill 
University, Royal Victoria Hospital, Montreal, PQ
Seventy-one cardiac transplantations were performed at the Royal 
Victoria Hospital between January 1985 and March 1989. Perioperative 
mortality was 10.5%. Overall survival was 80.3%. Among the long-term 
survivors, a total of 14 patients (24.5%) underwent major noncardiac 
surgical procedures under general anesthesia. Seven patients (12.5%) 
had emergency laparotomies, of which four were for biliary tract 
disease, one for ruptured abdominal aortic aneurysm, one for pancreati­
tis and one for Escherichia coli enterocolitis. Elective surgical interven­
tions included the repair of symptomatic abdominal wall hernias (two), 
hemorrhoids or perianal condylomata (three), hip replacement (one) and 
maxillary sinus drainage (one).
Preoperatively, all patients were on oral cyclosporine. Seven of the 14 
patients studied were on triple-drug immunosuppression consisting of 
cyclosporine, azathioprine and low-dose prednisone. One patient was 
only on cyclosporine, while all the remainder used both cyclosporine 
and prednisone.
There were no deaths. Complications were limited to residual 
choledocholithiasis, treated with percutaneous drainage, and a superfi­
cial wound infection. Immunosuppression was lower perioperatively and 
acute rejection was monitored by myocardial biopsies. Our experience 
indicates that noncardiac surgical procedures under general anesthesia 
may be safely performed in heart transplant patients.
R255
MANAGEMENT OF LARGE COLORECTAL POLYPS. D. Bernard, S. 
Morgan, D. Tasse, R. Wassef. Department of Surgery, Universite de 
Montreal, Division of Gastrointestinal Surgery, Hopital St-Luc, Mon­
treal, PQ
Before the advent of colonoscopy (Cs), polyps over 1 to 1.2 cm as seen 
on barium enemas were candidates for laparotomy. With Cs, nearly all 
polyps under 2 cm in size can be removed at endoscopy. What about the
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larger ones? Out of a total of 1743 polyps found at Cs, 167 (9.6%) in 
152 patients were > 2 cm in size. Colonoscopic excision was achieved 
in 112 (74%) patients: a total of 118 polyps (90 under 3 cm and 28 over 
3 cm in size). Pathology revealed adenomas in 107 (13 containing 
in-situ and 8 invasive carcinoma), hyperplastic polyps in 4, juvenile in 2, 
hamartoma in 1, angioma in 1 and adenocarcinoma in 3. Thirty-eight 
percent of adenomas were tubulovillous and 18% villous. Eight required 
a piecemeal excision technique during one to four sessions. There were 
no perforations or transmural burns, but eight patients presented with 
post-polypectomy bleeding (six early, two late); six stopped bleeding 
spontaneously and two required recoagulation of the base of the polyp. 
None was given blood. Colonoscopic excision was not attempted in 40 
patients (26%) because of the following reasons: too large and/or 
sessile, 13; suspicion of malignancy, 3; synchronous cancer, 6; divertic­
ular disease, 2; multiple, 2; other approaches preferred, 11 (transanal 9, 
Kraske 2) and miscellaneous reasons, 3. Conclusion: unless an indica­
tion for another approach becomes dominant, because of their size, 
location or concomitant pathology, the majority of large adenomas can 
be removed through colonoscopy with a lesser risk and disability than 
any surgical procedure and with a low complication rate.
R256
LASER FULGURATION FOR RECTAL TUMOURS. P.L. Birnbaum, 
C.D. Mercer. Queen’s University, Kingston, Ont.
Nd-YAG laser fulguration of rectal tumours was used for palliation in 
15 patients (7 females, 8 males), average age 75 ±  3 years (range 67 to 
93 years). Eight required general anesthesia and seven local anesthesia. 
Indications for laser treatment include palliation in nine patients with 
diffuse metastases; four refused operative therapy and two were 
medically unfit for surgery. Ten patients presented with bleeding with 
or without tenesmus, 3 had obstruction and 2 were asymptomatic. Four 
patients had previous surgery and two received radiotherapy. The 
tumours were on average 7.6 ± 1.3 cm (range from 0 to 15 cm) from 
anal verge. Adenocarcinoma was present in 14 patients and villous 
adenoma in 1. The average energy used was 5525 ±  945 J (range 1000 
to 11 000 J). Thirteen patients had successful reversal of preoperative 
symptoms immediately after laser treatment. One patient with circum­
ferential predominantly extrinsic tumour did not benefit from treatment. 
Mean post-laser stay was 4.5 ± 1.2 days (range 0 to 11 days). Seven 
patients underwent subsequent treatment at an average of 145 ±  75 
days (range 3 to 485 days) following initial procedure. Mean follow-up 
was 6.4 months (range 3 to 19 months) in 13 patients. Six patients 
were free of local tumour symptoms; three died of carcinomatosis with 
good palliation of local symptoms; four developed recurrence of 
tenesmus. The Nd-YAG laser provides effective nonoperative palliation 
for patients with obstructing or bleeding rectal tumours. Palliation of 
tenesmus is not as frequent or lasting.
R257
THE EFFECT OF AGE AND BODY COMPOSITION ON THE 
METABOLIC RESPONSES TO ELECTIVE SURGERY. D. Desai, 
M.L. Redmond, R.J. March, J.M. Watters. Department of Surgery, 
University of Ottawa, Ottawa Civic Hospital, Ottawa, Ont.
To evaluate the effects of age and body composition on the metabolic 
responses to surgery, we studied 20 generally healthy, active, independ­
ent nondiabetic males undergoing elective colonic resection. Total body 
water (TBW) was determined preoperatively in 17 patients by dilution 
of ,8oxygen-water. Respiratory gas exchange and other measurements 
were made daily at 07:00 hours from the morning prior to surgery until 
the third postoperative day, as well as 6 hours postoperatively. The
results are presented, in part, as mean ± SEM (*p < 0.01 versus 
preoperative by paired f-test):
Postop
Preoperative 6h Day 1 Day 2 Day 3
V02. ml/min 227 ± 8 271 ± 11* 264 ±  9 274 ± 9 267 ± 8
VC02. ml/min 191 ± 6 209 ± 9* 204 ± 7 213 ± 7 207 ± 6
Serum cortisol, nmol, 1, 463 ± 31 881 ± 82* 568 ± 51 528 ± 29
Serum glucose. mmol/L 5.3 ± 0.1 8.1 ± 0.3* 6.5 ± 0.3 6.2 ±  0.2 5.9 ± 0.2
Serum insulin. pmol/L 78 ± 7 99 ± 13 145 ± 18* 100 ± 12 97 ± 8
WBC. cells/mm3 6.6 ± 0.3 16.3 ± 1.4* 11.6 ± 0.6 11.1 ± 0.7 9.4 ± 0.5
Serum CRP, mg/L 8 ± 2 18 ±  8 77 ±  10 119 ± 10* 99 ± 9
Mean patient age was 62 ± 2 years (range 43 to 77 years), weight 
76.8 ±  2.1 kg and TBW 40.5 ± 1.1 (48% to 60% body weight). Age 
was not related to weight, TBW, diagnosis or duration of operation. 
Preoperative oxygen consumption (V02) was strongly related to TBW 
and age (31.9 + 6.1 X TBW -  0.9 X age, r2 = 0.80. p < 0.001). as 
were CO2 production (VCO2) and energy expenditure (EE). Postoperative 
(6 hours to day 3) V02 and VCO2 values were not different by ANOVA. 
Postoperative V02, VCO2 and peak serum cortisol, glucose, insulin and 
C-reactive protein and WBC were all significantly greater than preopera­
tive values. V02, VCO2 and EE responses to operation (absolute or % 
preoperative) were unrelated to age, diagnosis or duration of operation. 
Serum insulin, but not glucose, was increased with age (r2 =  0.29, p < 
0.05) 6 hours postoperatively: neither was related to any variable at 
other times. Postoperative hospital stay, WBC and serum cortisol and 
CRP were unrelated to age. diagnosis or duration of operation.
We conclude that unstressed, preoperative energy expenditure is a 
function of TBW and age, which together reflect body cell mass. 
Advancing age may be associated with minor changes in postoperative 
carbohydrate metabolism, but energy expenditure and other responses 
are unaltered. Age effects may be important in patients older than those 
studied or in a setting of more severe or prolonged stress.
(Supported by the Medical Research Council of Canada and Ontario 
Ministry of Health.)
R258
ALTERED CELLULAR IMMUNE FUNCTION IN THE ATELECTAT­
IC LUNG. D. Nguyen, H. Shennib, D.S. Mulder. McGill Lung 
Transplant Program, The Montreal General Hospital, Montreal, PQ
Lung atelectasis is a common component of many lung injuries. With 
the surge of interest in bronchoalveolar lavage (BAL) as a method of 
differentiating types of lung pathology, knowledge of changes in BAL 
cell phenotype and function due to atelectasis becomes essential. We 
studied cell phenotypes, natural killer (NK) and nonspecific lectin- 
mediated cytotoxicity (CTL) in BAL and peripheral blood (PBL) 
monocells from normal and atelectatic lower lobes in two groups of 
dogs (n = 8 in each). Results are expressed as percentage of control. 
Results:
NK Activity CTL Activity
Effector/target BAL* PBL* BAL* PBL*
50:1
25:1
12:1
62.7 ±  9.8 
58.1 ± 9.6 
48.0 ±  8.6
166.7 ±  9.2 
155.3 ± 12.5 
166.0 ±  12.0
61.5 ± 12.8
69.5 ±  17.4 
71.1 ±  14.2
144.7 ±  17
145.8 ±  20.8 
162.5 ± 6.2
*p < 0.01
While NK and CTL activity in the unaffected contralateral lungs were 
comparable to control values, NK and CTL were significantly impaired 
in the atelectatic lungs. This was associated with an influx of new cells 
predominantly polymorphonuclear leukocytes. The simultaneous signifi­
cant increase in NK and CTL activity in PBL in atelectatic animals 
signifies the discrepancy in immune response in the systemic and lung
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compartments. Moreover, such impairment of local pulmonary cellular 
defences may render atelectatic lungs more susceptible to infection.
R259
RELIABILITY AND CONSTRUCT VALIDITY OF THE OBJECTIVE 
STRUCTURED CLINICAL EXAMINATION (OSCE) IN ASSESSING 
SURGICAL RESIDENTS. R. Cohen, R. Reznick, B. Taylor, J. Provan. 
Department of Surgery, University of Toronto, Toronto, Ont.
The purpose of this research was to assess reliability and construct 
validity of the OSCE for assessing surgical residents. Reliability refers to 
precision of the examination and construct validity to the degree to 
which the examination can discriminate different levels of training. 
Twenty-seven PGY-2 surgical residents took a 38-station OSCE repre­
senting eight surgical specialties and testing history-taking, physical 
examination, problem solving, technical skills and attitudes. A couplet 
methodology was used wherein a simulated patient encounter was 
followed by questions aimed at testing problem solving and patient 
management capabilities. Thirty-six actors trained as standardized 
patients and 34 surgeons served as examiners, marking from structured 
checklists. Overall reliability, Cronbach’s Alpha, was 0.89. Construct 
validity was examined comparing the scores of the residents to a group 
of graduates of foreign medical colleges applying for pre-internship. For 
17/19 stations which both groups took, the residents performed 
significantly better, p < 0.01. Individual station validity was significant 
for 32 /38  stations, r = 0.36 to 0.82, p < 0.05. The examination took 
3.83 hours at a cost of $5293. The OSCE has been shown to be a 
reliable method of assessing clinical skills of surgical residents, 
construct validity has been established and inter-item validity confirmed. 
The reliabilities achieved are in excess of those traditionally required for 
both acceptance and promotion decisions.
R260
SKIN/MYOCUTANEOUS FLAP ISCHEMIA AND ALTERED NEU­
TROPHIL FUNCTION. C. Lee, C.L. Kerrigan, J.M. Tellado. Mi­
crosurgery Laboratory, Royal Victoria Hospital, McGill University, 
Montreal, PQ
The neutrophil has been implicated as a source of oxygen-free radicals 
in reperfusion injury of ischemic tissue. A two-phase study was 
designed (1) to examine neutrophils perfusing ischemic tissue for 
superoxide production and (2) to determine neutrophil delivery to 
ischemic tissue. Exp. 1: Bilateral isolated latissimus dorsi musculocu­
taneous (LD) regions, with thoracodorsal vascular supply, were created 
in 17 pigs. One LD in each pig was randomized to a 6- or 8-hour 
ischemic period. Neutrophils isolated from LD venous effluent at 
reperfusion were assayed for superoxide production with PMA stimula­
tion. Exp. 2: Bilateral LD were created in six pigs. One LD in each pig 
was randomized to a 6-hour ischemic period. Isolated blood neutrophils 
were radiolabelled with indium-111 and autotransfused prior to reperfu­
sion. Radioactivity was measured at 24 hours. Results Exp. 1: PMA 
stimulated neutrophils from venous effluent of ischemic tissue during 
the immediate reperfusion period showed a 64% ± 26% (p = 0.01) and 
15% ± 7% (p = 0.02) increase in production of superoxide radical over 
control values at 5- and 15-minute incubations respectively. Blood 
neutrophil counts from the immediate reperfusion period showed 
ischemic LD to sequester more neutrophils per gram hemoglobin 
perfusing the tissue than contralateral controls, respectively 22.2 ± 4.2 
versus 5.3 =t 5.3 millions of neutrophils/g hemoglobin (p =  0.00006). 
Results Exp. 2: Radioactivity in ischemic LD was increased by 101% ± 
30% (p = 0.01) over nonischemic LD.
Conclusions: (1) Neutrophil superoxide production exhibited an 
accelerated release of superoxide radical to PMA stimulation immediate­
ly following an ischemic insult. (2) Neutrophil delivery to ischemic 
tissue was increased; this began in the immediate reperfusion period.
The increased delivery and enhanced functional response to neutrophils 
induced by ischemia can in part explain the mediation of reperfusion 
injury.
R261
IBUPROFEN; POTENT SALVAGE OF ISCHEMIC/REPERFUSED 
MUSCLE. C. Lee, C.L. Kerrigan. Microsurgery Research Laboratory, 
Royal Victoria Hospital, McGill University, Montreal, PQ
Acute arterial impairment can lead to disastrous results. Short of early 
revascularization, there are few effective modalities for salvaging 
ischemic tissue. This study examined the drug ibuprofen as a protective 
agent in ischemia/reperfusion insults to skeletal muscle and skin.
Two pigs were dosed with 6.25, 12.5 and 25 m g/kg of ibuprofen. 
Using HPLC to determine serum drug levels, a crude pharmacokinetic 
profile was constructed. The serum half life was 2 hours, and a dose of 
25 mg/kg of ibuprofen was selected.
Ten pigs were subjected to two operations so that each pig served as 
its own control. At both operations unilateral latissimus dorsi (LD) 
myocutaneous flaps and buttock skin flaps were elevated and subjected 
to 6 hours of ischemia. Beginning intraoperatively, animals were treated 
with either ibuprofen or placebo every 8 hours for 2 days. A 24-hour 
“drug-free period” ensued to allow clearing of residual drug. The 
alternate treatment was then instituted for the second operation. Skin 
survival estimation was aided by intravenous fluorescein injection and 
Wood’s lamp illumination. Determinations of muscle viability were aided 
by nitroblue tetrazolium staining.
Results: Ibuprofen treatment dramatically improved the area of LD 
muscle survival by 30.4% ±  9.3% (p = 0.005). Latissimus dorsi skin 
survival was modestly improved by ibuprofen treatment, with a 6.0% ± 
3.2% (p = 0.046) measured increase in area survival. Buttock skin 
survival was not improved. Survival was unaffected by treatment order.
Conclusions: Ibuprofen showed effective salvage of ischemia/reper- 
fused LD muscle. A modest improvement of LD skin survival without 
improvement of buttock skin survival, suggests a primary muscle 
salvage with indirect secondary benefit to the overlying LD skin.
R262
RESUSCITATION OF A SWINE HEMORRHAGE MODEL WITH 
HYPERTONIC SALINE-DEXTRAN SOLUTION: COMPARISON OF 
BIOCHEMICAL PARAMETERS WITH SALINE RESUSCITATION. 
H. Chyczij, A. Hayashi, S. Hamilton. Department of Surgery, Universi­
ty of Alberta, Edmonton, Alta.
Hypertonic saline (7.5%) and Dextran-70 (6%) solution is being 
promoted as an effective fluid for resuscitation of trauma patients. 
Using an anesthetized swine hemorrhage model we compared changes 
in blood and mesenteric lymph biochemistry during resuscitation 
between controls (n =  9), a saline group (NS, n = 7) and a hypertonic 
saline and dextran group (HSD, n =  8).
Swine of either sex (30 to 40 kg) were anesthetized with barbituates 
and underwent placement of arterial, venous and mesenteric lymphatic 
catheters. The animal was bled 20 m l/kg (30%) over 15 minutes and 
observed for 6 hours. In the experimental groups resuscitation began 
30 minutes after hemorrhage (NS =  60 ml/kg; HSD = 4 ml/kg). 
Samples of lymph and venous blood were obtained at 15, 45, 75, 105 
and 195 minutes after resuscitation began. The blood and lymph 
samples were analysed for sodium (Na), chloride (Cl) and osmolarity 
(Osm). A sustained significant rise occurred in the blood Cl in both NS 
(107.4 ±  2 versus 97.8 ±  1, p < 0.02) and HSD (105.8 ± 3 versus 97.8 
±  1, p < 0.05) resuscitation. There was no significant change in lymph 
Cl in either group. Blood Na rose significantly in the HSD group at 105 
minutes, but subsequently returned to normal. Lymph Na was un­
changed. Blood Osm was significantly decreased in the NS group (248 
± 19 mOsm versus 283 ±  8 mOsm, p < 0.03) and unchanged in the 
HSD group.
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In conclusion, despite its hypertoxicity, HSD does not induce 
significant biochemical changes in the blood or in the extracellular fluid 
(lymph). It has the advantage over NS in being effective at much smaller 
volumes.
R263
INTESTINAL PERMEABILITY IN CRITICAL ILLNESS AND 
TRAUMA — EXPERIMENTAL AND CLINICAL OBSERVATIONS. 
D. Hurlbut, D. Lamont, R. Zhong, P. Wang, H. Chen, B. Garcia, W. 
Vezina, D. Grant, J. Duff. University of Western Ontario, London, 
Ont.
Critical illness and trauma may impair gut barrier function (GBF), 
resulting in systemic “soiling” by gut bacteria and intraluminal toxins. 
Impaired GBF may be a factor in the development of multiorgan failure 
(MOF). Gut barrier function was assessed in the following experimental 
and clinical studies to test these hypotheses.
Percent 24-hour urinary excretion of a 10-/xCi oral dose of chromi- 
um-51 ethylenediaminetetraacetate (51Cr-EDTA) was measured in male 
Sprague-Dawley rats after the following insults of graded severity: 
normal controls (NL); anesthesia alone (AN); surgical trauma (ST) from 
intestinal manipulation; reversible hemorrhagic shock (HS) to MAP of 
40 mm Hg X 90 minutes; and S. typhosa endotoxin (ET) 250 
intravenous push. Intestinal permeability was significantly increased in 
the HS and ET groups compared with NL; AN and ST rats had 
intermediate values.
Intestinal permeability was measured in 16 patients with MOF (three 
or more failing organ systems), 7 patients 1 day post-aortocoronary 
bypass (ACB) and 10 normal subjects (controls). Permeability to 51Cr- 
EDTA was greatest for MOF patients (3.68 ±  0.56) versus controls 
(1.55 ±  0.18) (p < 0.05). Permeability for ACB was elevated but not 
different from controls. There was no correlation between uptake and 
MOF severity scores (Goris, Apache II).
Shock in rats and critical illness in man are associated with impaired 
GBF. Prospective, sequential measurements in stressed patients may 
help to determine if impaired GBF is an etiologic factor in MOF.
R264
ANORECTAL INCONTINENCE MANOMETRY AND SURGICAL 
RESULTS. J. Yelle, M. Wells, J. Freeman. Division of General 
Surgery, Ottawa General Hospital, University of Ottawa, Ottawa, Ont.
Manometry, electromyography (EMG) and proctography were performed 
on 51 incontinent patients over 18 months. Twenty-five had correctable 
surgical causes; 26 were treated by physiotherapy and operant condi­
tioning. The surgical procedures were: anterior resection for prolapse — 
5; anterior external sphincter repair only — 10, with rectovaginal fistula 
repair — 6 or with sigmoid colostomy for sphincter trauma — 3; 
post-anal repair — 2; and rectocele repair — 1. Manometry and EMG 
were performed preoperatively and over a mean 7.1 month postoperative 
period.
There were no major complications. No patient was made worse with 
respect to continence or manometric readings. Two wound infections 
delayed discharge 6 days. One patient required sphincter repair after low 
anterior resection for prolapse with incontinence. Two were lost to 
follow-up. The remaining 23 improved as follows: completely continent 
— 9; continent with occasional straining or urgency — 5; intermittent 
incontinence to liquid stool and/or gas — 5; incontinent to air — 4. 
Mean resting pressure increased from 25 to 30 mm Hg. Average 
squeeze pressure improved from 48 to 54 mm Hg. These averages do 
not reflect the marked improvements in individuals, particularly those 
followed with serial manometry for more than 6 months. Electromyo­
graphic mapping detected anterior sphincter weaknesses in patients 
with apparent simple rectovaginal fistulas.
R265
TRIPLE HEMORRHOID BANDING IS A SAFE OFFICE PROCE­
DURE. M. Wells, P. Makarewicz, J. Freeman. Division of General 
Surgery, Ottawa General Hospital, University of Ottawa, Ottawa, Ont.
Band ligation is the treatment of choice for hemorrhoids. To avoid 
complications, many surgeons band only one or two per session. We 
postulated that complications are unrelated to the number of hemor­
rhoids banded.
Thirty-seven patients had triple band ligation and were studied 
prospectively over 6 months. All had hemorrhoids unresponsive to 
conservative treatment. After ligation each hemorrhoidal base and its tip 
superior to the band were injected with 0.5 ml of sodium tetradecyl 
chloride.
There were no major complications. Four of 37 were lost to 
follow-up. Eight of 33 (24.2%) had minor complications. Bleeding, alone 
or with pain, occurred in 7/88; 1 patient had a vasovagal attack. All 
eight were managed in the office. At 6 months, 26/33 (78.8%) had 
excellent or good results. Results were fair in 3 /33  (9.1%). These 
patients required local medications only. Results were poor in 4 /33  
(12.1%). All were cured after further banding. No patient required 
surgery. Since study completion 2 years ago, 150 patients have had 
triple ligation without incident.
Triple ligation is not associated with complication rates higher than 
those previously reported after single or double ligation. Pelvic sepsis is 
apparently unrelated to the number of hemorrhoids banded and more 
likely caused by grasping rectal wall rather than mucosa.
R266
THE SURGICAL MANAGEMENT OF RADIATION BOWEL INJURY 
AS A CONSEQUENCE OF TREATMENT OF CERVICAL CARCINO­
MA. A. Covens, G. Thomas, A. DePetrillo, C. Jamieson. University of 
Toronto, Toronto, Ont.
A retrospective chart review of 57 patients requiring surgery for 
radiation-induced bowel damage as a consequence of treatment of 
cervical carcinoma (RIBD-CX) during the years 1968 to 1988 was 
performed to determine whether any prognostic factors could be 
identified to provide the surgeon with guidelines on which to base 
management decisions. Actuarial 5-year survival rates for the various 
sites and types of injuries are listed below.
Site of injury N
5-year 
survival, % Type of injury N
5-year 
survival, %
Rectosigmoid 8 88 Stricture 18 82
Sigmoid 14 67 Fistula 5 75
Rectum 11 58 Inflammation 7 71
Ileum 14 41 Perforation 11 46
Multiple 9 22 Multiple 15 23
Age, stage of cervical cancer, previous surgery, year of radiation, 
dose of external and intracavitary radiation, number of fractions, 
radiation-surgery interval, site and type of bowel injury and type of 
surgery were all subjected to univariate and multivariate analysis. 
Univariate analysis revealed both site and type of injury to be 
statistically significant (p < 0.02, p < 0.001 respectively). The only 
independent variable for survival on multivariate analysis was type of 
injury (p =  0.0001). Treatment-related mortality in patients requiring 
surgery for RIBD-CX was 26%. Of surviving patients, 40% required a 
second and third surgical procedure for ongoing radiation damage. 
Fifty-eight percent (15/26) of the deaths were due to treatment 
complications. Future efforts should be aimed towards prevention of 
this disorder.
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PLEUROPULMONARY COMPLICATIONS FOLLOWING CORO­
NARY ARTERY BYPASS: INTERNAL THORACIC ARTERY VER­
SUS SAPHENOUS VEIN GRAFT. D. Hurlbut, M.L. Myers, M. Lefcoe, 
M.M. Goldbach. Victoria Hospital, University of Western Ontario, 
London, Ont.
Use of the internal thoracic artery (ITA) as a coronary bypass (CB) graft 
results in excellent patency rates and improved symptomatic relief and 
survival. Clinical observations at this centre, however, had suggested an 
increased incidence of pleuropulmonary complications in patients in 
whom the ITA was utilized. One hundred consecutive patients with left 
ITA grafts were studied prospectively and compared with a consecutive 
retrospective group of 100 patients undergoing CB with saphenous vein 
grafts (SVG) only. Preoperative, postoperative day (POD) 2, and POD 6 
chest x-rays were scored in a blinded fashion by a radiologist using a 0 
to 3 scale for each of atelectasis and effusion. There were no significant 
differences between SVG and ITA groups respectively with regard to 
percentage male (84%, 91%), number of grafts (2.9 ± 0.1. 2.9 ± 0.1), 
ischemic time (43.3 ±  1.3, 47.2 ±  1.6 min) or bypass time (88.1 ± 2.4, 
92.3 ±  3.0 min). The mean age of the ITA group was greater: 58.7 ± 
0.9 versus 54.7 ± 0.8 years, p < 0.01. The SVG group was ventilated 
longer postoperatively (25.7 ± 0.8 versus 21.9 ± 0.6 hours, p < 0.01) 
and had more mediastinal chest-tube drainage (1088 ± 48 versus 942 ± 
38 ml, p < 0.02). There were no significant differences between the 
groups with respect to effusion or atelectasis except a significantly 
higher incidence of small effusions at POD 6 in the ITA group (p < 
0.05). Thoracentesis and secondary chest-tube insertion for recurrent 
large effusion were required in two and one patient respectively in the 
ITA group. Postoperative hospital stay was actually shorter in the ITA 
group (9.9 ± 0.3 versus 10.9 ±  0.3 days). We conclude that use of the 
ITA results in a small increase in postoperative effusion, but this does 
not appear to lengthen hospital stay.
R49
PERICARDIUM FOR AORTIC OR MITRAL VALVULAR SUBSTI­
TUTE — THE MITROFLOW EXPERIENCE. W.R.E. Jamieson, C.L. 
Pelletier, J. Pomar. Vancouver and Montreal, Canada, and Barcelona, 
Spain
The Mitral Medical Mitroflow pericardial prosthesis was implanted in 
354 patients between 1983 and 1987 at three centres. The mean age of 
the patients was 60.1 years (range 14 to 94 years). The early mortality 
was 5.7% and the late mortality was 2.9% per patient-year. The total 
cumulative follow-up was 853 years, a mean of 2.4 years. The patient 
survival for AVR was 81.5% and for MVR was 74.8% at 4 years. The 
overall rate of valve-related complications was 4.8% per patient-year 
(41): thromboembolism 15; anti-thromboembolic therapy-related he­
morrhage 1; prosthetic valve endocarditis 15; nonstructural dysfunction 
3; and structural valve deterioration 7. There were 17 valve-related 
reoperations. There were seven valve-related deaths (thromboembolism 
1, hemorrhage 1, prosthetic valve endocarditis 4 and structural valve 
deterioration 1). The freedom from thromboembolism was 91.5% ± 
2.7% for AVR and 91.4% ± 4.0% for MVR at 4 years. The freedom from 
prosthetic valve endocarditis at the same time interval was 93.5% ± 
2.3% for AVR and 94.0% ± 2.9% for MVR. The freedom from structural 
valve deterioration was 97.3% ± 2.1% and 92.6% ±  3.2% for AVR and 
MVR, respectively, at 4 years. The freedom from valve-related mortality 
was 96.9% ± 1.4% for AVR and 97.5% ± 1.8% for MVR, while for
reoperation it was 93.5% ± 2.8% for AVR and 83.1% ±  5.1% for MVR 
at 4 years. The freedom from the composite of all valve-related 
complications at 4 years was 81.1% ± 4.2% for AVR and 75.3% ± 5.8% 
for MVR. The Mitral Medical Mitroflow valve has provided satisfactory 
clinical performance at the early stage of evaluation of 4 years. The 
pericardial prosthesis performance favoured aortic over mitral prosthe- 
ses with regard to structural valve deterioration.
R50
SPINAL CORD PROTECTION BY BALLOON OCCLUSION OF THE 
DISTAL AORTA DURING PROXIMAL AORTIC CROSS-CLAMP­
ING. H. Iida, Y.S. Sun, R.M. Lust, P.A. Spence, S.B. Pollock, J.M. 
Williams, E.H. Austin. Division of Cardiac Surgery, East Carolina 
University School of Medicine, Greenville, NC
Irreversible spinal cord hypoperfusion injury after proximal aortic 
cross-clamping remains a major problem. The pressure in the distal 
thoracic aorta is low because collaterals are normally poorly developed 
and the distal runoff for this limited flow is immense. This experiment 
was conducted to assess the effectiveness of restricting the distal aortic 
runoff to the thoracic segment by balloon occlusion of the entire 
abdominal aorta. After proximal aortic cross-clamping, the abdominal 
aorta was occluded by a balloon in 8 of 16 dogs (18 to 25 kg) with the 
remaining dogs serving as controls (CON). Mean pressures were 
measured in the ascending aorta (ASC), thoracic aorta (TH) and the 
cerebrospinal fluid (CSF) at baseline and every 10 minutes after 
cross-clamping (XC). The data demonstrate considerably higher TH 
pressures and spinal cord perfusion gradients (SCPG) in the animals 
with balloon occlusion.
Baseline
10 min XC 20 min XC 30 min XC
CON Balloon CON Balloon CON Balloon
ASC 109 ±  5 150 ±  7 147 ± 8 156 ±  8 157 ±  10 160 ±  8 141 ±  10
TH 108 ± 4 26 ±  1 77 ±  8* 28 ±  1 92 ±  7* 30 ± 2 8 4  ±  9*
SCPC 102 ±  4 18 ±  2 67 ±  7* 21 ±  2 83 ±  7* 23 ±  2 76  ±  9*
CSF 7 ±  1 8 ±  2 9 ±  2 7 ±  2 10 ±  2 7 ±  2 8 ±  2
All data  in mm Hg, mean ±  SEM, *p < 0.001 versus CON (f-test).
We conclude that distal aortic balloon occlusion significantly im­
proves thoracic aortic pressure and spinal cord perfusion gradient after 
proximal aortic cross-clamping. This may be a simple method to protect 
the spinal cord during aortic surgery.
R51
DELAYED CARDIAC TAMPONADE. W.T. Kidd, A.S. Goldstein. 
Department of Surgery, University of Calgary, Calgary, Alta.
Delayed cardiac tamponade is a rare but potentially lethal complication 
of open-heart surgery. The pathophysiology and management are still 
open to question. This review was done in an attempt to answer these 
questions.
Fourteen cases of delayed cardiac tamponade after open-heart 
surgery were analysed retrospectively from 1978 to the present. The 
operations performed included valve replacement in 11 patients, coro­
nary artery bypass grafting in 1 and miscellaneous procedures in 2
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patients. In 9 of 14 patients the diagnosis was suspected and confirmed 
immediately. However, five patients were treated as “low output 
syndrome” while still in hospital and all had a delay in diagnosis. 
Coumadin anticoagulation was used in 11 of 14 patients and 7 of these 
11 patients had excessively prolonged prothrombin times (greater than 
two times normal).
Treatment consisted of an open surgical procedure in 12 patients and 
needle pericardiocentesis combined with tube drainage in 2 patients. 
The mortality rate in this series was 7% with no deaths in the group 
with a delay in diagnosis.
This study confirms that most patients with delayed tamponade are 
anticoagulated, but not always excessively. Appropriate management is 
open surgical drainage which ensures a low mortality rate.
R52
WARM ISCHEMIA INDUCES ALTERATION IN LUNG IMMUNE 
CELL FUNCTIONS. D. Nguyen, D.S. Mulder, H. Shennib. McGill 
Lung Transplant Program/The Montreal General Hospital, Montreal, 
PQ
During lung transplantation, a period of warm ischemia is inevitable. 
We examined the effects of such injury on the local lung immune cells 
as harvested by bronchoaiveolar lavage (BAL) and peripheral blood 
lymphocytes (PBL). Warm ischemia was induced in dogs by clamping 
the left lung hilum for 1 hour (n =  7). Bronchoaiveolar lavage, from the 
left and the unaffected right lungs, and PBL were obtained preopera- 
tively, 2 hours, 72 hours and 7 days postoperatively. The prepared 
mononuclear cells were subjected to phenotypic analysis, natural killer 
(NK) and lectin-dependent cell-mediated cytotoxicity (LDCMC) assays.
Warm ischemia results in significant impairment of NK activity 
immediately within 2 hours of reperfusion (49.0% of preoperative 
control cytolysis, p < 0.01). Within 3 days, a significant increase in NK 
function in the BAL monocells was observed (178.4%, p < 0.01). 
Interestingly, these changes were not paralleled in the PBL or the 
opposite, nonaffected lung where NK activity appeared significantly 
impaired at 72 hours (67.6% and 58.8% respectively, p < 0.01). 
Similarly, LDCMC appeared increased in the BAL from the ischemic 
lung (179.5%, p < 0.01) but decreased in the BAL from the nonaffected 
lung and PBL at 72 hours after injury (74.3% and 61.2% respectively, p 
< 0.01). We conclude that warm ischemia results in alteration of 
bronchoaiveolar cell function. Nonspecific increase in NK and LDCMC 
function of local lung immune cells can be etiologic in the early damage 
observed in poorly preserved lung allografts. Furthermore, BAL may 
prove to be a useful method for the evaluation of adequacy of lung 
preservation techniques.
R53
RUPTURED ABDOMINAL AORTIC ANEURYSMS — A 13-YEAR 
REVIEW. J. Burgess, E. Busse, T. Boyd, A. Maitland. Plains Health 
Centre, Regina, Sask.
One hundred and seventy-three ruptured abdominal aortic aneurysms 
presenting to Regina hospitals in a 13-year period have been reviewed. 
One hundred and fifty-two patients were treated surgically. Twenty-one 
patients had no surgery attempted and died, or died prior to surgery.
There were 154 males and 19 females. Their mean age was 72 years, 
with a range of 41 to 100 years. Of the 152 operative patients, there 
were 21 intraoperative deaths (13 deaths pre-graft and 8 deaths 
post-graft) and 47 postoperative deaths (surgical day and after). 
Symptoms on admission revealed 136 patients with abdominal pain, 90 
patients with hypotension, 72 patients with back pain and 26 patients 
with nausea. Past medical history revealed 49 patients with hyperten­
sion, 22 with COPD, 22 with ischemic heart disease, 10 with cancer and 
5 with impaired renal function. The correct diagnosis was made prior to
surgery or death in 97% of the cases (168/173 patients). Postoperative 
complications revealed 33 cases of renal failure, 11 cases of respiratory 
failure, 11 cases of ischemic colitis, 8 cases of trash foot, 8 cases of 
gastrointestinal hemorrhage, 6 cases of septicemia and 3 cases of 
myocardial infarction.
Follow-up is complete for 73 of 75 surviving patients who were under 
the services of cardiovascular-thoracic surgeon: 42 (56%) are still alive, 
31 (41.3%) have since died and 2 (2.7%) have been lost to follow-up. 
The 3-year survival rate was 68.5% (50/73 patients). The 5-year 
survival rate was 34.2% (25/73 patients).
Despite improvements in technology, the mortality rate remains 
constant. This can only be reduced by recognizing the malignant 
potential of aneurysms and operating on them electively.
R54
CLINICAL PERFORMANCE OF THE DUROMEDICS BILEAFLET 
PYROLITE MECHANICAL PROSTHESIS. W.R.E. Jamieson, C.L. 
Pelletier, J. Pomar. Vancouver and Montreal, Canada and Barcelona, 
Spain
The Edwards-Duromedics mechanical prosthesis experience of three 
centres was examined to determine the influence of valve-related 
complications, especially structural valve deterioration, on clinical 
performance. The prosthesis was implanted in 486 patients between 
1984 and 1988 (Vancouver 131, Montreal 214, Barcelona 141). The 
mean age of the patients was 52.2 years (range 14 to 76 years). There 
were 174 aortic valve replacements (AVR), 225 mitral valve replace­
ments (MVR), 3 tricuspid valve replacements and 78 multiple valve 
replacements (MR). The cumulative follow-up was 682 years, mean of 
1.4 years. The early mortality was 7.8% (38) and the late mortality was 
4.1% per patient-year (28). The patient survival was 87.0% ± 3.7% for 
AVR and 81.9% ± 2.9% for MVR at 4 years. The overall valve-related 
complication rate was 2.8% per patient-year (47) — thromboembolism 
(TE) 19; antithromboembolic related hemorrhage (ATH) 11; prosthetic 
valve endocarditis (PVE) 15; nonstructural dysfunction (NSD) 2; and 
structural valve deterioration (SVD) 0. There were 19 valve-related 
reoperations (two in each of two patients) — TE 1, PVE 9 and NSD 7. 
The freedom from thromboembolism at 4 years was 94.3% ±  3.1% for 
AVR and 95.1% ± 1.8% for MVR. The freedom from prosthetic valve 
endocarditis at the same time interval was 95.3% ± 2.2% for AVR and 
96.2% ±  1.6% for MVR. The freedom from structural valve deteriora­
tion was 100%. The freedom from valve-related mortality was 98.7% ± 
1.3% for AVR and 96.2% ± 1.6% for MVR while for reoperation was 
95.3% ± 2.1% for AVR and 92.3% ± 4.3% for MVR at 4 years. The 
freedom from the composite of all valve-related complications at 4 years 
was 87.7% ± 3.8% for AVR and 85.7% ±  2.9% for MVR.'The 
experience with the Edwards-Duromedics prosthesis has been satisfac­
tory with no structural valve deterioration at the 4-year interval.
R55
PREGNANCY AND CHILDBEARING WITH PORCINE BIOPROS- 
THESES. B.R. Badduke, W.R.E. Jamieson, R.T. Miyagishima, A.I. 
Munro, A.N. Gerein, J. MacNab, G.F.O. Tyers. University of British 
Columbia, Vancouver, BC
Biological valves were implanted in 99 females 35 years of age and 
under, between 1975 and 1987. The 99 females (mean age 26.8 years, 
range 8 to 35 years) represented 3.3% of total biological population of 
3000 patients. The valves implanted were: Carpentier-Edwards Stan­
dard, 50 (AVR 10, MVR 32, MR 8); Hancock Standard, 18 (AVR 3, 
MVR 10, MR 4, PVR 1); Carpentier-Edwards Supra-Annular, 31 (AVR 
3, MVR 21, MR 6, TVR 1); Mitral Medical Mitroflow, 1 (MVR 1). 
Sixteen females had 24 births in 29 pregnancies. The patients were 
managed without anticoagulants except for one. The total patient
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population (99 females) had 31 valve-related complications (5.6% per 
patient-year) — structural valve deterioration (SVD) 18, prosthetic valve 
endocarditis (PVE) 6, thromboembolism (TE) 5, anticoagulant hemorrh­
age (ATH) 1 and nonstructural dysfunction (NSD) 1. Valve-related 
mortality (seven) was PVE two, TE two, SVD one, ATH one and sudden 
unexplained death one. Valve-related reoperation (23) etiology was SVD 
17, PVE 4, NSD 1 and acute dissection 1. The children were born a 
mean of 50 months after valve replacement. Three of the 16 patients 
had 10 of the 24 births. Four patients (25%) of the 16 subsequently had 
reoperation for SVD. Fourteen (16.7%) of the remaining 84 patients had 
reoperation for SVD. There was no mortality at reoperation for any 
cause, including SVD. Of the 22 patients who had reoperation, the 
prostheses utilized were: mechanical prostheses (12) and bioprostheses 
( 12) .
Biological prostheses provide the opportunity for successful pregnan­
cy. Pregnancy contributes to an acceptable increase in structural valve 
deterioration. The management of structural valve deterioration is 
highly successful in this young female population.
R56
DETERMINATION OF OPERABILITY IN CANDIDATES UNDER­
GOING LUNG RESECTION FOR BRONCHOGENIC CARCINOMA. 
T.P. Murphy, M.T. Casey. Division of General Surgery, Halifax 
Infirmary, Dalhousie University, Halifax, NS
A prospective study was undertaken to determine the effect of lung 
resection for bronchogenic carcinoma on ultimate pulmonary function. 
We wish to compare the postoperative pulmonary function of higher 
risk candidates, i.e., those patients with severe limitations of lung flows 
and. thus, those patients more likely to develop severe, progressive 
pulmonary failure, with those patients who had acceptable preoperative 
parameters.
Preoperative and postoperative pulmonary function tests were per­
formed on 20 candidates undergoing various resections for bronchogen­
ic carcinoma. Patients who had pneumonectomy had resultant changes 
in lung volumes and flows as were expected in a resection of that 
magnitude. Those patients having lesser resections, however, had much 
more variable postoperative lung volumes and flows.
The patients with the poorest preoperative parameters had the least 
change postoperatively with even some improvements in parameters. 
These were patients who were most likely to be denied surgery because 
of poor preoperative pulmonary function parameters.
We conclude that the operability of each lung resection candidate 
must be carefully assessed, and that the guidelines for safe operation 
established in the literature must be independently interpreted for each 
lung resection candidate.
R57
CHRONIC POST-THORACOTOMY PAIN. E. Dacjzman, A. Gordon, 
H. Kreisman, N. Wolkove. Pulmonary Department, Sir Mortimer B. 
Davis-Jewish General Hospital, McGill University, Montreal, PQ
Although chest-wall pain is recognized as a significant problem in the 
immediate postoperative period, it is less commonly appreciated that 
patients may have persistent pain. We have studied retrospectively the 
character and occurrence of prolonged pain in post-thoracotomy (PT) 
patients. Review of 206 thoracotomies done during the previous 5 years 
revealed 64 patients between 2 and 60 months post-surgery who were 
alive and well without evidence of progressive carcinoma. Fifty-nine 
patients were interviewed, but 3 subsequently developed metastatic 
disease and were excluded. A pain questionnaire was administered and 
patients were asked to grade their pain from 0 to 10 using a visual 
analogue scale (VAS). Thirty patients (54%) with a median follow-up of
19.5 months, had ongoing pain, whereas 26 patients were pain-free 
with a median follow-up of 30.5 months PT. Pain was reported in 24 of 
45 patients more than 1 year PT (55%), 13 of 29 patients greater than 2 
years post-surgery (45%) and 3 of 10 patients seen between 4 to 5 years 
PT. The intensity of the pain was low with an average VAS score of 3.1. 
Fifty-six percent stated that their pain had no impact on their lives, but 
the remaining 13 patients (44%) stated their pain “slightly” or 
“moderately” interfered with their lives. Five of the 56 patients had 
sufficiently prolonged and severe pain to seek relief with daily analgesic 
use, nerve blocks or referral to a pain clinic. We conclude that chronic 
chest-wall pain is common PT. It is generally not severe, but a small 
portion of patients may experience persistent, moderately disabling pain.
R58
COMPARISON OF DIFFERENT IMMUNOSUPPRESSIVE REGIMEN 
FOLLOWING HEART TRANSPLANTATION: EXPERIENCE OF 
THE UNIVERSITY OF MONTREAL TRANSPLANTATION GROUP. 
L.C. Pelletier, R.L. Beaudet, S. Busque, M. Carrier, C. Chartrand, D. 
Doyle, J-C. Fouron, M. Morissette, G. Pelletier, P. Stanley. Depart­
ment of Surgery and Department of Medicine, University of Montreal, 
Montreal, PQ
From July 1982 to February 1989, 100 patients underwent orthotopic 
heart transplantation (OHT) — 84 men and 16 women, aged 4 to 61 
years (mean 41 years). Preoperatively, 28 patients required pharmaco­
logic (19) or mechanical (9) circulatory support. There were 10 early 
and 12 late deaths. The overall actuarial survival at 1 and 5 years was 
80% and 73% respectively. Patients were divided into three groups 
according to their immunosuppressive regimen (IR) early postoperative­
ly: group 1 (36 patients) was given cyclosporine-prednisone (CP): group 
II (26 patients) received cyclosporine-prednisone-azathioprine (CPA); 
group III (38 patients) was given antilymphocyte or antithymocyte 
globulin or monoclonal antibody OKT3 immediately after surgery 
followed by CPA (CPAL). There were 85 episodes of acute rejection 
(0.85/pt) and 87 episodes of infection (0.87/pt). Only one rejection and 
four infection episodes occurred after the 6th postoperative month. The 
IR did not influence survival rate. However, rejection and infection 
rates, which average 1.2 and 1.3 episodes/pt with CP decreased to 0.6 
and 0.7 respectively with CPA and to 0.7 and 0.6 with CPAL. Actuarial 
freedom rates from rejection and infection at 3 years were 39% and 50% 
with CP, 56% and 64% with CPA and 61% and 70% with CPAL. Thus, 
changes in IR to decrease cyclosporine toxicity early postoperatively 
have not compromised survival and have resulted in an improved 
immunosuppression with a lower incidence of rejection and infection 
following OHT.
R59
TRANSHIATAL ESOPHAGECTOMY — RESULTS OF 120 CASES. 
R.J. Finley, R.L Inculet. University of Western Ontario, London, Ont. 
and University of British Columbia, Vancouver, BC
Between 1980 and 1988, 120 patients underwent resection of the lesser 
curve of the stomach and thoracic esophagus through abdominal and 
neck incisions, avoiding a thoracotomy. The esophagus was replaced by 
gastric tube (118) or colon (2). Indications for esophagectomy were: 
squamous cell carcinoma of the esophagus (26), adenocarcinoma of the 
cardia (45), adenocarcinoma in a columnar lined esophagus (36) and 
benign end-stage esophageal disease (13). There were 96 males and 24 
females ranging in age from 15 to 80 years (median 61 years). 
Significant preoperative risks included smoking (94), cardiac disease 
(22), chronic obstructive pulmonary disease (32), thromboembolic 
disease (6) and diabetes (13).
Hospital mortality was 3 /120  patients. Early postoperative morbidity 
included intraoperative hemorrhage (1), anastomotic leaks which dosed
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spontaneously (20), transient hoarseness (14), myocardial infarction (2), 
pulmonary embolus (7). supraventricular tachycardia (42) and atelecta­
sis or pneumonia (23). Median time to discharge was 16 days. Late 
postoperative complications include delayed gastric emptying (6), symp­
tomatic reflux (7), diarrhea (9) and anastomotic strictures (30). Nine of 
these 30 patients required more than three esophageal dilatations to 
maintain swallowing. Three months after surgery 94% of the patients 
were swallowing at least a soft diet.
Esophagectomy without thoracotomy provides a safe effective meth­
od of restoring swallowing in patients with obstructive esophageal 
disease.
R60
A COMPUTER-BASED PRIORITIZED WAITING LIST MANAGE­
MENT SYSTEM FOR CARDIAC SURGERY. J. Pym, J.L. Knight, 
E.J.P. Charrette. Queen’s University, Kingston, Ont.
In most provinces, the political reality of finite resources for health care 
has led to lengthening waiting lists for surgical procedures. For cardiac 
surgery, long delays can result in death, significant morbidity and a 
higher rate of emergency surgery which consumes more resources.
We have developed a computer-based prioritized waiting list manage­
ment system. Patients are assigned priority scores on the basis of 
perceived anatomical risk, symptomatic disability and other factors. 
These, together with demographic and clinical data, are entered into a 
computer database. Timing of cardiac surgery is dictated primarily by 
priority score and time on the waiting list. Reports are automatically 
generated for referring cardiologists, and information is sought to 
update priorities. High priority patients are readily identified to fill any 
vacant operating slots, thus allowing the most efficient use of 
resources.
An audit was conducted of 150 consecutive operated patients. 
Emergency surgery was performed in 20 (13%) of these, while 130 
(87%) were on the waiting list from 3 to 257 (mean 41) days before 
surgery. There was a significant negative correlation between assigned 
priority scores and time on the waiting list.
Although waiting lists for cardiac surgery are medically undesirable, 
they are a fact of life at the present time, and a simple prioritization 
system aids in their efficient management.
R61
DOES TRANSESOPHAGEAL ECHOCARDIOGRAPHY OBVIATE 
THE NEED FOR ANGIOGRAPHY IN AORTIC DISSECTION? K-L. 
Chan. University of Ottawa Heart Institute, Ottawa, Ont.
Transesophageal echocardiography (TE) has been shown to be reliable
in the diagnosis of aortic dissection. To assess whether TE can obviate 
the need for angiography in this clinical setting, the management of 18 
consecutive patients found to have aortic dissection by TE was analysed. 
There were 11 men and 7 women with a mean age of 59 years. 
Ascending aortic dissection was present in nine patients, of whom six 
had surgery with confirmation of TE findings in each case. In two 
patients who had surgery, angiography was performed and was falsely 
negative in one patient. Angiography was not done in the three patients 
who were not surgical candidates. In the nine patients with descending 
dissection, two had surgery for expansion. Both had angiograms which 
yielded no additional findings. In the seven patients managed medically, 
six had angiograms which also showed no additional information to the 
TE findings. Autopsy findings available in four patients with descending 
dissection confirmed the TE findings.
Thus, TE reliably differentiates ascending from descending aortic 
dissection, and angiography appears not to provide additional informa­
tion in both types of dissection. In most patients with aortic dissection, 
angiography appears not to be indicated if an adequate TE is obtained.
R62
SHOULD EURO-COLLINS SOLUTION BE USED FOR DONOR 
HEART TRANSPORTATION? P.J. Hendry, Y.A. Barry, R. Labow, 
W.J. Keon. University of Ottawa Heart Institute, Ottawa Civic 
Hospital, Ottawa, Ont.
Although Euro-Collins solution (EC) has gained popularity for the 
transportation of noncardiac allografts, its usefulness for heart preser­
vation is unclear. To assess EC, human right atrial trabeculae 
contracting isometrically in vitro were cooled to 12°C, arrested and 
maintained in EC for 24 hours. Control conditions were, then resumed 
and functional recovery of the trabeculae was followed for 30 minutes 
(expressed as % of control) and compared to other crystalloid solutions:
Solution Developed force (DF) Resting force (RF)
Euro-Collins 13.0 ± 5.9% 149.6 ±  23.8%
Saline 5.6 ± 4.5% 142.1 ± 13.6%
St. Thomas’s 78.1 ± 11.1% 126.7 ± 32.2%
Modified Krebs’ 70.3 ± 17.0% 85.4 ± 16.2%
Trabeculae recovering in EC did not differ significantly from those in 
saline, whereas both DF and RF were significantly different from those 
attained in St. Thomas’s and modified Krebs’ solutions (p < 0.05). 
Euro-Collins solution leads to poor return of function and damage with 
contracture. These data indicate that EC should not be used for the 
transport of donor hearts.
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GENERAL SURGEON AND ORTHOPEDIC 
SURGEON: BC -  For thriving BC sunshine 
coast community of 20 000 on the doorstep 
of Desolation Sound. Fully accredited 
140-bed hospital under construction. Medical 
staff includes 17 GPs, 4 GP anesthetists, 
internist, pediatrician and 2 surgeons. Excel­
lent year round recreation and cultural attrac­
tions include boating, fishing, golfing, modern 
indoor recreation theatre complex and com­
munity college. Frequent daily air and ferry 
connections to Vancouver. Contact: Dr. B.K. 
Cutler, Department of Surgery, Powell 
River General Hospital, 5871 Arbutus 
Ave., Powell River, BC V8A 4S3. Tel: 
(604) 483-3211. -S89-10
GENERAL SURGEON: BC -  Well-estab­
lished general surgical practice for sale in 
choice lower mainland location. Canadian fel­
lowship required. Reply in confidence with 
curriculum vitae to: Box 800, Canadian 
Journal of Surgery, PO Box 8650, Ottawa, 
ONK1GOG8. -S89-13
GENERAL SURGEON: BC -  General sur­
geon to retire to Sechelt, BC, a beautiful 
coastal community, 64 km from Vancouver. 
Willing to work up to 3 months a year 
relieving solo general surgeon during vaca­
tion. Reply to: Chief of Staff, St. Mary's 
Hospital, Box 7777, Sechelt, BC VON 
3A0. -S89-27
GENERAL SURGEON: BC -  St. Joseph s 
General Hospital, a fully accredited, modern, 
220-bed general hospital, including 75 ex­
tended care unit beds, on Vancouver Island, 
British Columbia, requires the services of a 
general surgeon. The hospital services an 
area population of 40 000, including commu­
nities of Comox, Courtenay and Cumberland. 
The current medical staff includes tw o  general 
surgeons (one retiring the end of 1989), four 
anesthetists, two orthopedic surgeons, one 
urologist, two internists, two ophthalmologists, 
one otolaryngologist, tw o  obstetric ian/ 
gynecologists, one psychiatrist, one pediatri­
cian, one pathologist, two radiologists, one 
dermatologist and twenty-five general practi-
SURGEON-IN-CHIEF
MOUNT SINAI HOSPITAL, TORONTO, ONTARIO
Mount Sinai Hospital, a 526-bed acute care, general teaching hospital, fully affiliated with the Faculty of Medicine, 
University of Toronto, requires a Surgeon-in-Chief.
The Department of Surgery consists of four major divisions: general surgery, orthopedic surgery, thoracic surgery 
and urology. There is also a single neurosurgeon, plastic surgeon (part of Division of Orthopedics) and vascular 
surgeon (part of Division of General Surgery). There are 21 full-time staff surgeons and a complement of 147 ac­
tive treatment beds. Clinical and research activities within all divisions have tw o major thrusts: oncology and 
transplantation. The planned relocation of the Ontario Cancer Institute/Princess Margaret Hospital next door to 
Mount Sinai Hospital has further stimulated development of oncology. The Department has a very active 
undergraduate and postgraduate teaching program, and an active research program, with eight staff members of 
the Department of Surgery holding peer-reviewed research grants. The Mount Sinai Hospital Research Institute 
provides an important research resource for the hospital clinical departments.
The successful candidate will have an FRCSC or equivalent; be eligible to practise medicine in Ontario; will be 
recognized as a skilled surgeon and an outstanding teacher; will have had a background in research, and be in­
terested in and capable of furthering an existing, successful research program; will have superior leadership 
qualities and planning abilities, with previous experience in a senior administrative position.
The successful candidate would be eligible for a senior academic appointment.
In accordance with Canadian immigration regulations, this advertisement is directed to Canadian citizens and per­
manent residents of Canada.
Interested candidates should forward their curriculum vitae to:
CHAIRMAN
SEARCH COMMITTEE FOR A SURGEON-IN-CHIEF 
MOUNT SINAI HOSPITAL,
C/O ROOM 341 
600 UNIVERSITY AVE.
TORONTO, ON 
CANADA
M5G1X5 -S-89-18
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tioners. Comox is located 240 km north of 
Victoria on beautiful Vancouver Island, and 
offers superb recreational opportunities, in­
cluding sailing, skiing, salmon fishing, alpine 
sports and a full range of outdoor activities. 
The communities offer gourmet dining and a 
remarkable variety of cultural and theatrical 
events. For further information please con­
tact: D. Blacklock, MD, Chairman, Search 
Committee, St. Joseph's General Hospital, 
2137 Comox Ave., Comox, BC V9N 4B1.
-S89-26
GENERAL SURGEON: MB -  Required to 
join a progressive group of twelve general 
practitioners, one obstetrician/gynecologist, 
and one orthopedic and plastic surgeon. 
Guaranteed income provided for first 12 
months, and thereafter, if mutually agreeable, 
partnership would be offered. Early partner­
ship by agreement is available. The clinic 
occupies three floors of a modern, downtown 
medical facility in a university city of 40 000, 
and services a large trading area. A 220-bed 
hospital with a 12-bed, intensive care unit, a 
201-bed geriatric and rehabilitation hospital, a 
large regional laboratory, and an ultrasound 
department, is located in the city. Interested
persons are asked to contact: Mrs. D.J. 
Mistal. Western Medical Clinic, 144 6th 
St., Brandon, MB, R7A 3N2, Tel: (204) 
727-6451. -S89-14
SURGICAL ASSISTANT: ON -  Surgical as- 
sistant/fellow required in cardiovascular and 
thoracic surgery operating room. Position 
may be permanent or temporary, full or part 
time, and may be adapted to meet specific 
educational needs, e.g. research, further uni­
versity courses, etc. Prior surgical experience 
helpful but not a prerequisite. Should have 
Ontario licence. Reply to: Dr. F.N. McKenzie, 
Chief, Division of CVT Surgery, University 
Hospital, PO Box 5339, London, ON N6A 
5A5. -S89-29
GENERAL SURGEON: ON — A general sur­
geon is required in late fall 1989 for a 
500-bed community hospital in a rapidly 
growing city on the outskirts of metropolitan 
Toronto. Please send curriculum vitae and 
enquiries to: Dr. T. Dickson, Chief of Sur­
gery, c/o Program Administration Office, 
Peel Memorial Hospital, 20 Lynch St., 
Brampton, ON L6W 2Z8. -S89-23
PLASTIC SURGERY SEARCH: ON -  The
Toronto Hospital is seeking a Head of Division 
of Plastic Surgery. This newly created posi­
tion will be responsible for the Division of 
Plastic Surgery at the Toronto General and the 
Toronto Western Hospitals. Clinical activity, 
research, undergraduate and postgraduate 
education, and long-range planning will be 
managed by the Head of Division. The suc­
cessful applicant will have an excellent reputa­
tion in clinical surgery, research and education 
and have shown evidence of leadership abili­
ty. In accordance with Canadian immigration 
requirements, this advertisement is directed 
primarily to Canadian citizens or permanent 
residents. Applicants should send a letter and 
accompanying curriculum vitae to: Dr. Alan 
R. Hudson, Surgeon-in-Chief, Toronto 
Hospital, Bell Wing, 1-636, 585 University 
Ave., Toronto, ON M5G 2C4. -S89-25
SPINAL SURGERY FELLOWSHIP: ON -
Available July 1, 1989 and July 1, 1990, 
Department of Surgery, Division Orthopedic 
Surgery, University of Western Ontario, Lon­
don. For information contact: Stewart I. Bai­
ley, MD, FRCSC, 345 Westminster Ave., 
London, ON N6C 4V3. Tel: (519)
439-0701. -S 8 9 -1 1
PEDIATRIC TRAUMA RESEARCH FELLOWSHIP
Department of Surgery 
Hospital for Sick Children, Toronto and 
University of Toronto
A 1 or 2 year research fellowship in pediatric trauma is 
available beginning Jan. 1 or July 1,1990.
This fellowship provides an excellent opportunity to 
participate in our ongoing epidemiologic, clinical and 
basic research program. At present, we have projects 
underway on preventable deaths, field triage, 
metabolic effects using open-circuit indirect 
calorimetry, late sequelae of major trauma and shock. 
The successful applicant would be encouraged to 
design and implement new ideas in these and related 
areas. The applicant would also be encouraged, but 
not required, to study for a Masters degree at the 
University of Toronto, which could be completed in 1 
year.
This fellowship is intended for anyone planning an 
academic career in pediatric general surgery or 
pediatric emergency medicine with a special emphasis 
on trauma.
Send enquiries and resume to:
Dr. D.E. Wesson, MD, FRCSC 
The Hospital for Sick Children 
555 University Ave.
Toronto, ON Canada
M 5G 1X8 -s-89-19
The Cold Lake Regional Hospital is a modern, multi­
level progressive facility with the potential bed capacity 
of 150. We seek an additional
Psychiatrist 
Surgeon 
GP /  Anesthetist 
GP /  Obstetrician /  Gynecologist
The Tri-town area in which the hospital is located is, 
approximately 300 kilometers East of Edmonton. Pri­
mary care and specialty referral care is offered to a 
growing population.
The successful candidates must be eligible for licensure 
in Alberta. In accordance with Canadian immigration 
requirements, priority will be given to Canadian citizens 
and permanent residents of Canada.
Please forward your confidential resume, including refer­
ences, to:
The Search Committee 
Cold Lake Regional Hospital 
Postal Service “A”
COLD LAKE, Alberta 
TOA 0V0
Tel: (403) 639-3322, Ext. 280.
Cold Lake Regional Hospital
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CHAIRMAN, DEPARTMENT OF SUR­
GERY: SK -  The College of Medicine, Univer­
sity of Saskatchewan, invites applications for 
the position of Chairman of the Department of 
Surgery. The successful candidate will also be 
Head of the Department of Surgery at the 
University Hospital and will be responsible for 
providing academic leadership in undergradu­
ate and postgraduate teaching, research and 
service. The Department of Surgery includes 
general surgery, orthopedic surgery, neuro­
surgery, cardiovascular surgery, plastic sur­
gery, urology and otolaryngology. The aca­
demic rank will be that commensurate with 
the successful candidate's qualifications and 
experience. Associated with the headship will 
be a tenure track academic appointment. In 
accordance with Canadian immigration re­
quirements, this advertisement is directed to 
Canadian citizens and permanent residents. 
Interested candidates should send a letter of 
application, curriculum vitae and the names of 
three referees, by July 15, 1989, to: I.M. 
McDonald MD, Dean of Medicine, Univer­
sity of Saskatchewan, Saskatoon, SK S7N 
0 W 0 . -S89-22
NEUROSURGEON, ACADEMIC APPOINT­
MENT: SK — The Department of Surgery, 
University of Saskatchewan, invites applica­
tions for a geographic full-time neurosurgeon 
in the Division of Neurosurgery. The incum­
bent will hold a joint appointment in the 
College of Medicine and University Hospital. 
Academic rank and salary will be commensu­
rate with experience. Candidates must be 
eligible for licensure in the province of Sas­
katchewan and hold or be eligible for special­
ist certification by the Royal College of Physi­
cians and Surgeons of Canada. The success­
ful candidate will be expected to teach at the 
undergraduate and postgraduate levels, and 
engage in ongoing and new research projects.
Clinical practice will be conducted within our 
600-bed teaching hospital, which is the terti­
ary care centre for the northern half of the 
province. In accordance with Canadian immi­
gration requirements, this advertisement is 
directed to Canadian citizens and permanent 
residents. An application accompanied by a 
detailed curriculum vitae, together with the 
names of three referees, should be forwarded 
to: Dr. Charles J. W right, Chairman, De­
partm ent of Surgery, University o f Sas­
katchewan, Saskatoon, SK S7N 0W 8. 
Deadline: August 15, 1989. -S89-28
LOCUM TENEN AVAILABLE: -  Experienced 
Canadian fellowship surgeon eligible and will­
ing to work anywhere in the Commonwealth. 
Available late summer for locums of any 
length. Reply Box 838, CMA Journal, PO 
Box 8650, Ottawa, ON K1G 0G8.
-S 89-24
SURGEONS
Ref. #89015- GENERAL SURGEON
A busy clinic in Southern Ontario 
specializing in colon and rectal 
surgery
Ref. #88028- GENERAL SURGEON
A community hospital in Vancou­
ver Island, B.C.
For further information about these positions and 
other opportunities for associates, locums and 
sale of practices, please contact:
CanMed Careers
jg i  jAfc 659 Mississauga Crescent
E==l J l jp  Mississauga, Ontario L5H 1Z9
Tel. (416) 274-0707 
Fax (41 6) 274-5211 -S89-21
INTERNATIONAL CONSULTANTS TO EXECUTIVES 
AND PROFESSIONALS IN THE 
HEALTH CARE SECTOR
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NEW  FROM MILES
DC 3L
ciprofloxacin hydrochloride
A REVOLUTIONARY 
ORAL ANTIBIOTIC
THE POWER OF RARENTERALS. 
THE FREEDOM OF TABLETS.
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AND FREEDOM
■  WIDE RANGE OF INDICATIONS — lower respiratory tract — urinary tract
— skin/soft tissue — bone and joint
■  BROAD SPECTRUM
Highly active* in vitro against a broad range of gram-positive and gram-negative 
pathogens, “...the most potent anti -pseudomonas agent...”1 Editorial, The Lancet.
■  HIGH TISSUE PENETRATION
Serum, tissue and fluid levels well above inhibitory levels.2
■  EXCELLENT PATIENT COMPLIANCE
Convenient B.I.D. dosage. Well tolerated — low incidence of side effects.2
CIPRO HOT LINE
For more information, 
please call 
1 - 800- 227-7766
*ln  vitro activity does not necessarily 
imply a correlation with in vivo results.
MILES
NEW TABLETS
POTENT
YETPO.
For prescribing information see page 274
%CARDIOVASCULAR SUTURES J
Improved Cardiovascular Needles Needles Resist Bending
Special highly adherent silicone 
lubricant further reduces 
resistance...first pass, last pass
Securely attached to the suture
New, stronger needle configuration
Superior sharpness
Lower penetration force reduces 
strain on needle -  minimizes 
bending and breaking
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